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Sickle cell disease (SCD) is one of the commonest inherited disorders worldwide.  
Acute chest syndrome (ACS) is the commonest cause of death in young adults and 
pulmonary dysfunction is a major contributor to morbidity in aging adults with SCD, 
but the aetiology is poorly understood.  The first four studies presented in this 
thesis test the hypothesis that pulmonary vascular abnormalities are involved in 
the pathogenesis of SCD-related lung disease.   
Significant  associations were found between small vessel pulmonary vascular 
dimensions, lung function abnormalities and echocardiographic estimates of 
ventricular function and cardiac output in adults with SCD; the decline in lung 
function observed in a subset of patients with longitudinal measurements 
correlated with changes in vascular dimension. Increased pulmonary capillary blood 
volume was shown to be related to the airways obstruction seen in SCD children. 
Respiratory system resistance and pulmonary capillary blood volume were 
significantly correlated in the SCD children, but not in the controls, suggesting the 
raised respiratory system resistance in the SCD children was, at least partly, 
explained by their increased pulmonary capillary blood volume. Additionally, fluid 
loading by means of blood transfusion in SCD children was found to acutely 
increase pulmonary capillary blood volume resulting in an increase in respiratory 
system resistance and worsening lung function. Furthermore, alveolar nitric oxide 
production was elevated in SCD children compared to controls and in the SCD 
children was correlated with pulmonary blood flow, but airway nitric oxide flux was 
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similar to that of the controls and did not correlate with biomarkers of airways 
obstruction.  
Lung function appears to deteriorate over time in children with SCD, but 
prospective longitudinal data with appropriate control groups were lacking.  The 
study presented in chapter five tested the hypothesis that lung function in SCD 
children, assessed longitudinally, would decline relative to controls and was related 
to ACS, and that restrictive abnormalities would increase in prevalence. In SCD 
children, but not controls, lung function declined significantly, and was significantly 
associated with ACS.  Restrictive abnormalities were significantly more common at 
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1.1 Sickle cell disease 
 
Sickle cell disease (SCD) is an inherited haematological disorder that is associated 
with multisystem organ damage, and is one of the commonest monogenetic 
diseases worldwide [1].  SCD  was first described in 1910 by James Herrick when he 
observed “peculiar elongated and sickle-shaped red blood corpuscles” in blood 
films from an African-American patient presenting with severe anaemia [2]. Since 
that time, our understanding of this condition has progressed rapidly.  In 1949 
Linus Pauling et al described SCD as “the first molecular disease” when they 
detected distinct electrophoretic anomalies in sickle haemoglobin [3], and this 
work formed the basis of the subsequent detailed characterisation of the 
fundamental genetic and biophysical basis of the condition.    With improved 
general healthcare the majority of patients with SCD in developed countries can 
expect to survive to adulthood, but despite the progress made, specific treatment 
options available for clinical management of the disease are limited. This is, at least 
in part, due to the highly varied and complex clinical presentation and underlying 
pathophysiology  seen in individual patients [4].  The work presented in this thesis 
aims to contribute to the understanding of the pathophysiology of the pulmonary 
complications in adults and children with SCD and hence aid in the determination 





1.2  Incidence of SCD 
 
SCD occurs most frequently in people of African origin, although it is also present in 
populations originating in India, the Middle-East, Latin America, and Southern 
Europe [5].  The heterozygous carrier state is thought to confer a degree of 
protection against malaria and the distribution of SCD is to a large extent 
coincident with that of  malaria [5].  Approximately three hundred thousand infants 
are born with SCD per year worldwide and the large-scale migration from Africa 
and Asia in the nineteenth and twentieth centuries has resulted in a substantial 
incidence of SCD in Western Europe and the United States. In the United Kingdom, 
SCD is now as common as cystic fibrosis with a prevalence of approximately  1:2000 
affected births, mostly concentrated in London and represents a substantial 




Figure 1-1 Geographical distribution of sickle cell disease in England: annual rate (per 1000 births) by county district.  




1.3 The pathophysiology of SCD 
 
Sickle cell disease refers to the clinical syndrome caused by one of a number of 
single-gene mutations and the resultant production of an abnormal haemoglobin 
variant, the commonest of which is haemoglobin-S (HbS).  Individuals who are 
homozygous for HbS are said to have sickle cell anaemia (HbSS) and constitute the 
majority of the SCD population, comprising approximately seventy percent of cases 
in populations of African heritage.  The majority of the remainder have 
haemoglobin SC disease (HbSC) resulting from the presence of the HbS and HbC 
alleles [7]. HbS/β-thalassemia, which occurs when HbS is inherited with one of a 
number of β-thalassemia alleles [8], is the third major group. The data presented in 
this thesis relate to HbSS disease.  
HbS results from a single point mutation in the gene which codes for β-globin 
whereby the seventeenth nucleotide, thymine, is substituted with adenine 
resulting in the replacement of glutamic acid with valine in the sixth position of the 
β-globin chain [9].  This results in a hydrophobic structural motif in the 
deoxygenated HbS tetramer which allows binding between the β1 and β2 chains of 
different haemoglobin molecules and thereby provides a polymer nucleus, with 
subsequent polymerization of HbS throughout the erythrocyte.  The resulting 
disturbance of cellular architecture reduces the flexibility of the erythrocyte and 
promotes water loss, resulting in mechanical and oxidative stress [10].  The key 
determinants of the extent and rapidity of this polymerization process are the 
intracellular HbS concentration, the degree and duration of haemoglobin 
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deoxygenation, and the concentration of fetal haemoglobin (HbF) which mitigates 
HbS polymerization  by reducing the average intracellular HbS concentration [11].     
Hereditary persistence of high HbF concentrations can ameliorate disease severity 
and induction of elevated HbF levels are a mainstay of SCD pharmacotherapy.  HbS 
polymers cause damage to erythrocytes and the erythrocyte membrane [12], 
resulting in abnormal rheological and hemodynamic properties characterized by 
increased cell density, bulk viscosity, and peripheral resistance [13].  There is 
considerable variability which is thought to be attributable to between-patient and 
between-erythrocyte variations in intracellular HbF distribution [14, 15].  In some 
erythrocytes, ion homeostasis is disrupted; loss of water and potassium ions results 
in an increased cell density. That process is mediated by the activation of channels 
such as the K+:CL- co-transporter and the potassium intermediate/small 
conductance calcium-activated channel (Gardos channel), in response to 
acidification, deoxygenation, influx of calcium ions, and erythrocyte sickling [16-18].  
Damage to the erythrocyte membrane also results in the release of lipid-
encapsulated micro-particles [19, 20].  HbS polymerization, and the injured sickle 
erythrocytes thereby produced, is the central pathophysiological event in SCD and 
manifests in two important disease processes: vaso-occlusion (and subsequent 







1.4 Vaso-occlusion in SCD 
 
The conformal changes that are caused by intracellular HbS polymerization result in 
erythrocytes that are less deformable than normal cells and this may result in the 
trapping of sickled cells in the microcirculation and consequent vascular 
obstruction.  This process is central to the acute painful crisis which is one of the 
commonest clinical manifestations of SCD.  Painful crises are often triggered by 
inflammatory processes and are the result of complex interactions between 
erythrocytes, leucocytes, plasma proteins, endogenous vaso-active substances and 
the vascular endothelium [21].  They are mediated by adhesion molecules including 
41 integrin, CD36, the Lutheran blood group antigen, and phosphatidylserine [22-
26]. Both sickled and un-sickled erythrocytes  also bind to leucocytes or platelets to 
produce cellular aggregates which substantially increase the likelihood of 
obstruction of the vascular lumen  [21, 27, 28]; the frequency of vaso-occlusive 
events has been shown to increase as the leukocyte count increases [29, 30].  
Leukocytes play a role in SCD vaso-occlusion via interaction with the vascular 
endothelium and by aggregation with each other and with different cell types [21].  
The formation of cellular aggregates by leucocytes, together with increased 
adherence to vascular endothelium is mediated by various adhesion molecules and 
high levels of the leukocyte adhesion molecules M2 integrin and L-selectin have 
been linked to more severe clinical expression of SCD [31].  These interactions are 
increased by inflammation and initiate vascular obstruction in the post capillary 
venules [21, 32-34].  An indirect role for leukocytes in vaso-occlusive episodes in 
25 
 
SCD via activation of the vascular endothelium has also been demonstrated.  
Monocytes activate vascular endothelium via the release of inflammatory cytokines 
including tumour necrosis factor alpha (TNF- ) and interleukin-1 [35].  Activated 
endothelium up-regulates the expression of ligands for leukocyte and erythrocyte 
adhesion molecules including intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) [36, 37].  By these mechanisms the 
adhesion of circulating blood cells is enhanced by monocyte action and the 
propensity for vaso-occlusion increased. Vascular occlusion leads to ischaemia and 
subsequent reperfusion injury when the circulation is restored. Repeated episodes 
of ischaemia and reperfusion result in increased oxidative and inflammatory stress, 
leading to vascular oxidase activation and further endothelial cell-adhesion 
molecule expression and a corresponding increase in inflammatory cytokines which 
may result in leucocytosis [21, 33, 38, 39].  Bone marrow infarction and the 










1.5 Haemolysis in SCD 
 
Abnormal sickle erythrocytes have a reduced lifespan and consequently, individuals 
with SCD suffer from haemolytic anaemia.  The degree of anaemia varies widely 
between SCD genotypes; it is most severe in HbSS disease and mildest in HbSC 
disease and HbS-β+ thalassemia.  Considerable variation is also seen within 
genotypes.  In HbSS disease, red cell survival varies between two and twenty-one 
days and this results in a similarly wide range in clinical markers of haemolysis, such 
as lactate dehydrogenase (LDH), bilirubin level, reticulocyte count and haemoglobin 
concentration [41].     Most haemolytic activity is extravascular and results from 
phagocytosis by reticulo-endothelial cells which are able to recognise damaged 
erythrocytes [42, 43].  Substantial intra-vascular haemolysis, however, can also 
occur and may constitute up to thirty percent of the total erythrocyte turnover [44, 
45]. Sustained extra-vascular haemolysis may result in saturation of Hb-binding 
proteins, predominantly haptoglobin, with a consequent increase in circulating cell-
free haemoglobin.  In addition to chronic anaemia, high haemolytic rates and 
chronically low haemoglobin concentration are associated with a number of 
distinct clinical complications, including cutaneous leg ulcers, cholelithiasis, 
priapism and pulmonary hypertension [46-48].  Furthermore, haemolysis has been 
implicated in the development of progressive vasculopathy, which typically 
features endothelial dysfunction, hypertension and vascular remodelling 
characterised by smooth muscle and intimal proliferation [48-51].  Increased 
severity of haemolytic anaemia has also been associated with the development of 
echo-cardiographically defined pulmonary hypertension in adults [48, 52, 53] and 
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children with SCD [54-56].  Kato et al.,  proposed that individuals with SCD with 
high haemolytic rates and correspondingly low stable haemoglobin concentrations 
constitute a distinct sub-phenotype with an increased likelihood of developing 
vasculopathy, in contrast to those patients with higher steady-state haemoglobin 
concentration and increased blood viscosity who are predisposed to vaso-occlusive 
pathology such as acute pain crisis and acute chest syndrome [46].  The increase in 
cell-free haemoglobin resulting from intravascular haemolysis has important 
consequences for vascular homeostasis.  Cell-free circulating haemoglobin 
generates reactive oxygen species including the hydroxyl and superoxide radical 
[57] – a potent scavenger of nitric oxide [45, 58].  Endothelium-derived nitric oxide 
is a key regulator of basal vasomotor tone, in addition to inhibiting platelet and 
haemostatic activation and transcriptional expression of nuclear factor κB (NF-κB)-
dependent adhesion molecules including ICAM-1 and VCAM-1, as well as the 
selectins [59-62].   By means of scavenging, haemolysis results in the rapid binding 
of NO and the formation of methaemoglobin, thereby inhibiting endothelial nitric 
oxide signalling and resulting in endothelial cell dysfunction and nitric oxide 
resistance [45, 47, 63].  Furthermore, the release of erythrocyte arginase-1 reduces 
plasma arginine levels and thereby decreases the substrate required for synthesis 
of nitric oxide, further reducing nitric oxide bioavailability [64].  Furthermore, 
chronically reduced NO bioavailability may play a role in the hyper-coagulable state 
found in individuals with SCD, as NO has been shown to have a role in the 
suppression of platelet aggregation and pro-coagulant proteins [45, 65-67]. The 
haemolytic rate has been shown to correlate with platelet activation levels and 
plasma pro-coagulant factors [68, 69].      
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1.6 Pulmonary complications of SCD 
 
The respiratory system is particularly vulnerable to the pathophysiological 
processes active in SCD. Pulmonary pathology is commonly found in cases of 
sudden death in SCD patients.  One study reported that over 70% of patients who 
died suddenly during an admission for SCD exhibited pulmonary pathology on post-
mortem. In the patients with pulmonary pathology, evidence of pulmonary 
thromboembolism was found in 47%, pulmonary oedema in 41%, fat emboli in 
33%, right ventricular hypertrophy in 33%, grades I – IV pulmonary arterial 
hypertension in 33% and microvascular thrombi in 29% of subjects [70].  Pulmonary 
manifestations of SCD, in particular the acute chest syndrome (ACS), and sickle 












1.6.1 Sickle chronic lung disease 
 
Adults with sickle cell disease can suffer from parenchymal lung disease, pulmonary 
vascular disease, or both.  This spectrum of abnormalities is commonly referred to 
as ‘sickle chronic lung disease’ (SCLD).  In some cases, these processes may 
progress to restrictive lung disease, and/or pulmonary hypertension.  There is no 
curative treatment for SCLD, but ACS is the most significant risk factor. 
Restrictive lung disease/pulmonary fibrosis 
 
An early case series of chest radiographs from twenty-six patients with SCD of 
mixed genotype described scattered areas of lung fibrosis [71] in conjunction with 
segmental infarction in more than one-third of cases; these abnormalities were 
more pronounced in patients who had suffered repeat episodes of ACS and were 
associated with an increased risk of early death [71].    More recently, high-
resolution computed tomography (HRCT) has been used to evaluate parenchymal 
abnormalities in adults with SCD.  One study showed that approximately forty 
percent of patients had evidence of interstitial disease on HRCT, however, no 
significant relationships between pulmonary function test results and HRCT 
abnormalities were observed [72].  The interval between pulmonary function 
testing and HRCT examination, however, was large, ranging from one month to 
more than one year.   A more recent study from our research group in which the 
lung function assessments and HRCT were conducted contemporaneously, 
demonstrated that the majority of a cohort of adult patients with SCD had 
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pulmonary vascular or parenchymal abnormalities on high-resolution CT (HRCT) 
[73] and the HRCT findings were significantly correlated with pulmonary function 
testing results. Of particular note, there were correlations between reductions in 
forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) and a 
qualitative scoring of prominence of the central vessels on HRCT. Prominent central 
vessels were found on HRCT in eight of the nine patients with restrictive 
abnormalities. The authors speculated that the prominent central vessels might 
reflect changes related to pulmonary hypertension suggesting a possible vascular 




In recent years, pulmonary arterial hypertension has emerged as a cause of 
morbidity and mortality in adults with SCD [48, 74, 75].  Chronic haemolysis may 
lead to reduced nitric oxide bioavailability and it has, therefore, been hypothesised 
that depletion of this important vasodilator in the pulmonary vascular bed leads to 
an increase in pulmonary vascular resistance and a consequent increase in 
pulmonary artery pressure, with deleterious long term effects [48].  Subsequent 
work has, however, called this hypothesis into question.  The initial large screening 
study by Gladwin et al [48]  used an elevated tricuspid regurgitant jet velocity (TRV) 
derived from echocardiography as a surrogate marker for an abnormally high 
pulmonary artery pressure (a TRV of ≥ 2.5 m/s was deemed to be abnormal) and 
observed that more than thirty percent of patients with SCD in their unselected 
cohort may have had pulmonary arterial hypertension. They also found that this 
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was linked to an increased likelihood of premature death [48].  This study was 
followed by others which also found a comparable prevalence of elevated TRV [52, 
53, 76].  More recent studies have used right-heart catheterisation to directly 
measure pulmonary arterial pressures and pulmonary vascular resistance in adults 
with SCD and elevated TRV and have reported a much lower prevalence of 
pulmonary hypertension [75, 77].  In a large study (n = 398), Parent et al reported 
that only six percent of SCD patients had pulmonary hypertension and that in over 
fifty percent of patients, this was pulmonary venous, rather than pulmonary 
arterial hypertension. It is at present not known if the increased mortality observed 
in SCD patients with elevated TRV in the large screening studies [48, 52, 53, 76] is 












1.6.2 The Acute Chest Syndrome 
 
ACS, defined as radiological evidence of new pulmonary infiltrates consistent with 
consolidation together with fever, chest pain, tachypnoea, cough, or wheezing [40, 
78, 79], is an acute lung injury syndrome that is common in patients with SCD.  ACS 
is a major source of morbidity and is the second most common cause of hospital 
admission [40, 80] and the leading cause of premature death [30, 78, 81-83].  The 
results of one study suggested that the mortality may be related to acute increases 
in pulmonary artery pressure in patients with underlying pulmonary hypertension 
and cor-pulmonale, and that ACS acts as a stressor rather than the primary cause of 
death [84].  The Cooperative Study of Sickle Cell disease reported a twenty-nine 
percent incidence of ACS over a two-year period in a large cohort of subjects with 
HbSS disease [82].    
ACS often occurs in hospitalised adult patients with SCD, with an incidence of 
between ten and twenty percent, where it is usually preceded by an acute vaso-
occlusive pain crisis [78, 85].  An increased risk of ACS is associated with younger 
age, higher steady-state haemoglobin concentration, elevated steady-state 
leucocyte count, lower HbF concentration [86], a history of smoking or smoke 
exposure [87] and in children, a diagnosis of asthma [83, 86, 88-92].  ACS tends to 
be more severe in HbSS disease compared to other genotypes [88, 93-95].  The 







In both adults and children, pulmonary infection is implicated in many cases of ACS.  
In a large cohort of patients in the USA (n = 538), an infectious pathogen was 
isolated in 54% of admissions for ACS from a total of 671 episodes [78]. These were 
predominantly atypical bacteria and viruses; community acquired encapsulated 
bacteria were only found in a minority of cases (< 10% of ACS episodes).   A total of 
twenty-seven different pathogens were identified of which C. pneumoniae was the 
most frequent (isolated in 71 episodes), followed by M. pneumoniae (isolated in 51 
episodes) and respiratory syncytial virus (isolated in 26 episodes). Parvovirus was 
identified in ten cases and was associated with severe reticulocytopenia [78].  
Compared to patients who were infected with mycoplasma strains, patients with 
chlamydia infections were significantly more likely to suffer a vaso-occlusive event 
during their hospital stay, and had higher mean haemoglobin levels [78].   Seasonal 
influenza infection has also been linked to ACS [96-99].  Furthermore, more than 
eighty percent of adult patients with SCD report a history of hospital admission due 
to “pneumonia” and necessitating treatment with intravenous antibiotics [48].  
Infection may precipitate ACS due to an enhanced susceptibility to inflammatory 
provocation.  In studies of transgenic mice expressing human HbS, SCD mice 
exhibited a heightened susceptibility to inflammatory provocation by 
lipopolysaccharide and bacterial endotoxin, resulting in lung injury at levels of 





Fat emboli and ACS 
 
Fat emboli may play a significant role in the pathogenesis of ACS.  Severe vaso-
occlusive pain crises, typically involving the proximal skeleton, result in bone 
marrow infarction and oedema and eventually to necrosis and the release of fatty 
contents into the bloodstream.   These contents then travel to the pulmonary 
vasculature where they trigger severe lung inflammation, acute pulmonary 
hypertension and hypoxaemia by means of direct mechanical occlusion and 
inflammation [102-105].  Fat-laden alveolar macrophages obtained during 
bronchoscopy are diagnostic of pulmonary fat embolism.  In the national ACS study 
cohort, fat embolism was diagnosed in sixteen percent of ACS cases in adults and 
children [78] by bronchoscopy.  Another study found that patients with ACS in 
whom lipid-laden macrophages were identified in induced sputum followed a more 
severe clinical course, with more severe extra-thoracic pain and a greater incidence 
of neurological symptoms compared to patients without evidence of fat embolus 
[104].  
 
Intrapulmonary red cell sequestration/thrombosis  
 
The adhesion and trapping of sickled erythrocytes is central to the pathophysiology 
of SCD.  The pulmonary vascular bed may be especially vulnerable to this process, 
as the pulmonary circulation is subject to vaso-constriction under hypoxic 
conditions.  This process is, however, difficult to demonstrate and the prevalence, 
severity and relative importance of this mechanism is unknown.  In a study of 125  
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patients with SCD during 144 ACS episodes, Mekontso et al found sub-segmental 
thromboembolism in seventeen percent of cases, with no evidence of peripheral 
thrombosis and concluded that the pulmonary emboli were due to in-situ cellular 
occlusion and thrombosis and that these mechanisms may therefore be more 
important than previously appreciated [84]. 
 
Alveolar hypoventilation  
 
Episodes of ACS are frequently temporally related to infarcts of the ribcage [106].  
This has led to the suggestion that, due to subsequent restriction of chest wall 
motion and alterations in breathing pattern due to the pain and discomfort, 
atelectasis and hypoventilation occur which contribute to the development ACS 
[107, 108].  A study of breathing patterns adopted by SCD patients with both 
thoracic and non-thoracic pain found  that a pattern of rapid shallow breathing is a 
feature of patients with thoracic bone pain [109].  Radiological studies have also 
highlighted an association between rib-infarction and radiographic changes of ACS 
[106, 108, 110].   In SCD children admitted to hospital with acute back and/or chest 
pain, incentive spirometry has been used to improve ventilation and to significantly 
reduce the incidence of acute pulmonary complications during the period of 
admission [111].  The use of opiates for analgesia during painful crisis has also been 







Asthma has been linked to an increased risk of ACS in children with SCD.  In a 
retrospective review of 139 children with SCD, Boyd et al found that children with 
SCD and asthma had four times as many ACS episodes as non-asthmatics (95% CI, 
1.7 - 9.5) together with an increased length of hospitalisation per episode (p = 0.01) 
[113].  Nordness et al also found, in a retrospective study of ninety-six children with 
SCD, that those with asthma had a significantly greater frequency of ACS episodes 
than those without (p = 0.03) [91]. Asthma is also associated with recurrent ACS 
episodes. In a study of eighty children with SCD, Knight-Madden et al found that 
asthma (80% v 40%, p = 0.005) and particularly atopic asthma (53% v 12%, 
p<0.001), were more common in children with SCD who had suffered recurrent 
episodes of ACS than in those who had suffered a single or no episode [88].  In a 
subsequent prospective study, Boyd et al found that children with SCD and asthma 
suffered twice as many ACS episodes as those without asthma (0.39 vs. 0.2 
episodes per patient-year, p < 0.001) and that the children with asthma developed 
their first ACS episode at a significantly younger age (2.4 vs. 4.6 years, p = 0.010) 
[86].  Those results were consistent with a study by Sylvester et al of 165 children 
with SCD which found that a greater number of the children who had an ACS (n=83) 
compared to those who had not were taking anti-asthma medication (p = 0.02). 
Importantly, the children with a history of ACS had been diagnosed as asthmatic at 
a median of 3.5 (range 0.5-7) years prior to their first ACS episode, suggesting that 
asthma may predispose children with SCD to subsequent ACS episodes [83].  Those 
results were similar to those obtained in a later retrospective analysis of 297 
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children with ACS which found that SCD children with a diagnosis of asthma had an 
increased rate of ACS (0.31 events per patient-year vs. 0.16 events per patient-
year,  p = 0.002) compared to those who did not [93].  
Doubt has, however, been cast on the attribution of wheezing symptoms in 
children with SCD to asthma.  Asthma is characterised by variable airflow 
obstruction and bronchial hyper-reactivity resulting from chronic inflammation 
[114].  Although a diagnosis is made more reliable by evidence of reversible airflow 
obstruction on pulmonary function testing, laboratory markers of atopy or 
inflammation, and/or a family history of atopic or allergic disease, in practice the 
diagnosis is often made on the basis of the clinical presentation alone [115].  In the 
majority of the studies of asthma in SCD described above, the diagnosis was made 
by medical records review [86, 91, 113] or current use of anti-asthma medication 
[83, 86].  The study by Knight-Madden et al did, however, provide supporting 
evidence for a diagnosis of asthma by performing skin-prick testing for atopy [88].  
Interestingly, whilst a diagnosis of asthma was significantly more common in the 
SCD children compared to controls (48% vs. 22%, p = 0.002), there was no 
significant difference in the prevalence of atopy between the SCD and control 
groups.  In asthmatic populations, atopy is in general significantly more common 
compared to healthy subjects [116, 117].   
There is evidence to suggest that wheezing in SCD may be due to disease processes 
other than asthma.  In a study of 187 patients, physician diagnosed asthma was 
associated with a personal and family history of atopy, but  many of the SCD 
patients had recurrent wheezing  and had not been diagnosed with asthma [118].  
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Furthermore, wheezing symptoms were associated with an increased risk of ACS, 
irrespective of a diagnosis of asthma [118].  In another study of 262 patients with 
SCD attending emergency departments, nineteen percent had one or more 
episodes of physician-documented wheeze and fifty-three percent did not have a 
diagnosis of asthma [119].  The patients with wheeze had a greater number of 
attendances for painful crisis and ACS, but those with asthma had a greater number 
of attendances for painful crisis only.  Those data suggest that asthma may be 
substantially underdiagnosed in children with SCD or that sickle-related wheezing 
and asthma may be two distinct disease entities with different pathophysiological 
bases. 
Measurement of exhaled nitric oxide (feNO), which reflects airway NO production 
and is  a marker for eosinophilic airways inflammation, might help to further 
elucidate whether asthma is increased in SCD children as FeNO  is often elevated in 
patients with asthma  [120]. Data on feNO levels in SCD are, however,  sparse.  The 
only published measurements are by Girgis et al, who found that adults with SCD 
had a significantly lower feNO than healthy control subjects [121], but the control 
group was not matched for race which hampers interpretation of the results.   
Exhaled NO (eNO) has been shown to be elevated in patients with atrial septal 
defects, a condition which is associated with a hyper-dynamic pulmonary 
circulation and eNO correlated with increased pulmonary blood flow [122]. Since 
children and adults with SCD often have a hyper-dynamic circulation due to the 
raised cardiac output resulting from chronic anaemia [123] any investigation into 
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feNO in SCD must consider the potential impact of elevated pulmonary blood flow 
on feNO measurements.  This was one of the aims of this thesis.  
The haemodynamic changes associated with chronic anaemia, characterised by an 
increased cardiac output and dilation of the pulmonary vasculature, may also 
provide an alternative explanation for airflow obstruction and wheeze in SCD.  
Inflation of the leg compartments of pneumatic trousers increases thoracic blood 
volume and has been shown in healthy volunteers to increase respiratory 
resistance [124]. In addition, in patients with impaired left ventricular function,  
acute intravascular volume expansion by means of fluid loading impairs alveolar-
capillary membrane function and increases airflow obstruction [125], an effect 
which has also been observed in healthy subjects [126, 127].  Those results suggest 
that the airflow obstruction was mediated, at least in part, by dilation of the 
pulmonary vessels [128].  Children and adults with SCD have an increased 
pulmonary vascular blood volume which is a response to their chronic anemia 
resulting in a raised cardiac output and increased vascular recruitment and 
distension [123, 129, 130], but the possible effect of this on lung function has not 
been investigated. Therefore, an aim of this thesis was to assess the effects of 
pulmonary vascular changes related to a hyperdynamic circulation on lung function 
in adults and children with SCD. This would provide insights into the mechanisms 
underlying the lung function abnormalities observed in SCD patients and hence aid 





1.7 Lung function abnormalities in SCD  
 





The first measurements of pulmonary function in patients with SCD were made in a 
cohort comprising six adults with SCD of mixed genotypes and thirty healthy 
control subjects. Total lung capacity (TLC) and vital capacity (VC) were found to be 
reduced in the SCD group compared to the controls, suggesting a restrictive defect 
[129].  The transfer factor for carbon monoxide (DLCO) was elevated in the SCD 
group when corrected for reduced haemoglobin, due to an increased pulmonary 
capillary blood volume  [131].  Similar results were subsequently described by 
Miller et al in a  study of 25 patients with HbSS disease [132].   
In a more recent study by Santoli et al in a cohort of 49 patients with SCD 
comprising forty-two subjects with HbSS, four with HbSC, and three with HbSβ-
thalassemia disease [133],  lung function results were classified as normal, 
restrictive (TLC < 80% predicted), obstructive (ratio of forced expiratory volume in 
one second (FEV1) to forced vital capacity (VC): (FEV1: VC) < 80% predicted) or 
mixed (both TLC and FEV1: VC < 80% predicted).  A restrictive pattern was the most 
common finding, observed in twenty (41%) of the patients, whilst eight patients 
(17%) were obstructive were and  ten (20%) had a mixed obstructive/restrictive 
defect [133].  The prevalence of obstructive and restrictive defects did not differ in 
those patients with a history of ACS compared to those without, although the ACS 
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group had a higher DLCO and DLCO per unit lung volume (KCO) when corrected for 
haemoglobin level.  Interestingly, the respiratory system resistance (Rrs) measured 
by the forced oscillation technique (FOT) was  higher in patients with a history of 
ACS, leading the authors to speculate that the increase in Rrs was related to an 
increase in pulmonary blood volume [133].  
In the largest study of lung function in SCD to date, Klings et al examined lung 
function test results performed as part of the cooperative study of sickle cell 
disease from three-hundred and ten adults with HbSS disease [134].  Lung function 
defects were classified as restrictive, obstructive, mixed obstructive/restrictive, or 
‘isolated low DLCO’ according to an American Thoracic Society position statement 
[135].   Whilst the definition of a restrictive defect was comparable to the criteria 
used in the study of Santoli et al, in order to be classified as obstructive or mixed 
the DLCO had to be normal, which precluded the possibility that impaired gas 
transfer coexisted with airway abnormalities.  As a result, the prevalence of 
obstructive disease may have been underestimated.  Nevertheless, that study 
found a high incidence of restrictive defects (74%).  Thirteen patients had an 
isolated reduction in DLCO, but only four percent were deemed to have an 
obstructive defect, lower than that found by Santoli et al [133].  Furthermore, no 
significant difference was observed in those patients with a history of ACS 
compared to those without, although there was a trend towards a more restrictive 
pattern (TLC = 69.2%predicted versus 72.8%predicted, p=0.06) in the ACS group 
[134]. On multiple linear regression, a significant association was found between 
reduced DLCO and thrombocytosis, hepatic dysfunction (as assessed by elevated 
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alanine aminotransferase), and renal dysfunction (as assessed by elevated blood 
urea nitrogen and creatinine) leading the authors to conclude that gas exchange 
dysfunction was likely to be the result of more severe sickle vasculopathy 
characterised by impaired renal and hepatic function.  Sylvester et al classified lung 
function test results from thirty-three patients with HbSS disease as either normal, 
restrictive, obstructive, or mixed obstructive/restrictive using diagnostic criteria 
comparable to those used by Santoli et al. Nine patients (27%) had a restrictive 
lung function abnormality, five (15%) an obstructive abnormality and four (12%) a 
mixed restrictive/obstructive abnormality.   
All of those studies used fixed percentage cut-offs to define lung function 
abnormalities.  Current American Thoracic Society/European Thoracic Society 
guidelines recommend that abnormalities are classified according to the lower limit 
of normal (LNN) based on percentiles [136], as fixed cut-offs do not take into 
account the fact that that the limits of the normal range for all lung function indices 
vary with age, sex and ethnicity.  This may have resulted in some misdiagnosis and 
may explain some of the variability in the reported prevalence of obstructive and 
restrictive defects.  A subsidiary aim of this thesis, therefore, was to characterize 
the nature and prevalence of lung function defects in SCD using classification 








In a study of 37 children with SCD of mean age thirteen (six – eighteen) years 
(comprising twenty with HbSS, fourteen with HbSC, and three with HbS-β 
thalassemia disease) and twenty-two control subjects matched for sex, race, and 
height, Pianosi et al observed a reduction in FEV1 (88%predicted versus 
105%predicted, p < 0.0001), VC (89%predicted versus 106%predicted, p < 0.001), 
and TLC (90%predicted versus 100%predicted, p < 0.05) in the SCD group compared 
to the controls [137].  No significant differences were observed between the SCD 
and control groups for FEV1:VC or RV:TLC, suggesting a primarily restrictive 
abnormality.   
A later study by Sylvester et al compared sixty-four children with HbSS disease, of 
mean age ten (five to sixteen) years, with sixty-four age, sex, and race-matched 
controls; the SCD children had a significant reduction in FEV1 (1.5L versus 1.9L, p = 
0.0008), VC (1.7L versus 2.1L, p = 0.001), and FRC measured by helium dilution (1.2L 
versus 1.3L, p = 0.04).  Furthermore, the effect of age differed significantly for TLC 
(p = 0.03), VC (p = 0.03), and FRC (p = 0.01) in the SCD group, for whom these 
measurements increased more slowly with advancing age compared to the control 
subjects. These findings are consistent with restrictive abnormalities becoming 
more prominent with increasing age [138]. Those results contrast with the findings 
of three other studies.  In a retrospective study of twenty infants with SCD of mean 
age fifteen (three to thirty) months (comprising twelve infants (60%) with HbSS, 
five (25%) with HbSC, and three (15%) with HbSβ-thalassemia disease), 
Koumbourlis et al found that patients in the group with HbSS disease and the group 
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comprising the mixed milder genotypes had high-normal or elevated FRC (112% 
and 129%predicted) and reduced maximum expiratory flow at FRC (V’max,FRC) 
(49.8%predicted and 55.7%predicted), suggesting hyperinflation and airflow 
obstruction [139].  In the HbSS group Rrs measured by infant body plethysmography 
was also elevated (145.3%predicted).  Interpretation of these results, however, is 
limited as no control subjects were tested.  The number of individual patients with 
an FRC above and/or a V’max,FRC below the limit of normal was not reported, 
although the authors did state that only three patients (all in the HbSS group) had 
an FRC below the lower limit of normal, suggesting that restrictive defects were 
relatively uncommon at this age.  Comparing the two groups, the authors found 
that FRC and V’max,FRC were lower in the HbSS group (p < 0.004 in both cases). Later, 
Koumbourlis et al carried out a retrospective study of sixty-three children with SCD 
of mean age eleven (five to eighteen) years.  Lung function results were classified 
as normal, restrictive (TLC < LLN and normal FEV1:VC), or obstructive (FEV1: VC < 
LLN, and/or the forced expiratory flow between 25% and 75% of vital capacity 
exhaled (FEF25-75) < LLN with a normal VC) [140].   Spirometry was performed 
before and after administration of a bronchodilator: a positive response was 
defined as an increase in FEV1 or FVC > 10% or in FEF25-75 > 20% from baseline.  
Twenty-two patients (34%) had an obstructive and five (8%) a restrictive pattern, 
and twenty-two (34%) had a significant response to bronchodilator (14 of whom 
were obstructive, two restrictive, and six normal at baseline). Subsequently, Tassel 
et al retrospectively analysed lung function test results for 184 children with SCD of 
mean age thirteen (4.8 to 20.0) years from the Creteil SCA Cohort [141] (comprising 
159 with HbSS, 17 with HbSC, and eight with HbS-β thalassemia disease) [142].  
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Lung function results were classified as normal, restrictive (TLC < 80% predicted), or 
obstructive (FEV1: VC < LLN); a mixed category was not defined.  Whilst the 
definition of obstruction was based on the LLN as recommended by ATS/ERS 
guidelines [136], the criterion for restriction was based on a fixed percentage-
predicted cut-off. Twenty patients (13%) had a restrictive and nine (5%) an 
obstructive pattern [138]. Spirometry was also repeated after administration of a 
bronchodilator: a positive response was defined as an increase in FEV1 > 12% with 
an absolute increase of > 200mls from baseline; a positive response was observed 
in nine patients (4.9%), two of whom were in the obstructive group.  On multiple 
linear regression, older age and increased leukocyte count were both associated 
with lower FEV1 (p = 0.0008, p = 0.0003), VC (p = 0.042, p < 0.0001), and TLC (p = 
0.001, p = 0.001) respectively i.e. restrictive. The incidence of ACS was not 
recorded.  
The impact of ACS on lung function in children was assessed by Sylvester et al in a 
cohort of forty children aged six to sixteen years with HbSS disease, twenty of 
whom had experienced at least one episode of ACS prior to lung function testing 
[89].  Children with a history of ACS had a significantly higher RV (113%predicted 
versus 97%predicted, p = 0.003) and total airways resistance measured by body 
plethysmography (265%predicted versus 194%predicted, p = 0.03) and lower 
FEV1:VC (95%predicted versus 100%predicted, p =0.04) compared to the non-ACS 
group, demonstrating an association between ACS and airflow obstruction [89]. 
Due to the cross-sectional study design, it was not possible to determine if the 
obstructive abnormalities described preceded or were a consequence of ACS 
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episodes.  The results of that study highlight a need for a longitudinal study to 
assess the effect of ACS on the decline of lung function in children with SCD and to 
determine whether obstructive abnormalities precede ACS episodes.  
 
 
1.7.2 Longitudinal studies 
 
Longitudinal data for pulmonary function in SCD are sparse.   Field et al report the 
only longitudinal study in adults with SCD (aged twenty to sixty years) in a 
retrospective analysis of lung function test results from the European 
Haemoglobinopathy Registry [143].  At the final visit, spirometry data were 
available in ninety-four and static lung volumes in eighty-five patients.  Results 
were classified as normal, restrictive (TLC < LLN), or obstructive (FEV1:VC < LLN) as 
per current ATS/ERS guidelines [136]; a mixed category was not included.  A 
restrictive defect was the most common abnormality (35.7%), although patients 
with obstructive defects were observed (18.5%). Longitudinal analysis was 
performed for FEV1 only, using generalised estimating equations to model the 
trajectory of FEV1 against age. Raw values, rather the percent predicted, were used 
for the longitudinal analysis which may have introduced error as normal age-
related changes in lung volume would not be taken into account. Subjects included 
in the longitudinal analysis had between two and four repeated measures over a 
mean period of thirteen years, but the interval between tests was not reported 
[143].  FEV1 declined significantly (p < 0.05) over time at an average rate of 49mls 
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per year and the authors observed that this was faster than the 20-26ml decline 
expected in healthy subjects [144].  No association was found between increased 
rate of pain and a subsequent restrictive (p = 0.97), or obstructive defect (p = 0.09); 
there was also no association between the occurrence of ACS and the subsequent 
development of restrictive (p =0.28) or obstructive (p =0.67) defects.  Furthermore, 
no association was found between the rate of decline in FEV1 and SCD genotype, 
hereditary persistence of HbF, or smoking history.  The effect of ACS on the rate of 
decline in FEV1 was not reported. 
Two longitudinal studies in children have been reported. In a retrospective analysis, 
Koumbourlis et al assessed lung function in a cohort of forty-five children with 
HbSS disease aged 5.4 to 18 years [145]; spirometry and static lung volumes were 
measured on two occasions with a median time to follow-up of 3.5 years. Lung 
function results were classified as normal, restrictive (TLC < LLN and normal 
FEV1:VC), or obstructive (FEV1: VC < LLN, and/or the forced expiratory flow between 
25% and 75% of vital capacity exhaled (FEF25-75) < LLN with a normal VC) [140]. At 
baseline, ten patients (22%) had an obstructive and ten (22%) a restrictive defect. 
At follow-up, the number of patients with an obstructive defect had increased to 
twenty (44%), and the number with a restrictive pattern to 12 (27%).  A significant 
decline was observed in FEV1 (87%predicted to 80%predicted, p < 0.001), VC (84% 
to 82%, p < 0.05), FEV1: VC (89% to 85%, p < 0.001), and FEF25-75(89% to 76%, p < 
0.001).  No change was seen in TLC, RV, or RV:TLC (p > 0.05).    The impact of ACS 
was not assessed.  Those results led the authors to conclude that lung function 
defects in children with SCD are primarily obstructive and those defects increase in 
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prevalence and severity over time [145].   A potential flaw in the analysis 
performed by Koumbourlis et al was to attribute longitudinal decline in FEF25-75 to 
increasing airflow obstruction, as this is only valid where the VC does not also 
change [146, 147].   In a larger retrospective study, MacLean et al, analysed 
spirometry and static lung volumes from a very large cohort (n = 294) of children 
aged between eight and eighteen years (comprising 112 (38.1%) with HbSS, 49 with 
HbSC (16.7%), 15 with HbS-beta thalassemia disease (4.8%), one with genotype 
specified as ‘other’ (0.3%), and 117 (39.8%) in whom genotype data were not 
available) [148].  All patients included in the final analysis were tested annually on 
at least two occasions, but the exact data on the number of tests and the time to 
follow-up were not reported.  Lung function results were classified as normal, 
restrictive (TLC < 70%predicted), or obstructive (FEV1:VC < 80% absolute); a mixed 
category was not defined.  At eight years of age, 2.6% of patients had a restrictive 
and 0.9%, an obstructive pattern.  At seventeen years of age, the prevalence of 
restrictive defects had increased to 18.7%, and obstructive defects were no longer 
present.  Linear mixed effect modelling (LMM) was used to model the trajectories 
of lung function indices with increasing age [148].  Results were stratified by sex 
and a significant decline was observed in FEV1 (2.15%/year for males, p < 0.0001; 
2.95%/year for females, p < 0.01), VC (2.64%/year for males, p < 0.0001; 
2.36%/year for females, p < 0.0001), FEF25-75 (3.42%/year for males, p < 0.0001; 
4.10%/year for females, p < 0.0001), and TLC (2.15%/year for males, p < 0.0001; 
2.43%/year for females, p < 0.0001).  No significant change was seen in FEV1:VC 
ratio for either sex (p > 0.05).  HbSS genotype was associated with a faster decline 
in FEV1, VC, FEF25-75, and TLC compared with HbSC and with a greater likelihood of 
49 
 
developing a restrictive defect (likelihood ratio 9.19, p =0.0002).  Lower Hb was 
significantly associated with a lower FEF25-75 at time of testing (β=0.0031, p =0.05).   
The effect of ACS was not investigated. The authors therefore concluded, in 
contrast to the study by Koumbourlis et al [145], that lung function in children with 
SCD is characterised by a progressive decline towards a predominantly restrictive 
defect.   MacLean et al found also a much lower prevalence of lung function defects 
at baseline and follow-up than Koumbourlis et al (3.5% versus 44% with obstructive 
or restrictive defects at baseline and 18.7% versus 71% at follow-up).  This was 
particularly pronounced for obstructive defects (22% versus 0.9% at baseline and 
44% versus 0% at follow-up). This may in part be because MacLean et al used fixed 
percentage-predicted cut-offs to define lung function abnormalities.  Current 
American Thoracic Society/European Thoracic Society guidelines recommend that 
abnormalities are classified according to the lower limit of normal LNN based on 
percentiles [136], as fixed cut-offs do not take into account the fact that that the 
limits of the normal range for all lung function indices vary with age, sex and 
ethnicity.  Furthermore, it is not clear from the paper by MacLean et al whether the 
prevalence of lung function defects was assessed for each patient individually, or 
predicted from the LMMs derived for TLC and FEV1:VC. A limitation of the studies 
[145, 148] is the lack of an appropriate control group; thus it is not possible to 
determine whether the decline in lung function reported was only seen in SCD 
patients and hence the magnitude of the effect of SCD.  Hence, an aim of this thesis 
was to examine the rate of decline in lung function in children with SCD in 
comparison to age and ethnic matched controls and to determine the effect of ACS 
on any longitudinal change observed. 
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2. SUMMARY  
 
Sickle cell disease (SCD) is one of the commonest inherited disorders worldwide, 
affecting an estimated 300 000 new-borns every year. In adulthood, SCD can be 
associated with multiorgan damage, including pulmonary complications. Acute 
chest syndrome and sickle chronic lung disease are important sources of morbidity 
and mortality in children and adults with SCD, and lung function abnormalities are 
common, even in young children.  Acute chest syndrome is associated with poorer 
lung function and is the most important risk factor for SCLD, for which treatment is 
only supportive.  Asthma and wheezing are associated with an increased risk of 
acute chest syndrome in children with SCD.  The obstructive lung function defects 
commonly seen in children are often attributed to asthma, but studies have 
suggested a possible pulmonary vascular origin for airflow obstruction in SCD. 
Restrictive lung function abnormalities appear to become more prominent with 
increasing age, but prospective longitudinal studies with appropriate control 











 Airway obstruction in SCD may be additionally explained by pulmonary 
vascular abnormalities resulting from a hyper-dynamic circulation. 
 
 Lung function in SCD children would decline relative to controls particularly 




To determine if: 
 Lung function abnormalities in adults with SCD were related to pulmonary 
vascular changes reflecting increased pulmonary vascular volume.  
 
 Increased pulmonary capillary blood volume was related to the airways 
obstruction seen in SCD children. 
 
 Blood transfusion in SCD children would acutely increase pulmonary 
capillary blood volume resulting in an increase in airflow obstruction. 
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 Airway and alveolar nitric oxide production would differ between SCD 
children and controls and alveolar/airway NO production was related to a 
hyper-dynamic pulmonary circulation and/or airways obstruction.  
Also to: 
 To describe the longitudinal changes in lung function in SCD and to assess 






















2.3 Methods protocols 
 
2.3.1 Study 1: Pulmonary function, CT and echocardiographic abnormalities in 
sickle cell disease 
 
Patients with HbSS disease were assessed using pulmonary function tests 
(spirometry, body plethysmography, transfer factor for carbon monoxide, and 
impulse oscillometry) together with quantitative high resolution CT-angiography 
and echocardiography.  Lung function abnormalities were documented and the 
relationship between these abnormalities and interstitial and pulmonary vascular 
morphological changes was investigated. A subgroup of this cohort had been 
assessed approximately seven years earlier, and these data were used to 
investigate longitudinal changes in lung function and to relate these changes to the 
progression of pulmonary interstitial and vascular disease. 
 
2.3.2 Study 2: Pulmonary capillary blood volume and lung function in children 
with SCD 
 
Children with HbSS disease, together with age and race-matched healthy control 
children were assessed using pulmonary function tests (spirometry, body 
plethysmography, transfer factor for carbon monoxide, and impulse oscillometry).  
Pulmonary capillary blood volume was measured using the DLNO-DLCO method, 
and the relationship between lung function and pulmonary capillary blood volume 
was assessed.  A subgroup of the SCD and control children were assessed before 
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and after administration of a bronchodilator drug to test for reversible airflow 
obstruction.  
 
2.3.3 Study 3: The acute effects of transfusion on pulmonary capillary blood 
volume and lung function in children with SCD 
 
Children with HbSS disease who were being treated with regular blood transfusions 
were assessed using pulmonary function tests (spirometry, body plethysmography, 
transfer factor for carbon monoxide, and impulse oscillometry) and measurement 
of pulmonary capillary blood volume using the DLNO-DLCO method. Spirometry, 
transfer factor for carbon monoxide, impulse oscillometry and pulmonary capillary 
blood volume measurements were repeated immediately following blood 
transfusion and the acute effects of fluid loading were assessed.  
 
2.3.4 Study 4: Exhaled nitric oxide, lung function, and pulmonary blood flow in 
children with sickle cell disease 
 
Lung function (spirometry, static lung volumes using whole body plethysmography 
and gas transfer for carbon monoxide), exhaled nitric oxide (using multiple 
exhalation flows), alveolar NO production and effective pulmonary blood flow 
(using an inert gas rebreathing method) were measured in eighteen children with 
HbSS disease and eighteen healthy age and race-matched controls and the 
relationships between airway and alveolar nitric oxide production and pulmonary 
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blood flow and indices of airflow obstruction (FEV1:VC and respiratory system 
resistance) were assessed.  
 
2.3.5 Study 5: Longitudinal assessment of lung function in children with sickle 
cell disease 
 
A prospective longitudinal study was undertaken to examine the rate of decline in 
lung function, as assessed by spirometry and body plethysmography, in children 
with HbSS disease in comparison to age and ethnic matched controls.  Two cohorts 
were studied.  Cohort one were younger children who were followed for 
approximately two years, that is at an age when ACS episodes are more common.  
Cohort two were older and followed for approximately ten years.  The impact of 













The following techniques were used in all studies: 
 
1. Informed consent. 
Written informed consent was obtained from all participants, in the case of 
adult subjects, or from the participants’ parent(s) or legal guardian(s) in the 
case of children.  Potential participants were contacted by post initially, and 
after a period of at least two weeks had elapsed, were then approached by 
the research fellow (A. Lunt), whilst attending their regular clinic 
appointment at King’s College Hospital, London.  Potential participants were 
given an opportunity to ask questions, and if they were interested in taking 
part, a provisional appointment to attend the Chest Unit for testing was 
booked.  Participants were telephoned one week before their appointment 
to confirm they still interested in attending and given a further opportunity 
to ask any questions.  Written consent was obtained at the beginning of the 
appointment. For children, an age appropriate description of the testing 
procedure was given, as well as an opportunity to see the equipment used, 
and to ask questions. Paediatric studies were only conducted with the full  
support of the child themselves. The studies were approved by the King’s 
College Hospital Research Ethics Committee under approval numbers LREC 




3. Measurement of respiratory system resistance by forced oscillation. 
4. Measurement of dynamic lung volumes and forced expiratory flows by 
spirometry. 
5.  Measurement of static lung volumes by body plethysmography. 
6. Assessment of gas exchange function and estimation of pulmonary capillary 
blood volume by measurement of the transfer factor for carbon monoxide 
and nitric oxide.  

















Standing height was measured using a wall-mounted Harpenden stadiometer 
(Holtain Ltd, Dyfed, UK), with a resolution of 0.1cm.  The subject was asked to 
remove any footwear and stand with the back and buttocks against the back-plate 
of the stadiometer.  The feet were positioned such that the heels were in contact 
with the stadiometer heel plate and the palms were directed medially.  The subject 
was asked to relax the shoulders whilst the head was placed in the Frankfurt plane, 
such that the inferior margin of the left orbit and the upper margin of the left 
external auditory meatus was horizontal [149, 150]. When correctly positioned the 
carriage was lowered until resting on the top of the subject’s head.   A small weight 
was applied to the carriage for stability and the height read from the counter.  
Weight was measured using a set of electronic scales (Seca, Hamburg, GmbH).  The 
subject was asked to remove footwear and any extraneous clothing.  After stepping 
onto the scales the subject was asked to remain still for the duration of the 
measurement and the weight recorded to the nearest 0.05kg. 
Stadiometer accuracy 
 
The accuracy of the stadiometer was assessed by measurement of three certified 
calibration rods of length 100, 200, and 250 centimetres respectively (figure 3.1, 
table 3.1).    In each case the error was 0.1% or less and the instrument was linear 




Figure 3-1  Measured height versus rod height for Harpenden stadiometer.  
The dashed line is the line of identity. 
 
 
Rod height (cm) Measured height (cm) Error (cm) Error (%) 
100 99.9 -0.1 -0.10 
150 150.0 0.0 0.00 
200 199.9 -0.1 -0.05 
250 249.8 -0.2 -0.08 
 









Weighing scales accuracy 
 
The accuracy of the weighing scales was assessed using certified calibration weights 
with a total mass of 15, 30, 45, and 60 kilograms respectively (Figure 3.2, Table 3.2).    




Figure 3-2 Measured versus applied weight for SECA weighing scales.  






Applied weight (kg) Measured weight (kg) Error (kg) Error (%) 
15 14.88 -0.12 -0.78 
30 29.67 -0.33 -1.11 
45 45.02 0.02 0.04 
60 59.91 -0.09 -0.14 
 


















3.2. Measurement of pulmonary function 
 
3.2.1. Measurement of respiratory system resistance 
 
Respiratory system resistance was measured using a form of forced oscillation 
known as impulse oscillometry (IOS). IOS determined respiratory mechanics by 
superimposing small external pressure signals on the spontaneous breathing 
pattern of the subject [151]. Since IOS does not involve forced respiratory 
manoeuvres or deep inspiration, it was unlikely to alter airway dynamics by 
modification of smooth muscle tone [152]; this was important since the diagnosis 
of airflow obstruction in reactive airways disease may be missed if substantial 
bronchodilation takes place as results of deep inspiration [153].   The technique 
used the external applied pressure signals and their resultant flows to determine 
lung mechanical parameters.  These pressure-flow interactions are largely distinct 
from the natural respiratory flow parameters and therefore, IOS results are 
essentially independent of the spontaneous breathing pattern upon which they are 
superimposed.  The physical basis of impulse oscillometry rests on the application 
of an impulse-shaped multi-frequency external forcing signal to the respiratory 
flow pattern.   
The IOS measuring system is shown in figure 3.3.  The head apparatus generated 
recurrent aperiodic forcing signals of alternating direction.  Flow was measured by 
a Lilly-type heated screen pneumotachograph, with a resistance of 36PasL-1, a 
common mode rejection ratio of >60dB for the combination of pneumotachograph 
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and flow transducer system and a linearity within 2% for flows of <15Ls-1.  The 
proximal side of the pneumotachograph was connected to a pressure transducer.  
Pressure and flow signals were sampled at 200Hz and digitised by an analogue-
digital converter, before post-acquisition digital filtering.  The terminal resistor 
provided a low-impedance pathway for normal respiratory flow, whilst providing a 
sufficiently high resistance to minimise loss of energy from the superimposed 
pulses in order that enough impulse pressure is transmitted to the respiratory tract.  
The range for the device is determined by the value of the terminal resistance and 
the displacement of the loudspeaker cone and was set according to international 
recommendations [154, 155].  In this system a terminal resistor of 0.1PasL-1 and a 
speaker volume displacement of 40ml, accelerated to its endpoint in <40ms yielded 
peak-peak impulse pressures of around 0.3kPa and acted to minimise 
contamination of the oscillatory flow and pressure signal by high-order harmonics 
of the respiratory pattern [156] by ensuring that the generated pressure and flow 
are sufficiently distant in terms of frequency from the patient’s breathing 
frequency and providing a forcing signal of sufficient amplitude to ensure adequate 
signal-to-noise ratio. 
The measurement was performed as follows: whilst seated, the subject was asked 
to breathe room air in a relaxed manner for ninety seconds via the tubing between 
the mouthpiece and terminating resistor.  A rigid mouthpiece with integral tongue 
guard was used (SpiroGard, Carefusion Ltd., Basingstoke, UK) , and the test was 
performed with the subject’s head in a neutral position, wearing a nose clip, with 
the cheeks supported by the operators gloved hands.  A bacterial filter was used, 
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with an automated correction for the additional resistance. The loudspeaker 
transmitted short-duration pressure impulses via the Y-adaptor, 
pneumotachograph and mouthpiece into the respiratory tract. The 
pneumotachograph and pressure transducer registered the composite signals 
containing breathing activity and the forcing impulse signal, which were acquired 
for further processing using Fourier analysis by propriety software (JLAB version 5.4 
Carefusion Ltd., Basingstoke, UK).  A coherence value of at least 0.9 across the 
frequency range was required for a technically acceptable measurement. 
 
Figure 3-3 Schematic of impulse oscillometry system.  
Loudspeaker enclosure at top, connected to a Y-adaptor at one upper arm, an exit for flow with terminal 
resistor at the second upper arm and a lower arm connected to the pneumotachograph.  Pulsed flows 
produced by the loudspeaker are shown as a lightly shaded thick line, a component of which exits through 
the terminal resistor and a component of which passes through the pneumotachograph and mouthpiece.  
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The subject’s spontaneous respiratory flow is shown as a shaded thick line from the mouthpiece through the 
Y-connector, exiting through the terminal resistor.  Adapted from Oostveen et al [162].  
 
 
The indices of respiratory mechanics provided by IOS were derived from the 
respiratory system impedance (Zrs).  Flow and pressure channels characterised both 
the underlying respiratory flow and pressure, and the superimposed forced 
oscillation signals.  Zrs was defined as the ratio of effective pressure (Prs) and 
effective flow (V’rs) derived from the superimposed forced oscillations, after being 
separated from the underlying respiratory pressure and flow and their harmonics, 
at each frequency present in the forced oscillation signal.  IOS is a multi-frequency 
oscillation method and provided measures of respiratory mechanical properties in 
terms of Zrs, as a function of frequency (f), hence allowing the recognition of 




Zrs is the complex sum of lung resistance and reactance and expresses the overall 
impediment to airflow in the lung.  Respiratory system resistance (Rrs) is the 
component of lung impedance associated with frictional loss in both the airways 
and the lung parenchyma and represents the component of transpulmonary 
pressure that is in-phase with flow.  Rrs is the sum of viscous resistances within the 
lung and therefore includes proximal and distal airways, lung tissue and chest wall 
resistance.  In general, airway resistance dominates, while lung tissue and chest 
66 
 
wall resistance are usually negligible [157]. Rrs was recorded over a frequency 
range of five to twenty Hertz and frequency-specific Rrs values were obtained using 
a Fourier decomposition of the Rrs signal. Impulse oscillometry was used to 
measure airways resistance because, whilst the results are comparable to those 
obtained by body plethysmography, the requirements for patient cooperation are 
less stringent (e.g., cheek support can be provided by the operator, rather than the 
patient) [158].  Furthermore, the multi-frequency nature of IOS provides additional 
information regarding the anatomical site of airflow obstruction.  Collection and 
analysis of IOS data also forms part on an ongoing departmental data collection 
effort aimed at characterizing IOS parameters in various patient groups (including 
community measurements, where body plethysmography is not feasible) 
 
Accuracy of the IOS pneumotachograph 
 
The accuracy of the IOS system pneumotachograph was assessed by comparing the 
measured volume to the certified volume supplied by calibration syringes with a 
stroke-volume of 1, 2, 3, 4, 5, 6, and 7 litres.  Three strokes were applied manually 
from each syringe using a steady motion and the mean value plotted (figure 3.4, 
table 3.3).  In each case the error was 1.29% or less and the instrument was linear 





Figure 3-4 Measured volume versus syringe volume for the IOS system pneumotachograph.  




Syringe volume (L) Measured volume (L) Error (L) Error (%) 
1 1.00 0.00 0.00 
2 1.98 -0.02 -1.00 
3 3.00 0.00 0.00 
4 4.04 0.04 1.00 
5 5.03 0.03 0.60 
6 6.04 0.04 0.67 
7 7.09 0.09 1.29 
 
 






The forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and 
peak expiratory flow (PEF) were measured using a Jaeger Masterscreen PFT system 
(Carefusion Ltd., Basingstoke, UK).  Flow was measured by a Lilly-type heated 
screen pneumotachograph and volume measurements were derived using a 
software-based integrator (JLAB software version 5.4).   
Spirometry was performed according to ATS/ERS guidelines [159]. The technique 
was explained to the subjects before commencing testing.  The subject was seated 
wearing a nose-clip and asked to breathe normally through the pneumotachograph 
via a mouthpiece.  The subject then performed a slow inspiration to TLC followed 
by a maximal forced expiration to RV, as hard and as fast as possible.  Verbal 
encouragement was given to expire for as long as possible and to refrain from 
breathing in again until instructed.  The system allowed the flow-volume and 
volume-time traces to be visualised in real-time to determine when expiratory flow 
had ceased and the manoeuvre could be terminated.  Any traces showing air leak, 
incomplete inspiration, a slow rise to PEF, cough, or early termination of expiration 
were rejected.  A minimum of three attempts were made, and testing continued 
until two manoeuvres with an FEV1 and FVC within 5% of each other were 
recorded.  For each subject, spirometry was performed after lung volume 
measurements and measurement of airway mechanics to avoid changes in lung 
volume from spirometrically-induced bronchoconstriction and changes in airway 
function due to altered bronchomotor tone following deep inspiration. 
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Accuracy of the spirometer pneumotachograph 
 
The accuracy of the spirometer pneumotachograph was assessed by comparing the 
measured volume to the certified volume supplied by calibration syringes with a 
stroke-volume of 1, 2, 3, 4, 5, 6, and 7 litres.  Three strokes were applied manually 
from each syringe using a steady motion and the mean value plotted (figure 3.5, 
table 3.4).  In each case the error was 1.00% or less and the instrument was linear 
over the range. 
 
Figure 3-5 Measured volume versus syringe volume for the PFT system pneumotachograph.  






Syringe volume (L) Measured volume (L) Error (L) Error (%) 
1 1.00 0.00 0.00 
2 2.00 0.00 0.00 
3 3.00 0.00 0.00 
4 3.96 -0.04 -1.00 
5 5.00 0.00 0.00 
6 5.99 -0.01 -0.17 
7 7.04 0.04 0.57 
 
 
















3.2.3. Body plethysmography 
 
Total lung capacity (TLCpleth), residual volume (RVpleth), and functional residual 
capacity (FRCpleth) were measured using a constant volume 850 litre body 
plethysmograph incorporating a Lilly-type heated screen pneumotachograph 
(Carefusion Ltd., Basingstoke, UK).  Calibration of the plethysmograph 
pneumotachograph and mouth pressure and box pressure transducers was 
performed prior to each testing session using the propriety calibration software 
(JLAB version 5.4).  Barometric pressure, temperature, and humidity were recorded 
automatically by an external sensor array. The pneumotachograph was calibrated 
using a certified calibration syringe of 3L volume (Hans Rudolph Inc, Kansas City, 
USA).  Pressure transducers were calibrated using an integral sinusoidal pump with 
a stroke volume of 50ml and automatic calibration software (JLAB version 5.4). 
 
Measurements were performed according to ATS/ERS guidelines [160].  The subject 
was asked to sit in the plethysmograph for at least two minutes to allow 
equilibration of the temperature and pressure within the box.  The subject was 
then requested to breathe normally through the mouthpiece for a period of 30 – 60 
seconds.  After the period of quiet breathing and at end-expiration, the mouthpiece 
was occluded by a shutter mechanism mounted at the distal end of the 
pneumotachograph. The subject made inspiratory and expiratory efforts against 
the occlusion, during which time measurements of box and mouth pressure were 
recorded.  The shutter remained closed for a fixed duration of three seconds, after 
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which time the subject was instructed to make a maximal expiratory effort to 
residual volume.  The breathing trace was monitored on the visual display and 
when expiratory flow had ceased, the subject was instructed to perform a maximal 
inspiratory effort to TLC.  Static lung volumes were calculated from Boyle’s Law 
which states that, if temperature is constant, the volume of a given mass of gas is 
inversely proportional to its pressure.  During the inspiratory efforts against the 
occluded mouthpiece, there was a resultant decrease in alveolar pressure and a 
corresponding increase in lung volumes.  Boyle’s law can therefore be rewritten as: 
   VVPPVP  1111  
Where: 
V1 = the initial volume of the lungs (equivalent to FRCpleth) 
P1 = barometric pressure 
V = the change in lung volume during a respiratory effort 
P = the change in alveolar pressure corresponding to V 
Therefore, multiplying out: 
VPPVVPVPVP  111111  
But the product VP is negligible therefore the equation simplifies to: 















 11  
The change in lung volume was derived from the change in box pressure during the 
manoeuvre, and the relationship between changes in box pressure and volume was 
determined during the sinusoidal calibration.  Mouth pressure was assumed to 
accurately reflect alveolar pressure during the occlusion when there was zero flow. 
The flow during the vital capacity (VC) manoeuvre was recorded by the 
pneumotachograph, and integrated to yield volume.  From this the expiratory 













Accuracy of the body plethysmograph pneumotachograph 
 
The accuracy of the spirometer plethysmograph pneumotachograph was assessed 
by comparing the measured volume to the certified volume supplied by calibration 
syringes with a stroke-volume of 1, 2, 3, 4, 5, 6, and 7 litres. Three strokes were 
applied manually from each syringe using a steady motion and the mean value 
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plotted (figure 3.6, table 3.5). In each case the error was 1.71% or less and the 
instrument was linear over the range. 
 
 
Figure 3-6 Measured volume versus syringe volume for the body plethysmograph pneumotachograph.   
The dashed line is the line of identity. 
Syringe volume (L) Measured volume (L) Error (L) Error (%) 
1 1.00 0.00 0.00 
2 1.99 -0.01 -0.50 
3 2.98 -0.02 -0.67 
4 4.04 0.04 1.00 
5 5.05 0.05 1.00 
6 6.09 0.09 1.50 
7 7.12 0.12 1.71 
 
 
Table 3-5  Measured volume versus syringe volume for the body plethysmograph pneumotachograph. 
75 
 
3.2.4. Lung gas transfer 
 
Total lung transfer factor for carbon monoxide (DLCO), alveolar volume (VA), and 
gas transfer for carbon monoxide per unit lung volume (KCO) were measured using 
the single-breath breath-hold method [161].  The system comprised a 
katharometer-based helium analyser, and an infrared analyser for carbon 
monoxide (Masterscreen PFT, Carefusion Ltd., Basingstoke, UK). Flow was 
measured by a Lilly-type heated screen pneumotachograph and volume 
measurements were derived using a software-based integrator (JLAB software 
version 5.3).  The katharometer detected changes in helium concentration by 
relating it to changes in thermal conductivity, which is related inversely to the 
molecular weight of a gas.  The katharometer consists of two parallel tubes with 
integral heating elements arranged in a bridge circuit configuration so that 
resistance changes due to unequal cooling by the gases in each tube could be 
detected.  One tube received a reference gas, while the second tube received the 
gas mixture to be analysed. The infrared analyser comprised two parallel chambers 
mounted between and infrared light source and an infrared receiver. A reference 
gas was passed through the first chamber and the sample gas fed into the second.  
The difference in absorption of infrared energy between the reference and sample 
gases allowed the concentration of carbon monoxide to be determined. The gas 
analysers and pneumotachograph were calibrated prior to each testing session.   
Katharometer calibration was performed using certified test gas containing 9% 
helium; whilst the infrared analyser was with a certified cylinder containing 9%He 
and 0.28% carbon monoxide. The pneumotachograph was calibrated using a 
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certified calibration syringe of 3L volume (Hans Rudolph Inc., Kansas City, USA).  
The subject was instructed in the technique required prior to testing.  Wearing a 
nose-clip, the subject was seated and asked to breathe normally through the test 
circuit via a flanged mouthpiece attached to the pneumotachograph.  The subject 
was then asked to inspire maximally to TLC, expire maximally to RV, and then 
perform a second maximal inspiration to TLC.  The test gas (9%He, 0.28%CO, 19%O2 
and balance N2) was automatically introduced at the start of the second maximal 
inspiration.  The subject was instructed to hold their breath for 10 seconds at TLC, 
whilst the volume trace was monitored for leaks or Valsalva efforts.  A shutter was 
automatically closed at the end of maximal inspiration to occlude the mouthpiece. 
After 10 seconds the shutter was released and the subject instructed to exhale to 
RV.  The first 750ml, representing a bronchial sample, was discarded, and the 
following 750ml, the alveolar sample, was retained for analysis.  If the subject’s VC 
was less than 1.5L the discard volume was reduced to 600ml. 




















Vin = inspiratory VC during manoeuvre  
Vds = total deadspace, comprising anatomical and equipment deadspace 
Heinit = initial concentration of helium in test gas 
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Hefinal = the helium concentration in the expired alveolar sample 
 
Due to dilution of the test gas by the residual volume, the alveolar starting 
concentration of CO is not equivalent to the cylinder concentration, but may be 


















COalv(t=0) = the starting concentration of CO in the lung prior to gas exchange 
COcyl = the nominal CO concentration in the test gas 
 
The breath-hold time was defined according to the system of Jones and Meade 
[162].  The time for gas exchange was defined as the period between the time at 
one-third of the inspiratory volume ([CO] = COalv(t=0)) and one half of the total 
expired volume after breath-holding ([CO] = COalv(t=10)).  By taking the slope defined 
by ln(COalv(t=0)) and ln(COalv(t=10)), the gradient of the CO uptake curve over the 
contact time was derived.  This is the rate constant for CO uptake, which is 




















KCO     
A minimum of two tests were performed, with the mean value of two results within 
10% of each other reported.  A maximum of five attempts were made, with an 
interval of four minutes between each test run in order to ensure wash-out of 
helium [161]. 
The reported result was adjusted for haemoglobin concentration [163], using a 
blood test performed within six weeks of the test date as part of the patient’s 






















Pulmonary capillary blood volume 
 
Prior to testing, nitric oxide (NO) was added to the test gas mix to a concentration 
of 40ppm, which allowed the transfer factor for nitric oxide (DLNO) to be assessed 
simultaneously with DLCO using the same procedure described above.  NO 
concentration was measured using an electrochemical sensor incorporated into the 
gas analyser system.   The method of Borland et al [164] was used to estimate 
pulmonary capillary blood volume as follows.   According to the equation of 








DmCO = the pulmonary membrane diffusing capacity for carbon monoxide 
(equivalent to the carbon monoxide conductance across the alveolar-capillary 
tissue membrane and plasma barrier) 
ΘCO = the rate of carbon monoxide uptake by whole blood and combination with 
haemoglobin 
Vc = the pulmonary capillary blood volume. 
 
The same relationship applies to the DLNO, but since the reaction rate of NO 
binding with haemoglobin is approximately 280 times faster than that of CO, the 
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rate of NO uptake by the blood (ΘCO) is extremely large and therefore the term 
1/(ΘCO.Vc) becomes very small and  may be neglected, yielding: 
 
NODNOD mL  . 




















and therefore NODCOD mm 93.1  [166]. 
Where: 
MWCO = the molecular weight of CO = 28 
MWCO = the molecular weight of NO = 30 
αCO= the solubility factor of CO in water at 37.5⁰C = 0.0183 ml-1atm-1 
αNO = the solubility factor of NO in water at 37.5⁰C = 0.0364 ml-1atm-1 
 
DmCO was then substituted back into the Roughton-Forster equation which was 


















Accuracy of the gas transfer system pneumotachograph 
 
The gas transfer system used the same pneumotachograph used to perform 
spirometry.  The accuracy of this device is assessed in section 3.2.2 (figure 3.5, table 
3.4).   
 
Accuracy of the gas transfer system gas analysers 
 
The accuracy of the Masterscreen PFT gas analysers was checked using a gas 
dilution method.  A certified calibration syringe of known volume was used as a 
‘simulated’ patient, and the DLCO test was performed as described above, with the 
stroke volume set to half of the syringe volume.  Since the system was sealed and 
there was no gas uptake by the ‘patient’, the reduction in CO and Helium 
concentrations at the end of the test was solely due to dilution by the syringe 



















Vstroke = syringe stroke volume  
Vds = system deadspace 
Concinit = initial concentration of helium or CO 
Concfinal = initial concentration of helium or CO after manoeuvre 
The difference between the measured and certified syringe volumes is the analyser 
error. Testing was performed with syringe volumes of 2, 3, 4, 5, 6, and 7 litres; in 
each case the error was 4.6% or less and the analysers were linear over the range 




Figure 3-7 Measured volume by gas dilution versus syringe volume for the helium analyser.  
The dashed line is the line of identity 
 
 
Syringe volume (L) Measured volume (L) Error (L) Error (%) 
2 2.06 0.06 2.78 
3 2.91 -0.09 -2.94 
4 4.08 0.08 2.06 
5 5.07 0.07 1.38 
6 6.13 0.13 2.23 
7 6.92 -0.08 -1.16 
 
 




Figure 3-8 Measured volume by gas dilution versus syringe volume for the CO analyser.  
The dashed line is the line of identity 
 
 
Syringe volume (L) Measured volume (L) Error (L) Error (%) 
2 1.97 -0.03 -1.27 
3 2.98 -0.02 -0.51 
4 3.98 -0.02 -0.39 
5 4.77 -0.23 -4.60 
6 6.15 0.15 2.44 
7 6.87 -0.13 -1.84 
 
 




Figure 3-9 Measured volume by gas dilution versus syringe volume for the NO analyser.  





Syringe volume (L) Measured volume (L) Error (L) Error (%) 
2 1.92 -0.08 -3.77 
3 3.13 0.13 4.21 
4 4.11 0.11 2.70 
5 4.87 -0.13 -2.54 
6 5.92 -0.08 -1.28 
7 7.04 0.04 0.58 
 






3.2.5. Multiple-flow exhaled nitric oxide 
 
Exhaled nitric oxide was assessed according to American Thoracic Society/European 
Thoracic Society criteria [168] using a commercial online NO analyser system 
(Hypair feNO, Medisoft Cardio-respiratory Instrumentation, Sorinnes, Belgium) 
employing an electrochemical fuel-cell NO sensor.  Whilst seated comfortably, the 
subject was asked to insert the mouthpiece connected to the analyser circuit and 
inhale to total lung capacity over a period of two to three seconds.  During 
inspiration, the breathing circuit was switched through an NO-scrubbing filter to 
prevent contamination of the expired sample by ambient NO in the inspired gas.  A 
nose clip was not worn to avoid accumulation and leakage of nasal NO from the 
posterior nasopharynx [169].  
Upon reaching TLC, subject was asked to exhale steadily into the breathing circuit. 
A constant expiratory flow rate was achieved by exhaling against a fixed resistor 
with real-time visual feedback to maintain the expiratory flow within 10% of the 
desired value for duration of the measurement phase. Mouth pressure was 
maintained at 16cmH2O throughout the exhalation to ensure velum closure and 
minimise contamination of the expired sample with NO of nasal origin [170].  The 
exhalation was maintained for at least ten seconds to ensure washout of the airway 
compartment, and NO level was monitored continuously to ensure that a plateau 
had been reached.  The plateau concentration of NO (feNO) was evaluated over a 
three-second window of the exhalation profile such that the difference in NO 
concentration at the start and end of the window was less than 10%, and at no 
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time during the three second window did the NO concentration differ from the 
value at the start or end by more than 10%.  FeNO was defined as the mean NO 
concentration over the three-second window.  Measurements with evidence of 
cough, air leak, nasal contamination, or failure to maintain constant flow were 
discarded.  Measurements were performed at expiratory flows of 50, 100, 150 and 
350ml/s, and at each flow rate feNO was reported as the mean of three technically 
acceptable measurements within 10% of each other. 
Derivation of alveolar and airway NO 
 
The trumpet-model with axial diffusion (TMAD) developed by Condorelli et al was 
used to estimate alveolar NO concentration (CA,NO) and maximal airway NO flux 
(J’aw,NO) from multi-flow feNO measurements [171].  The model assumes that a 
plateau concentration (FeNO) is reached in the exhaled air measured at the mouth 
and that during the constant-flow exhalation manoeuvres the concentration and 
flux of NO in the distal (alveolar) and proximal (airway) zones of the lung approach 
steady-state (and are therefore independent of time), which is valid for flow rates 
greater than approximately 50ml/s [171-173]. Under these circumstances the 
model yields the following relationship: 
 







Where V̇NO is the rate of NO exhaled, which is given by the product of NO 
concentration in nanolitres per litre and expiratory flow rate in litres per minute 
(BTPS).   Thus a plot of V̇NO versus exhaled flow produces a linear relationship in 
which the slope is equal to CA,NO+J’aw,NO.*0.00078 and the intercept is equal to 
J’aw,NO/1.7.  Therefore, CA,NO and J’aw,NO were estimated from a plot of V̇NO versus 
exhaled flow using the following relationships: 
 










𝐽′𝑎𝑤,𝑁𝑂 = 1.7 ∙ 𝐼 
 
Where S was the slope and I was the y-intercept obtained using simple linear 





Figure 3-10 Illustrative data demonstrating the rate of NO exhalation vs. flow technique to estimate mean 
alveolar concentration and maximum airway NO flux. 
 
Accuracy of the exhaled NO system flow sensor 
 
The accuracy of the Hypair FeNO system flow sensor was assessed by comparing the 
measured volume to the certified volume supplied by calibration syringes with a 
stroke-volume of 1, 2, 3, 4, 5, 6, and 7 litres.  Three strokes were applied manually 
from each syringe using a steady motion and the mean value plotted (figure 3.11, 






Figure 3-11: Measured volume versus syringe volume for the Hypair FENO system flow sensor.   
The dashed line is the line of identity. 
 
Syringe volume (L) Measured volume (L) Error (L) Error (%) 
1 1.03 0.03 2.81 
2 1.99 -0.01 -0.71 
3 2.97 -0.03 -0.87 
4 4.01 0.01 0.15 
5 4.97 -0.03 -0.65 
6 5.94 -0.06 -0.94 
7 7.01 0.01 0.08 
 








Accuracy of the exhaled NO system gas analyser 
 
The accuracy of the electrochemical NO analyser cell was assessed using certified 
calibration gas cylinders with NO concentrations of 0, 33, 66, and 112ppb.  Each 
cylinder was connected to the analyser in turn using a dedicated calibration inlet 
valve and the measured values displayed.  In each case the error was less than 
2ppb and the analyser was linear across the range (Figure 3.12, table 3.10). 
 
Figure 3-12 Measured versus cylinder NO concentrations for the Hypair FENO analyser.   






Cylinder NO concentration 
(ppb) 






0 0 0 0 
33 34.2 1.2 3.64 
67 68.6 1.6 2.39 
112 112.5 0.5 0.45 
 

























3.2.6. Pulmonary blood flow 
 
Effective pulmonary blood flow was measured by the inert-gas rebreathing method 
using a commercially available system (Innocor, Innovision ApS, Glamsbjerg, 
Denmark).   The system used an inert soluble gas (0.5% nitrous oxide), an inert 
insoluble gas (0.1% sulphur hexafluoride) and 28% oxygen in N2.  Wearing a nose 
clip, rebreathing was performed from a 2 – 4 litre rubber bag and gases were 
sampled continuously at the mouth and passed to a rapid photo-acoustic 
spectrograph analyser within the Innocor unit [174].  Respiratory flow was 
measured during the rebreathing manoeuvre by an integrated Lily-type heated 
pneumotachograph.  The volume to which the bag was filled with the test gas was 
adjusted to 60% of the subjects’ vital capacity.  Rebreathing was performed over a 
thirty second period and subjects were trained to follow a graphical tachometer on 
the Innocor display screen and verbal prompts in order to ensure a constant 
respiratory rate of 20 breaths/min.   Subjects were instructed to empty the 
rebreathing bag fully with each breath in order to ensure a constant ventilation 
volume.  The pulmonary blood flow (Qpulm) was calculated from the rate of uptake 
of nitrous oxide into the blood as described below.  To adjust for body size, the 
pulmonary blood flow index (QIpulm) was derived by dividing Qpulm by the predicted 
body surface area using the formula of Mosteller [175].   
 
Calculation of pulmonary blood flow was based on single-compartment lung model 
which assumed that pulmonary blood flow was constant and mixed venous 
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concentration of the soluble gas was negligible during the manoeuvre, and that 
complete mixing of all gases in the volume comprising the lung and bag volume 
takes place.  
Before calculating pulmonary blood flow, the total systemic volume (𝑉𝑠,𝑡𝑜𝑡) of the 
lung-rebreathing circuit system was calculated, which comprises: 
 
𝑉𝑠,𝑡𝑜𝑡 = 𝑉𝐿 + 𝑉𝑑𝑠 + 𝑉𝑑𝑠,𝑟𝑏 + 𝑉𝑟𝑏. 
Where: 
VL = Lung volume at end-expiration during the rebreathing manoeuvre 
Vds = Dead space volume of the rebreathing valve (RBU) 
Vds,rb = Residual volume of the rebreathing bag when empty 
Vrb = Volume of rebreathing bag 
 
During the rebreathing period the concentration of insoluble gas (SF6) decreased 
from the initial value in the bag (denoted Fi
0) until equilibration had taken place 
and the concentration remained constant (denoted Fi,eq).   The single-compartment 
model uses the total systemic volume at time zero (denoted t0), where zero is 
defined as the middle of the first inspiration and before shrinkage has taken place 
due to oxygen uptake.  This volume is, however, difficult to measure as the gas 
dilution technique requires the insoluble gas to be fully mixed which is not the case 
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at time zero and therefore a back-extrapolation method was used to provide an 
estimate.  Least-squares linear regression was used to fit a straight line through the 
end-expiratory points of the insoluble gas dilution curve where adequate mixing 
was obtained.  The insoluble gas concentration at time zero was then determined 
as the point where the extrapolated line crossed time zero (figure 3.13). 
 
Figure 3-13 Insoluble gas concentration during rebreathing 
 












0 = Initial concentration of insoluble gas in the rebreathing bag 
Fi,eq = Equilibrium concentration of insoluble gas (back extrapolated to t = 0) 
Vrb = Rebreathing bag volume 
 
Pulmonary blood flow was derived from the rate of disappearance of the soluble 
gas (NO2) during the rebreathing manoeuvre.   Assuming a constant Qpulm, the 
disappearance curve describes a monotonically decreasing exponential function of 
time, where the rate constant is proportional to Qpulm.  By plotting on semi-
logarithmic axes, a linear decay function was obtained, where the slope (β) was 
determined by fitting a least-squares linear regression line through the expiratory 





Figure 3-14: Semi logarithmic plot of soluble gas concentration during the rebreathing manoeuvre.  The slope 







𝛽 =  
ln(𝐹𝑠,2






The pulmonary blood flow was then calculated from: 
 
𝑄𝑝𝑢𝑙𝑚 =  −𝛽 ∙







Qpulm = Pulmonary blood flow 
β = least-squares linear regression line through the expiratory points of the 
logarithm of the soluble gas concentration 
Vs,tot = Total systemic volume 
C1 = Constant to correct for barometric pressure = 760/(PB – 47) mmHg 
C2 = αt·Vt = Constant to correct for the absorption of soluble gas into lung tissue 
 αb = Bunsen solubility coefficient in blood [ml STPD/ml/atm @ 37°C] (αb, N2O = 
0.412) 
 αt = Bunsen solubility coefficient in blood [ml STPD/ml/atm @ 37°C] (αt, N2O = 
0.407) 










Accuracy of the Innocor pneumotachograph  
 
The accuracy of the Innocor pneumotachograph was assessed by comparing the 
measured volume to the certified volume supplied by calibration syringes with a 
stroke-volume of 1, 2, 3, 4, 5, 6, and 7 litres.  Three strokes were applied manually 
from each syringe using a steady motion and the mean value plotted (Figure 3.15, 
table 3.11).  In each case the error was 2.85% or less and the device was linear 
across the range. 
 
 
Figure 3-15 Measured volume versus syringe volume for the Innocor pneumotachograph.   




Syringe volume (L) Measured volume (L) Error (L) Error (%) 
1 0.98 -0.02 -2.24 
2 2.06 0.06 2.85 
3 2.97 -0.03 -0.89 
4 4.05 0.05 1.34 
5 4.97 -0.03 -0.69 
6 5.98 -0.02 -0.27 
7 6.93 -0.07 -1.03 
 
Table 3-11 Measured volume versus syringe volume for the Innocor pneumotachograph 
 
 
Accuracy of the Innocor photo-acoustic spectrograph gas analyser 
 
The accuracy of the Masterscreen PFT gas analysers was checked using a gas 
dilution method as described in section 3.3.4 for the gas transfer system gas 
analysers.  A certified calibration syringe of known volume was used as a 
‘simulated’ patient, and the inert gas rebreathing test was performed as described 
above, with the stroke volume set to half of the syringe volume.  Testing was 
performed with syringe volumes of 2, 3, 4, 5, 6, and 7 litres; in each case the error 
was 0.94% or less and the analysers were linear over the range (figure 3.16 and 





Figure 3-16  Measured volume by gas dilution versus syringe volume for the Innocor SF6 analyser.  
The dashed line is the line of identity 
 
 
Syringe volume (L) Measured volume (L) Error (L) Error (%) 
2 2.01 0.01 0.60 
3 2.97 -0.03 -0.94 
4 4.02 0.02 0.47 
5 5.01 0.01 0.12 
6 6.00 0.00 0.00 
7 7.00 0.00 -0.07 
 





Figure 3-17 Measured volume by gas dilution versus syringe volume for the Innocor N2O analyser.  




Syringe volume (L) Measured volume (L) Error (L) Error (%) 
2 2.05 0.05 2.54 
3 3.05 0.05 1.77 
4 3.96 -0.04 -1.02 
5 4.92 -0.08 -1.62 
6 5.96 -0.04 -0.72 
7 6.99 -0.01 -0.15 
 





3.3. Computed tomography 
 
3.3.1. Scoring of CT parenchymal abnormalities 
 
Patients were scanned on a 64-channel multidetector CT machine (GE 64 VCT 
Lightspeed machine; GE Healthcare, Waukesha, Wisconsin, USA; 100 kV, Auto 
mA/Smart mA; pitch 1.375, 0.5 sec tube rotation, beam collimation 40 mm, 
detector size 0.65 mm). Contrast was injected at a rate of 4-5 ml/s and scanning 
was performed cranio-caudally with the subject in a supine position and breathing 
suspended at maximal inspiration. The period of CT scanning was timed to coincide 
with optimal contrast opacification of the pulmonary arterial tree using bolus-
tracking. Interspaced HRCT images (1.5mm collimation at 10 mm intervals) had 
been acquired at total lung capacity, in the supine and prone positions. Images 
were reconstructed using a high-spatial-frequency (bone) algorithm. All CT studies 
were securely stored on CD for subsequent review. 
 
The following CT patterns [176] were quantified to the nearest 5%:  
i) A reticular pattern defined as innumerable interlacing line shadows which, 
by summation, produce an appearance resembling a mesh. 
 
ii) Ground-glass opacification (defined as a hazy increased lung opacity in 





iii) Areas of decreased attenuation as part of a mosaic attenuation pattern 
defined as a patchwork of areas of differing lung densities.  
 
iv) Consolidation, defined as a homogeneous increase in lung parenchymal 
attenuation which obscures the margins of airway and vessel walls. In 
patients with consolidation, the extent to the nearest 5% of sub-pleural 
consolidation was also recorded.  
 
For ground glass opacification, a score was assigned based on the observed extent 
(0=none; 1= <10% extent; 2= 10-50% extent; 3 >50% extent).  
 
The following CT signs were scored semi-quantitatively: 
i) Thickening of interlobular septa (0=none; 1= <5 thickened interlobular 
septa [ILS]; 2= >5 thickened ILS or 4 <50% pleural surface involved; 3= 
>50% pleural surface involved or 4 = diffusely thickened ILS). 
 
ii) Lobar volume loss (0=none; 1=mild or 2=severe).  
 
The presence or absence of the following signs was recorded: 
i) Traction bronchiectasis defined as irregular bronchial/bronchiolar 
dilatation caused by surrounding retractile pulmonary fibrosis in a 
reticular pattern and/or ground-glass opacification 
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ii)  Linear bands of attenuation. 
 
iii)  Sub-pleural curvilinear lines defined as a thin curvilinear opacity of 1-3 
mm thickness and lying within one centimetre of and parallel to the 
pleural surface.  
 
 
iv) Pulmonary infarcts defined as a peripheral irregular opacity associated 
with a linear opacity no more than 2 cm in length. 
 
 Whole-lung scores were produced by taking the mean of all lobes for signs which 
had been measured to the nearest 5% and by summing the lobar scores for signs 
recorded as present/absent. 
 
3.3.2. Measurement of CT vascular dimensions 
 
 Vascular dimensions were assessed in two ways. First, proprietary electronic 
callipers were used to measure the widest short axis diameters of the upper lobe 
apical or apico-posterior segmental arteries and the lower lobe posterobasal 
segmental arteries together with the widest external short axis diameter of the 
corresponding segmental bronchi on the same axial image in at least three out of 
four lobes [177]. Based on those measurements, the mean segmental artery/ 
bronchus (A/B) ratio in at least three out of four lobes was calculated.  
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Distal vessel dimensions, including both arteries and veins at the 
subsubsegmental level [178] were measured using the method of Matsuoka et al 
[179, 180]. Three CT slices were selected from each examination. The upper 
cranial slice was located approximately one centimetre above the upper margin 
of the aortic arch, the middle slice approximately one centimetre below the 
carina, and the lower caudal slice approximately one centimetre below the right 
inferior pulmonary vein. The measurements were performed using the Java-
based semi-automated image analysis software ‘ImageJ’ (Rasband, W.S., ImageJ, 
U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2012). Before processing, each selected image 
was smoothed using Gaussian blurring to filter image noise. The lung field was 
then segmented using a thresholding technique to include all pixels between -500 
and -1024 Hounsfield Units (HU) (Figure 3.18A) and the segmented image was 
converted to a binary image with a window level of -760 HU (Figure 3.18B). The 
‘Analyze Particles’ function was then used to count and measure the cross-
sectional area of vessels within a range of 0-5mm2. The ‘Circularity’ function was 
then used to select only those vessels running approximately perpendicular to 
the scan plane based on their apparent shape in the slice image, setting the 
circularity range to 0.9-1.0 (Figure 3.18C). The total summated cross-sectional 
area for those vessels was then expressed as a percentage of the total lung area 






Figure 3-18  Measurement of small vessel cross-sectional area (CSA)<5 mm% using ImageJ software.  
(A) High-resolution CT image of lung field segmented with threshold values of −500 to −1024 HU. (B) 
Segmented image converted to binary image with window level of −720 HU, with pulmonary vessels 
displayed in black. (C) Mask image for particle analysis with vessel size set to 0–5mm2 and the circularity 






The segmental A/B ratio has been shown to correlate with pulmonary artery 
pressure in a mixed cohort of patients with lung disease [181]. CSA<5mm% has 
been measured in patients with HRCT-defined emphysema due to COPD and has 
been shown to correlate with pulmonary artery pressure in this group [179, 180]. 
CT total lung volume (TLVCT), comprising air plus tissue components, was derived 
using a proprietary lung segmentation algorithm (Apollo, Vida Core Lab Services, 
Vida Diagnostics Inc, Iowa, USA) which uses a localized and adaptive threshold 
method to delineate lung tissue on a lobar basis from surrounding tissues (Figure 




Figure 3-19 Example of a segmented CT examination used to derive CT total lung volume (TLVCT).  
The lobes are shown in different colours. 
For a subset of patients in whom longitudinal measurements are available, initial 
and follow-up CT scans were compared. Two observers identified anatomically 
comparable sections as judged by vascular and bronchial landmarks on the two CT 
scans from each individual and recorded their impression of whether the overall 
appearance of the interstitium on the follow-up scan compared to the initial scan 
had deteriorated. Patients who had deteriorated were assigned a ‘gestalt’ change 





Two and three dimensional echocardiography was performed using digital 
acquisitions on a Phillips Sonos 7500 ultrasound system and a 2.5 MHz matrix array 
with standalone transducers (Philips Medical Systems BV, The Netherlands).  Scans 
were perfumed according to American Society of Echocardiography guidelines 
[182] by a single expert cardiographer.  Images over multiple views were obtained 
over at least three cardiac cycles; tricuspid and mitral inflow recordings were 
obtained using pulsed Doppler.  Tricuspid regurgitant jet velocity (TRV) was 
measured by continuous-wave Doppler: the largest value measured in any of four 
standard views was reported.   
Valvular regurgitation was graded from Doppler determinations of trans-valvar 
flow. Tricuspid regurgitation (TR) was assessed in the parasternal right ventricular 
inflow, parasternal short axis and apical four-chamber views. A minimum of five 
sequential complexes were recorded. Continuous-wave Doppler signals of the peak 
regurgitant jet velocities (TRV) (normal <2.5 m/s) were used to estimate the right 
ventricular systolic pressures (RVSP) using the Bernoulli equation: 
 
𝑅𝑉𝑆𝑃 = 4 ∙ 𝑇𝑅𝑉2 
 
PAP (normal <25 mm Hg) was calculated as the sum of RVSP and right atrial systolic 
pressures. Cardiac output (CO) (normal range 4.0–8.0 L/s) and right-ventricular 
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diastolic volumes (RVDV) (normal range 100–160 mL) were also measured. Right 
and left ventricular function were assessed by measurement of the tricuspid 
annular plane systolic excursion (TAPSE) (normal >1.5 cm) and the ratio of early 
diastolic LV inflow (E) to lateral mitral annulus velocity (e’) measured by tissue 

















3.5. Statistical methods 
 
Comparisons between groups were performed using Mann-Whitney U or Wilcoxon 
signed-rank tests for unpaired and paired data respectively.   The strength of 
relationships between variables was assessed using Spearman’s rank correlation.  
Tests of proportions between groups were performed using Fisher’s exact test.  
Adjustments for multiplicity were not performed, since the majority of individual 
statistical tests conducted within each study were complementary (i.e. not 
independent).  This is the case for tests on the subdivisions of lung volume and 
forced expiratory flows (which are dependent on lung volume) and for the 
correlated multiple-flow exhaled nitric oxide measurements in Chapter Seven.  
Correction of p-values for multiple testing (e.g.: by Bonferroni adjustment) is 
generally only appropriate where individual statistical tests are independent.  
Nevertheless, there remains the possibility of an increased rate of type two errors 
due to the large number of statistical tests conducted – it is recommended, 
therefore, that the results from each study are considered in their totality, 
particularly in terms of internal consistency, rather than regarding each significant 
p-value as a definitive test for an individual null hypothesis.    
Multiple linear regression was used to test for associations between lung function 
and morphologic and haematological variables.  Regression diagnostics were 
performed to ensure that all models satisfied the assumptions of multiple linear 
regression as determined by assessment of homoscedasticity and the absence of 
multicollinearity between predictors.  Where the condition of homoscedasticity 
was not satisfied, analyses were performed on the log-transformed dependent 
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variable to normalise the residuals.  For binary outcome variables, logistic 
regression was used.  Linear mixed-effect models (LMMs) were used to analyse 
longitudinal data. Statistical testing was performed using Prism (Graphpad Software 
Inc., San Diego, CA), SPSS (IBM Corp. Armonk, NY) or R (version 3.1.1, R Foundation 
for Statistical Computing, Vienna, Austria) software. Power analysis was performed 














4. PULMONARY FUNCTION, CT AND 
ECHOCARDIOGRAPHIC ABNORMALITIES IN SICKLE 
CELL DISEASE 
 
Note: All lung function tests and statistical analyses were performed by the 
candidate.  Parenchymal abnormalities on HRCT were scored by Dr Sujal Desai 
(King’s College Hospital NHS Foundation Trust) and Prof David Hansell (Royal 
Brompton & Harefield NHS Foundation Trust).  Echocardiography was perfomed by 
Dr Sitali Mushemi (King’s College London) Prof Atholl Wells (Royal Brompton & 




Adults with SCD can suffer from parenchymal lung disease and pulmonary vascular 
disease or both; affected individuals can suffer premature death. A previous study 
conducted by this research group  demonstrated that the majority of a cohort of 
adult patients with SCD had pulmonary abnormalities on high-resolution CT (HRCT) 
[73]. The HRCT findings significantly correlated with pulmonary function testing 
results; in particular, there were correlations between reductions in FVC and FEV1 
and the prominence of the central vessels on HRCT. Prominent central vessels were 
found on HRCT in eight of the nine patients with restrictive abnormalities. The 
prominent central vessels may reflect the raised pulmonary capillary blood volume 
as a result of chronic anaemia causing an increased cardiac output (CO)  [123] and 
dilation of the pulmonary vessels [185]. 
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This study was conducted, therefore, to test the hypothesis that enlarged 
pulmonary vessels would be associated with elevated cardiac output, impaired 
ventricular function, and lung function abnormalities.  This was achieved by 
prospectively undertaking HRCT studies, lung function tests and echocardiographic 
assessments. A further aim of this study was to reassess the cohort examined seven 
years ago [73] to determine whether any decline in lung function correlated with 





Adults with SCD were assessed between 2009 and 2013. Subjects included in the 
study of Sylvester et al had also initially been assessed between 2003 and 2005.  
The study was approved by King’s College Hospital Research Ethics Committee 
(LREC 02-0080). All participants gave written informed consent.  
 
4.2.1 Lung function assessments 
 
FEV1, vital capacity (VC), forced expiratory flow between 25 and 75% of VC (FEF25-
75), total lung capacity (TLC), residual volume (RV) and mean respiratory system 
resistance (Rrs) were measured as previously described (Section 3).  Results were 
expressed as percent predicted for height, age, and sex using the ethnic-specific 
reference equations for spirometry [186] and the European Community for Steel 
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and Coal Statement of the European Respiratory Society reference equations for 
lung volumes and gas transfer [187]. 
The mean respiratory system resistance (Rrs(0)) and frequency dependence of 
resistance (Rrs(1)) from 5-25Hz were measured using impulse oscillometry and 
expressed as the percent predicted for height, weight, and age [188].  The 
frequency dependence of resistance was assessed using the mean slope of the 
resistance-frequency curve over the range 5 to 25Hz. The Rrs(0) and Rrs(1) were 
used as the only published predicted values for Rrs in adults report these indices but 
do not report Rrs at individual oscillation frequencies and normalisation to 
predicted value is necessary to account for known age and sex related variation in 
Rrs [189].  Respiratory resistance was considered to be elevated if Rrs(0) was greater 
than the upper limit of normal, defined as a standard-deviation score of greater 
than 1.64, based on the reference data of Pasker et. al [188]. Spirometry was 
repeated following administration of a bronchodilator (400μg salbutamol via a MDI 
and spacer: the MDI was vigorously shaken between puffs and the delivery of each 
puff was followed by five normal breaths) and a positive response was defined as 
an increase in FEV1 of greater than or equal to 12% from baseline and an increase 
of at least 200ml. Oxygen saturation was measured using a pulse oximetry (Masimo 
Radical 7 and a rainbow probe, Masimo, California, USA). 
The predicted values for total lung capacity were reduced by 12%, and residual 
volume by 7% to correct for ethnicity [136]. The lower and upper limits of normal 
were defined as the fifth and ninety-fifth percentiles respectively of the 
appropriate reference range. Patients were diagnosed as having a restrictive 
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abnormality if their TLC was less than the lower limit of normal (LLN), with a normal 
FEV1:VC. An obstructive abnormality was diagnosed if the FEV1:VC was less than 
the LLN with a normal VC, or if VC was less than the LLN with a normal TLC and an 
RV:TLC greater than the upper limit of normal (ULN). A mixed abnormality was 
diagnosed if the TLC and FEV1:VC were less than the LLNs. 
 
4.2.2 Computed Tomography 
 
CT patterns were quantified independently by two thoracic radiologists (SD and 
DH) blinded to the clinical and functional data: for the longitudinal analysis, scans 
at the two time points were assessed blinded. The extent and severity of CT 
abnormalities were recorded in individual lobes, the lingula being considered a 
separate lobe for scoring purposes. Distal vessel dimensions, including both arteries 
and veins at the sub-subsegmental level were measured using the method of 
Matsuoka et al. as previously described. The total summated cross-sectional area 
for the vessels was then expressed as a percentage of the total lung area of the 
three selected slices using threshold values between −500 and −1024 HU (cross-
sectional area (CSA)<5 mm%). The mean segmental artery/bronchus (A/B) ratio in 
at least three of four lobes was calculated. CT total lung volume (TLVCT) was derived 
using a proprietary lung segmentation algorithm. For the longitudinal analyses, 
initial and follow-up CT scans were compared. Two observers identified 
anatomically comparable sections as judged by vascular and bronchial landmarks 
on the two CT scans from each individual and recorded their impression of whether 
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the overall appearance of the interstitium on the follow-up scan compared to the 
initial scan had deteriorated. Patients who had deteriorated were assigned a 




Two-dimensional and three-dimensional transthoracic echocardiography was 
performed according to the international guidelines as previously described 
(section 3). TRV was used to derive RVSP. Cardiac output (CO) (normal range 4.0–
8.0 L/s) and right-ventricular diastolic volumes (RVDV) (normal range 100–160 mL) 
were also measured. Right and left ventricular function were assessed by 
measurement of the tricuspid annular plane systolic excursion (TAPSE) (normal >1.5 
cm) and the ratio of early diastolic LV inflow (E) to lateral mitral annulus velocity 
(e′) measured by tissue Doppler (E/e′) (normal <8). Technically acceptable TAPSE 
measurements were available in 32 patients and E/e′ in 33 patients.  
 
4.2.4 Haematological and clinical data 
 
Haemoglobin, lactate dehydrogenase (LDH), bilirubin levels and reticulocyte counts 
were obtained from routine blood tests taken within one month of testing when 
patents were clinically stable.  A review of medical records was conducted to 
determine historical ACS status.  Complete records were obtained for the previous 
twenty-eight to thirty-six years in thirty out of thirty-five patients (86%); for the 
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remaining three patients, records were available only for the nine to twelve years 
prior to the study visit.   Patients were deemed to have a history of ACS if they had 
suffered at least one episode of chest pain, dyspnoea and pyrexia together with a 
new pulmonary infiltrate on chest radiograph [78].   
 
4.2.5 Statistical analysis 
 
Data were tested for normality using the D’Agostino and Pearson omnibus 
normality test. Since data were not normally-distributed, comparisons were made 
with Mann-Whitney U tests and paired analyses were performed using paired-
sample Wilcoxon matched-pairs signed rank tests. In the longitudinal cohort, non-
parametric tests were used for baseline-follow up comparisons as the number of 
patients was too small too meaningfully perform normality testing. For the 
descriptive data in the larger cohort (n=35), who were tested once, data were 
displayed as median (range) to demonstrate the wide range in lung function. On 
HRCT, whilst GGO score, bands, curvilinear bands, and A/B ratio were not normally 
distributed, the residuals in all of the final regression models did not differ 
significantly from a normal distribution (Pearson omnibus normality test p>0.05). 
The strength of relationships were assessed using the Spearman rank correlation. 
Stepwise linear regression with backward elimination was used to identify HRCT 
parenchymal and vascular results which correlated with the results of the lung 
function tests. HRCT variables examined in the preceding bivariate analyses were 
entered as initial predictors, unless predictors were multi-collinear. All regression 
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models were built in the sample size n=35. All final models satisfied the 
assumptions of multiple linear regression. In the longitudinal cohort, exploratory 
models were generated to test whether baseline vascular markers predicted 
subsequent deterioration of parenchymal disease and progression of lung function 
abnormalities. Logistic regression was used to assess the effect of baseline 
segmental A/B ratio and CSA<5mm on the deterioration in the overall CT 
appearance (‘Gestalt’ change score) and linear mixed model analysis (LMM) to 






Thirty-five patients with a median age of 43 (range 17-73) years were assessed. 
Twenty of the 35 patients (median age at initial assessment 38, range 17 – 66 
years) had been assessed at a median of 6.6 (range 5.5-6.7) years previously. Of the 
thirty-three patients who participated in the original study 20 were tested at 
follow-up: three had died, six were lost to follow-up three declined to participate in 
the follow-up study and one declined to undergo HRCT scanning and was excluded. 
The twenty patients who were tested at follow-up were included in the 2009-2013 
cohort, together with fifteen new patients making a total of thirty-five patients 
(Figure 4.1). Patient characteristics for the combined cohort of thirty-five patients 




Figure 4-1  Consort diagram showing flow of subjects for the main and longitudinal studies. 
 
 Median (range) 
n=35 
Age (yrs) 43.3 (17.1 – 73.5) 
[Hb] (g/dl) 7.9 (4.3 – 12.7) 
LDH (IU/L) 454 (173 – 1044) 
Reticulocytes (109/L) 260.7 (130.0 – 588.4) 
Bilirubin (mmol/L) 41 (11 – 168) 
ACS ever n (%)* 13 (37.1) 
Table 4-1 Clinical characteristics of the entire cohort (n=35).   





4.3.2 Lung function test results 
 
There was a wide variation in the lung function of the cohort (table 4.2). In total, 28 
of the 35 patients (80%) had lung function abnormalities: 8 (23%) had a restrictive 
abnormality, 6 (17%) an obstructive abnormality, 4 (11%) a mixed abnormality and 
10 (29%) an isolated reduction in carbon monoxide diffusing capacity (DLCO). Six 
patients (17%) had a significant response to bronchodilator; three had an 
obstructive, one a mixed and one a restrictive abnormality, and one no lung 
function abnormality. Sixteen patients (46%) had elevated Rrs; six of whom 














 Median (range) 
n=35 
FEV1 77.4 (27.4–114.2) 
VC 81.3 (27.8–113.0) 
FEV1:VC  96.3 (75.9–115.8) 
FEF25-75 69.6 (13.7–129.2) 
TLC 87.8 (63.8–109.6) 
RV 93.5 (50.1–162.6) 
RV:TLC 106.3 (64.6–197.4) 
DLCOc 73.6 (43.9–104.8) 
KCOc 94.0 (67.5–124.8) 
Rrs(0) 128.2 (79.4–209.0) 
Rrs(1) (kPa L−1 s−1 Hz)*  0.018 (0.001–0.042) 
SpO2 (%)*  96.0 (85.0–100.0) 
 
Table 4-2 Lung function test results in the whole cohort for the CT study  (n=35). 
 Includes the follow-up visit for the subgroup with longitudinal measurements. 





Figure 4-2 TLC and FEV1:VC expressed as z-scores for the whole cohort, showing the presence of restriction 
and airflow obstruction.   






4.3.3 HRCT abnormalities 
 
A reticular pattern on HRCT was the most prevalent and extensive abnormality, 
seen in 26 patients (median 5 (range 0–17.5) %). Ground glass opacification was 
present in nine patients (median extent 0 (range 0–3)). Consolidation was seen in 
nine patients (median extent 0.4 (0–4.2)). Reduction in lobar volume was seen in 19 
patients (median severity 1 (range 0–7)). Linear bands were seen in 23 patients 
(median 1 (range 0–6)) and subpleural curvilinear lines in 9 patients (median 0 
(range 0–3)). Subpleural consolidation (n=6), thickened interlobular septa (n=2), 
infarcts (n=7) and traction bronchiectasis (n=0) were present in a minority of 
patients and excluded from further analysis. The median A/B ratio was 1.30 (range 
1.0–2.50) and CSA<5 mm% 0.48 (range 0.22–10.2). The extent of a reticular pattern 
was positively correlated with the presence of linear bands (r=0.64, p<0.0001) and 
ground glass opacification score (r=0.42, p=0.0115). The presence of linear bands 
was positively correlated with subpleural curvilinear lines (r=0.39, p=0.0204), which 
were positively related to the A/B ratio (r=046, p=0.0056). The A/B ratio and CSA<5 
mm% were positively correlated (r=0.72, p<0.0001). 
 
4.3.4 Relationships between pulmonary function and HRCT results 
 
Subpleural curvilinear lines were negatively correlated with FEV1 (r=−0.39, 
p=0.0230) and FEF25-75(r=−0.44, p=0.0403), and the extent of a reticular pattern was 
negatively correlated with Rrs(0) (r=−0.40, p=0.0198). TLVCT was positively 
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correlated with FEV1 (r=0.57, p=0.0014), VC (r=0.66, p < 0.0001) and TLC (r=0.82, 
p<0.0001). The segmental A/B ratio was negatively correlated with FEV1 (r=−0.53, 
p=0.0011), VC (r=−0.48, p=0.0036), FEF25-75 (r=−0.44, p=0.0403) and SpO2 (r=−0.47, 
0.0037), and positively with RV:TLC (r=0.45, p=0.0073), and Rrs(1) (r=0.22, 
p=0.0267) (Figure 4.3). The CSA<5 mm% was negatively correlated with FEV1 
(r=−0.71, p<0.0001), VC (r=−0.72, p<0.0001), FEF25-75 (r=−0.51, p=0.0010) and SpO2 
(r=−0.44, p=0.0070), and positively to RV (r=0.51, p=0.0020), RV:TLC (r=0.695, 
p<0.0001), Rrs(0) (r=0.35, p=0.0417) and Rrs(1) (r=0.67, p<0.0001) (Figure 4.4).  
 
The segmental A/B ratio and CSA<5 mm% exhibited a strong degree of 
multicollinearity. Therefore, separate models were generated with segmental A/B 
ratio or CSA<5 mm% as predictors. On stepwise regression, the segmental A/B ratio 
was independently related to a reduced FEV1, VC, FEF25/75 and SpO2 and to an 
increased RV, RV:TLC, Rrs(0) and Rrs(1) (table 4.3). Linear bands were independently 
linked to a reduced FVC and TLC (table 4.3).The CSA<5 mm% was independently 
linked to a reduced FEV1, VC, FEF25-75 and SpO2 and to an increased RV, RV:TLC, 
Rrs(0) and Rrs(1) (table 4.4). The extent of a reticular pattern was associated with a 
reduced Rrs(0) and Rrs(1) (table 4.4).  On multiple linear regression, restrictive and 
mixed obstructive/restrictive, but not purely obstructive defects, were associated 
with a significant reduction in TLVCT (β= -1.092, p=0.0045; β= -1.231, p=-0.0212; β = 
-0.014, p=0.9783), suggesting that CT measurement of lung volume may provide an 
alternative method of diagnosing restrictive lung disease in patients unable to 





HRCT R2 β (95% CI) p Value 
FEV1 Segmental A/B ratio 0.40 −0.636 (−0.937 to −0.335) <0.0001 
VC Segmental A/B ratio 0.42 –0.561 (−0.855 to −0.267) 0.0002 
Bands  −0.288 (−0.563 to −0.013) 0.0397 
FEF25-75 Segmental A/B ratio 0.19 −0.447 (−0.772 to −0.122) 0.0070 
TLC Bands 0.11 −0.336 (−0.670 to −0.001) 0.0484 
RV Segmental A/B ratio 0.32 0.478 (0.168 to 0.788) 0.0026 
GGO score  −0.344 (−0.645 to −0.043) 0.0249 
RV:TLC Segmental A/B ratio 0.40 0.623 (0.312 to 0.934) 0.0001 
Rrs(0) Segmental A/B ratio 0.32 0.431 (0.104 to 0.758) 0.0098 
Reticular pattern  −0.497 (−0.827 to −0.167) 0.0032 
Rrs(1) Segmental A/B ratio 0.33 0.554 (0.232 to 0.876) 0.0008 
Reticular pattern  −0.316 (−0.620 to −0.012) 0.0414 
SpO2 Segmental A/B 
ratio 
0.22 −0.466 (−0.789 to −0.143) 0.0047 
 
Table 4-3 Results of multivariate analysis with the segmental A/B ratio as a predictor.  
 HRCT, high-resolution CT; GGO, ground glass opacification; RV:TLC, residual volume:total lung capacity ratio; 





Figure 4-3  Relationship between lung function tests and segmental artery-bronchus ratio on HRCT. 
  Lung function tests are expressed as percentage of predicted except where indicated.  Lines represent the 






Lung function HRCT R2 β(95% CI) p Value 
FEV1 CSA<5 mm% 0.52 −0.666 (−0.948 to −0.384) <0.0001 
Curvilinear bands  −0.213 (−0.458 to 0.032) 0.0885 
VC CSA<5 mm% 0.51 −0.721 (−1.006 to −0.436) <0.0001 
0.0209 
FEF25-75 CSA<5 mm% 0.26 −0.508 (−0.826 to −0.190) 0.0018 
TLC Bands 0.11 −0.336 (−0.670 to −0.002) 0.0484 
RV CSA<5 mm% 0.36 0.518 (0.213 to 0.823) 0.0009 
RV:TLC CSA<5 mm% 0.61 0.763 (0.468 to 1.058) <0.0001 
Rrs(0) CSA<5 mm% 0.34 0.422 (0.122 to 0.722) 0.0058 
Reticular pattern  −0.516 (−0.836 to −0.196) 0.0016 
Rrs(1) CSA<5 mm% 0.58 0.748 (0.458 to 1.038) <0.0001 
Reticular pattern  −0.516 (−0.964 to −0.068) 0.0237 
SpO2 CSA<5 mm% 0.36 −0.593 (−0.913 to −0.273) 0.0003 
 
Table 4-4 Results of the multivariate analysis with CSA <5 mm% as a predictor.   




Figure 4-4  Relationship between lung function tests and CSA<5mm% on HRCT.   
Lung function tests are expressed as percentage of predicted except where indicated. Lines represent the 





4.3.5 Echocardiography results 
 
The median TRV was 2.65 (range 1.19–3.60) (m/s), the median estimated PASP 33.5 
(range 9.0–70.0) (mm Hg), the median CO 6.0 (range 3.3–9.1) (L/min) and the 
median RVDV 93.9 (range 36.7–182.6) (mL). The median TAPSE was 2.30 (1.00–
3.95) (cm), and the median E/e′ ratio was 7.60 (4.70–16.60). Significant correlations 
were observed between CO and the A/B ratio (r=0.41, p=0.0120) and the CSA<5 
mm% (r=0.35, p=0.0440), but not with the estimated PAP. There was a correlation 
of CSA<5 mm% with E/e′ (r=0.45, p=0.009). There was also a correlation of CSA<5 
mm% with TAPSE (r=−0.38, p=0.035), but only one subject had an abnormal TAPSE 
result (<1.5) and thus it is not possible to comment on the relationship between 
HRCT indices of vascular dilatation and echo indices of RV dysfunction.  
 
The segmental A/B ratio and the CSA<5 mm% were significantly correlated with the 
haemoglobin level (r=−0.50, p=0.0021; r=−0.42, p=0.0090, respectively) and the 
lactate dehydrogenase (LDH) level (r=0.33, p=0.0450; r=0.33, p=0.0492, 
respectively). The segmental A/B ratio was related to the bilirubin level (r=0.47, 







4.3.6 Longitudinal analysis 
 
The lung function results of the 20 patients who were reassessed had declined 
significantly (table 4.5, Figure 4.5). There were, however, no significant changes 
seen in the prevalence or extent/severity of lung parenchymal abnormalities on CT, 
but both the median segmental A/B ratio and CSA<5 mm% had increased 
significantly over the follow-up period (table 4.6). Four patients (20%) had a gestalt 
change score of one. The percentage change from baseline in the A/B ratio 
correlated negatively with that in FEV1 (r=0.330, p=0.0156) and carbon monoxide 
transfer coefficient, corrected for haemoglobin concentration (KCOc) (r=−0.554, 
p=0.0139) and positively with that in RV (r=0.475, p=0.0342) and RV:TLC (r=−0.557, 
p=0.0107). The percentage change from baseline in CSA<5 mm% correlated 
negatively with that in FEV1 (r=−0.330, p=0.0079) and VC (r=−0.487, p=0.0357) and 
positively with RV:TLC (r=0.557, p=0.0164). Logistic regression demonstrated that a 
higher CSA<5 mm% at baseline was predictive of a subsequent overall deterioration 
in HRCT appearance, that is, a gestalt change score of 1 (OR 2.62 (95% CI 1.14 to 
6.01) per unit increase in CSA<5 mm%, p=0.023). Linear mixed model analysis 
demonstrated a significant association of baseline CSA<5 mm% with subsequent 
decline in TLC, with an increased decline of −1.84% (95% CI −3.31 to −0.37) per year 
for each unit increase in CSA<5 mm% at baseline, p=0.014. CSA<5 mm% was also 
predictive of a more rapid change in RV:TLC, with a change in slope of +4.93% (95% 
CI 0.88 to 8.99) per year per unit increase in CSA<5 mm% at baseline, p=0.017.  
Plots of the percentage change from baseline in TLC and RV:TLC versus CSA<5mm% 









FEV1 80.6 (41.9–115.4) 70.9 (25.5–98.4) 0.0004 
VC 80.5 (48.4–102.3) 74.5 (27.1–106.6) 0.0347 
FEV1:VC  104.8 (90.9–129.3) 98.7 (74.0–113.0) 0.0261 
FEF25-75 87.0 (33.5–136.3) 70.1 (19.6–129.2) 0.0033 
TLC 87.6 (67.2–107.0) 85.5 (63.8–109.6) 0.5628 
RV 87.6 (46.3–125.0) 90.0 (50.1–162.6) 0.1213 
RV:TLC 102.0 (56.1–160.4) 111.1 (64.6–197.0) 0.0383 
DLCOc 74.1 (42.7–104.1) 74.3 (45.3–104.8) 0.9879 
KCOc 111.5 (85.0–154.9) 104.8 (77.0–137.8) 0.0325 
SpO2(%)*  97 (84–99) 97 (85–100) 0.4380 
 
Table 4-5 Pulmonary function results at initial and follow-up assessment in the subgroup with longitudinal 
measurements (n=20).   
Data are expressed as median (range) and presented as per cent predicted for height, age and sex unless 






Figure 4-5 Pulmonary function results at initial and follow-up assessment. 
Lung function tests are expressed as percentage of predicted except where indicated. Individual data are 













Reticular pattern 5.4 (0.0–17.5) 5.8 (0–17.5) 0.1987 
Ground glass 
opacification score 
0 (0–3) 0 (0–3) 0.3458 
Decreased attenuation 1.3 (0.0–16.7) 1.3 (0.0–16.7) 0.9793 
Consolidation 0.0 (0.0–4.2) 0.0 (0.0–1.7) 0.5000 
Lobar volume loss 1 (0–7) 1 (0–7) 1.0000 
Linear bands 1 (0–5) 1.5 (0–6) 0.0961 
Subpleural curvilinear 
lines 
0 (0–2) 0 (0–2) 0.0890 
A/B ratio 1.26 (0.90–1.70) 1.50 (1.05–2.50) 0.0347 
CSA<5 mm% 0.26 (0.14–0.52) 0.54 (0.22–1.10) <0.0001 
 
Table 4-6  High-resolution CT (HRCT) parenchymal and vascular analysis at initial and follow-up assessment.  





Figure 4-6  Percentage change from baseline for TLC and RV:TLC versus baseline CSA<5mm% in the subgroup 








These data demonstrate that pulmonary vascular abnormalities on HRCT are 
significantly related to pulmonary function impairment in adults with SCD. The 
segmental A/B ratio and CSA<5 mm% were independently linked to reductions in 
FEV1, VC and FEF25/75 and to increased respiratory system resistance and RV:TLC. In 
addition, small vessel size correlated with reduced oxygen saturation and 
haemoglobin concentration and increased LDH, bilirubin and reticulocyte levels. 
Those results suggest relationships between anaemia, haemolysis, hypoxia and 
pulmonary function abnormalities. A positive correlation was observed between 
CSA<5 mm% (a measure of distal arteries and veins) and E/e′ which is a marker of 
left atrial filling pressure that is elevated if there is LV diastolic dysfunction. A 
higher E/e′ would result in some elevation of pulmonary venous pressure, and this 
result suggests a role for precapillary and postcapillary pulmonary vascular changes 
in SCD-related lung disease. There was a negative relationship with vascular 
dimensions and VC, FEV1, FEF25-75 and SpO2 and a positive relationship with RV, 
RV:TLC, Rrs(0) and Rrs(1), suggesting vascular dimensions were related to an 
obstructive defect. VC, FEV and FEF25-75, however, can be reduced in both 
obstruction and restriction and thus the correlations with markers of vascular 
dilation and reductions in VC, FEV1 and FEF25-75 may also indicate a relationship 




In this cohort, 23% of patients had evidence of a restrictive lung function defect 
and 17% had evidence of an obstructive defect. Those results are consistent with 
those of Santoli et al [133] but differ from those of Klings et al, [134] who found a 
much lower incidence of airflow obstruction. The differences may be due to a 
number of factors. This study used a recently reported ethnic-specific reference 
range for spirometry, [186] whereas Klings et al [134] used a Caucasian reference 
range with fixed correction factors to adjust for ethnicity. In this study 
abnormalities were classified based on the lower limit of normal based on 
percentiles recommended by the American and European Thoracic Societies, [136] 
whereas Klings et al used a fixed percentage predicted value to define the lower 
limit of normal for all lung function indices, which does not take into account that 
the limits of the normal range vary with age, sex and ethnicity [190]. Furthermore, 
the classification scheme in the Klings study specified that in order to be classified 
as obstructive or mixed, the DLCO had to be normal, which precluded the 
possibility that impaired gas transfer coexisted with airway abnormalities.  
 
Restrictive lung function defects, that is, a reduced TLC and RV, were not associated 
with the extent of ground glass opacification or a reticular pattern and showed only 
a modest association with linear bands, suggesting interstitial fibrosis may not be 
the predominant mechanism for loss of lung volume in patients with SCD. Indeed, 
most CT markers of pulmonary fibrosis showed no association with reductions in 
VC, FEV1, FEF25/75, RV:TLC SpO2, Rrs(0) or Rrs(1). The extent of a reticular pattern was 
associated with a reduction in respiratory system resistance; it is reasonable to 
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speculate that this might be due to the tractional effects of areas of fibrosis on 
adjacent bronchi. Subpleural curvilinear bands were noted in 26% of patients; this 
is an unusual CT sign, formerly believed to be pathognomonic of early asbestosis 
[191]. Subpleural curvilinear bands have subsequently been described in 
association with micro-atelectasis in patients with atrial septal defect [192] or 
respiratory muscle weakness [193] and as reversible sign caused by interstitial 
oedema resulting from pulmonary congestion [194]. Observations in subjects 
without lung disease and undergoing lymphography have led to the suggestion that 
the sign may represent an engorged subpleural lymphatic network [195].  Given the 
presence of a high-output state in SCD, and the correlation of subpleural curvilinear 
lines with markers of small-vessel dilatation observed in this cohort, it is tempting 
to speculate that this pattern may be related to interstitial oedema and/or 
increased lymphatic drainage.  
 
This study highlights a decline in lung function over a median of 6.6 years in adults 
with SCD. A significant decrease was observed in VC, FEV1, FEF25-75, FEV1:VC and 
KCOc with a significant increase in RV:TLC. There were no significant changes in the 
results of the CT assessments other than in vascular dimension assessments, where 
both the A/B ratio and CSA<5 mm% significantly increased. Those results indicate 
an association between changes in pulmonary vascular dimensions and the decline 
in lung function. Furthermore, a greater baseline CSA<5 mm% was predictive of a 
more rapid progression of both obstructive (increasing RV:TLC) and restrictive 
(decreasing TLC) lung disease and an increased likelihood of a deterioration in 
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parenchymal disease, as evidenced on HRCT examination, suggesting that the 
association observed between markers of pulmonary vascular dilatation may 
represent a causal relationship. Whilst TLC and RV did not decline significantly over 
the follow-up period for the group as a whole, these exploratory analyses suggest 
that suggest that there may be a degree of heterogeneity in the response to ageing 
and that a subgroup of patients do suffer a continued progression of restrictive 
disease. It may be of benefit, therefore, to test this hypothesis in a larger cohort. 
Our results emphasise the phenotypic heterogeneity of SCD lung disease. The 
changes in vascular morphology related to obstructive defects and to the likelihood 
of deteriorating interstitial lung disease, suggesting that there may be a shared 
mechanism involving small pulmonary vessels. Field et al [196] demonstrated that 
bone marrow-derived fibrocytes may be mobilised into the circulation and 
subsequently extravasate into the lungs of SCD mice. There they function as 
mesenchymal progenitor cells for the production of extracellular matrix and 
contribute to the development of fibrosis. Elevated levels of circulating fibroctyes 
have been observed in humans with SCD [196].  It is tempting, therefore, to 
speculate that pulmonary vascular engorgement and distension may potentiate 
extravasation of circulating fibrocytes.  
 
This study has strengths, but some limitations too. A strength of this study was the 
use of two different quantitative methods for assessing pulmonary vascular 
morphology, the segmental A/B ratio and CSA<5 mm%, which yielded similar 
results. Ethnic-specific reference ranges were used for spirometric indices, but the 
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static lung volume results were related to reference ranges derived from Caucasian 
subjects with a fixed correction factor to account for ethnicity. All the study 
population, however, were African or Caribbean, thus correlations within the 
cohort and comparisons between results at baseline and follow-up were valid. A 
limitation is that subjects did not undergo right heart catheterisation to obtain 
pulmonary artery pressures and pulmonary vascular resistance, but all the patients 
underwent the same echocardiographic protocol. Studies have demonstrated a 
minority of patients with elevated TRV have elevated pulmonary artery pressure. In 
a recent study, only 8 of 26 patients with elevated TRV at echocardiography had 
elevated pulmonary artery pressure confirmed by right heart catheterisation [77] 
and similar findings were reported in a larger study with 10.4% of 243 patients with 
elevated TRV having pulmonary hypertension [197]. Different HRCT protocols were 
used in the earlier study [73], and in this study, however, care was taken to ensure 
that all the images used for comparisons were from anatomically comparable 
sections. In addition, scoring was undertaken by observers who were blinded to the 
results of lung function and echocardiography results. The consistent relationship 
between CSA<5 mm%, A/B ratio and lung function test results suggests the 
different protocols did not adversely influence the results. Furthermore, this study 
has shown that, if TLVCT is measured, volumetric HRCT scans are able to capture 
both restrictive and obstructive functional abnormalities, providing an alternative 








In conclusion, this study has demonstrated an association between small-vessel 
pulmonary vascular dimensions on HRCT reflecting pulmonary vascular volume, 
lung function abnormalities and echocardiographic estimates of CO and ventricular 
function in adults with SCD. These results suggest that abnormalities in pulmonary 
vascular volumes may explain some of the lung function abnormalities and the 













5. AIRWAYS OBSTRUCTION AND PULMONARY 
CAPILLARY BLOOD VOLUME IN CHILDREN WITH 
SICKLE CELL DISEASE 
 
Note: The twenty-five SCD patients in the bronchodilator subgroup were recruited 
by Dr Catherine Wedderburn (King’s College London), who assisted with testing.  
Lung function tests and statistical analyses were performed by the candidate.   
5.1 Introduction 
 
Obstructive lung function abnormalities appear to be common in children with SCD 
[139, 140, 145], but the aetiology is unclear. Dilation of the pulmonary vasculature 
resulting from the increased pulmonary capillary blood volume, which occurs in 
SCD patients as a result of chronic anaemia [123, 129, 130, 198], may increase 
peripheral airway obstruction. Inflation of the leg compartments of pneumatic 
trousers increases thoracic blood volume and increased respiratory resistance in 
healthy volunteers [124]. Acute intravascular volume expansion increased air flow 
obstruction in patients with left ventricular dysfunction [125]. In addition, in 
patients with impaired left ventricular function, pre-treatment with methoxamine a 
potent vasoconstrictor, fully prevented the methacholine induced decrease in 
forced expiratory volume in one second (FEV1) suggesting that the 
bronchoconstriction was mediated, at least in part, by vascular dilatation [128]. The 
aim of this study was to determine whether in children with SCD their increased 
pulmonary capillary blood volume was associated with airways obstruction.  This 
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study, therefore, determined whether there were significant correlations between 
lung function tests and pulmonary capillary blood volume in children with SCD and 
age and ethnic matched controls. In a subset of subjects, measurements were 
repeated before after bronchodilator administration to assess whether any airflow 
obstruction observed was reversible, and whether any relationships between 
airflow obstruction and pulmonary capillary blood volumes were still present after 





Children with HbSS disease were recruited. Age and ethnic matched children 
without HbSS were recruited as controls; they were siblings of the SCD children or 
from local schools. Controls were recruited such that overall group characteristics 
were matched (Table 5.1) all control subjects were of a similar ethnic background 
to the children in the SCD group.  Only children over seven years of age were 
recruited as they were likely to be able to complete the lung function tests. 
Respiratory system resistance, spirometry, body plethysmography and then 
pulmonary capillary blood volume were assessed. In a subset of SCD patients 
(n=25) and controls (n = 25), comprising the first twenty-five consecutive subjects 
recruited in each group,  respiratory system resistance, spirometry and pulmonary 
capillary blood volume were measured before and 30 minutes after bronchodilator 
(ipratropium bromide) administration. An anticholinergic, ipratropium bromide, 
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was used as the bronchodilator as it has minimal cardiovascular side effects [199]. 
In the bronchodilator subgroup each subject was given eight puffs of ipratropium 
bromide via a metered dose inhaler and spacer device (20 μg per metered 
inhalation, i.e., total dose 160 μg) - the MDI was vigorously shaken between puffs 
and the delivery of each puff was followed by five normal breaths. Children in this 
subgroup were assessed pre and post-bronchodilator to determine whether any 
changes in response to the bronchodilator were greater in the SCD children and to 
evaluate whether any correlations observed between lung respiratory system 
resistance and pulmonary capillary blood volume remained after bronchodilation. 
For SCD children who underwent regular transfusions as part of their clinical care, 
lung function tests were performed immediately before their monthly transfusion 
to obviate any acute effects of blood transfusion on lung function. The study was 
approved by the King's College Hospital Research Ethics Committee and parents 
gave informed written consent for their child to take part. 
 
5.2.1 Lung function assessments 
 
FEV1, vital capacity, forced expiratory flow between 25 and 75% of VC, total lung 
capacity, residual volume and respiratory system resistance were measured as 
previously described (Section 3).  Since airways resistance can be altered by deep 
inspiration, Rrs was measured before any of the other lung function tests. 
Furthermore, as the majority of the pulmonary blood volume is in the periphery of 
the lung [199], a resistance at 5 Hz was used (Rrs5), as low oscillation frequencies 
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have been shown to be transmitted more distally in the lung and therefore may 
reflect changes in peripheral airway calibre, [200] which are more likely to be 
influenced by an increased pulmonary capillary blood volume. The Rrs5 results 
were expressed as the percent predicted for height using the reference range of 
Nowoweijska et al [201]. The mean of two measurements within 5% of each other 
was reported. 
Patients were diagnosed with an obstructive abnormality if their FEV1:FVC was less 
than the lower limit of normal (LLN), based on the ethnic specific reference range 
of Quanjer et al [186]. A restrictive abnormality was diagnosed if the TLC was below 
the LLN based on the reference range of Rosenthal et al [202], with a −12% 
correction factor applied [136]. A mixed abnormality was diagnosed if the TLC and 
FEV1:VC were less than the LLNs. 
 
5.2.2 Pulmonary capillary blood volume 
 
Pulmonary capillary blood volume was measured using the single breath-hold 
method for gas transfer for carbon monoxide (DLCO) and nitric oxide (DLNO) as 
previously described.  Pulmonary capillary blood volume was expressed as Vc per 
unit alveolar volume (Vc/VA). The mean of two measurements within 5% was 
reported. Results were corrected for haemoglobin concentration [Hb]. 
 




Haemoglobin, lactate dehydrogenase (LDH), bilirubin levels and reticulocyte counts 
were obtained from routine blood tests taken within one month of testing when 
patents were clinically stable.  For the control subjects, Hb was measured non-
invasively using Hb-pulse oximetry with a paediatric probe (Masimo Radical 
7 + rainbow probe, Masimo, CA). 
 
5.2.4 Sample size 
 
For the bronchodilator sub-analysis, comparison of 25 children in each group 
allowed detection of a change in respiratory system resistance at 5Hz  of 
0.31kPa/l/sec (one standard deviation of the normative data of Tomalak et al. 
[203]) between the groups and before and after bronchodilator administration with 
90% power at the 5% level. 
5.2.5 Statistical analysis 
 
Data were tested for normality using the D’Agostino and Pearson omnibus 
normality test. Since data were not normally-distributed, comparisons were made 











Sixty-seven children with SCD and thirty-six controls were tested.  Testing this 
number of patients allowed the relationships between spirometric measures of 
airflow obstruction to additionally be assessed reliably as these measurements are 
less sensitive than respiratory system resistance.  The SCD children and the controls 
were of similar age, but the median haemoglobin levels of the SCD children were 
significantly lower than that of the controls (P < 0.0001; Table 5.1).  There was a 
trend towards a greater proportion of girls in the control compared to the SCD 
group, although this did not reach statistical significance. 
 SCD children Controls p 
n 67 36 
 
Age (years) 13.4 (7.4–18.2) 14.4 (7.4–18.0) 0.2247† 
Male gender, n (%) 36 (54) 12 (33) 0.0627‡ 
Haemoglobin (g/dl) 8.2 (6.1–10.9) 12.5 (10.1–15.0) <0.0001† 
 
Table 5-1 Demographics by SCD status.   





Sixteen SCD children (24%) had a physician diagnosis of asthma (clinician 
documented asthma in the medical records) and twenty-two (33%) had had at least 
one acute chest syndrome (ACS) episode.  Ten SCD children (15%) were receiving 
hydroxyurea treatment and sixteen (24%) were undergoing regular transfusions.  
Four of the controls had a physician’s diagnosis of asthma (11%), this did not differ 
significantly to the proportion of SCD children with a physician’s diagnosis of 
asthma (p=0.1904). 
In the SCD group, 11 children (16%) had an obstructive, 10 (15%) a restrictive and 
three (4%) a mixed abnormality.  Fourteen SCD children (21%) had evidence of 
airflow obstruction; i.e., had an obstructive or mixed obstructive/restrictive 
abnormality.  In the control group three children (8%) had an obstructive and none 
a mixed restrictive pattern.  Both obstructive and restrictive abnormailities were 
significantly more common in the SCD group compared to the controls (p = 0.0479, 
p = 0.0035 respectively). 
 
5.3.2 Lung function and pulmonary capillary blood volume 
 
The SCD children compared to the controls had significantly higher median Rrs5 (p 
< 0.0001), RV:TLC (p=0.022) and KCOc (p = 0.0082) and lower FEV1 (p < 0.0001), VC 
(p < 0.0001), FEV1:VC (p = 0.0116), FEF25-75 (p < 0.0001), TLC (p < 0.0001) (Table 5.2).  
Pulmonary capillary blood volume was significantly higher in the SCD children (p < 












    
   Rrs5 123.1 (77.1-204.5) 98.8 (64.3-155.4) <0.0001 
    FEV1  82.0 (54.8-139.6) 104.4 (73.4-131.8) <0.0001 
    VC 89.5 (58.2-142.1) 106.0 (80.2-140.7) <0.0001 
    FEV1:VC 93.9 (70.0-108.8) 99.4 (74.5-112.8) 0.0116 
   FEF25-75 63.1 (22.5-127.0) 102.3 (37.5-160.7) <0.0001 
    TLC  90.3 (63.1-135.2) 101.0 (84.5-125.3) <0.0001 
    RV  86.0 (31.8-131.2) 89.8 (55.1-155.3) 0.3667 
    RV:TLC 114.8 (49.9-179.2) 108.3 (69.1-157.5) 0.2275 
   DLCOc 90.3 (64.9-138.3) 91.0 (66.1-127.7) 0.6756 
   KCOc 94.8 (75.9-140.2) 87.6 (77.8-115.1) 0.0082 
    
   Vc/VA* (ml/L) 24.9 (14.0 - 50.5) 18.2 (12.2 - 28.2) <0.0001 
 
Table 5-2 Lung function and pulmonary capillary blood volume data by SCD status.  
The results are expressed as median (range) and percent predicted for height except where indicated
*
. 





Figure 5-1 Impulse oscillometry and spirometry in SCD and control children.  
Data are presented as  





Figure 5-2 Lung volumes in SCD and control children.   





Figure 5-3 Gas transfer and pulmonary capillary blood volume in SCD and control children.  
Data are presented as percentage of predicted for height and sex except where indicated.  The red point 








There was a significant positive correlation in the SCD children between pulmonary 
capillary blood volume and Rrs5 (p < 0.0001) and RV:TLC (p = 0.0009) and a 
significant negative correlation with FEV1 (p = 0.0015), VC (p =0.0169) and FEF25-75 
(p = 0.0062) (Table 5.3). In the controls, there were no significant correlations 
between pulmonary capillary blood volume and any of the lung function tests 
(Table 5.4). Figure 5.1 shows the relationship between Rrs5 and pulmonary 
capillary blood volume in the SCD and control children.    
 In the SCD children the pulmonary capillary blood volume was significantly 
correlated with haemoglobin concentration (r = - 0.459, p < 0.0001), but not with 










LFT r† p† 
   
   Rrs5 0.500 <0.0001 
   FEV1 -0.390 0.0029 
   VC -0.291 0.0010 
   FEV1:VC -0.201 0.1011 
   FEF25-75 -0.433 0.0062 
   TLC -0.160 0.1187 
   RV:TLC 0.470 0.0009 
   RV 0.220 0.0739 
   
 
Table 5-3 Correlations between pulmonary capillary blood volume and lung function results in the SCD 
children. 









LFT r† p† 
   
   Rrs5 -0.120 0.4920 
   FEV1 -0.231 0.1735 
   VC -0.230 0.1845 
   FEV1:VC -0.081 0.6566 
   FEF25/75 -0.193 0.2718 
   TLC -0.02 0.8874 
   RV:TLC 0.343 0.4360 
   RV 0.333 0.0501 
   
 
Table 5-4 Correlations between pulmonary capillary blood volume and lung function results in the control 
children.  




Figure5-4  Rrs5 and pulmonary capillary blood volume (Vc/VA) in the SCD (red points) and control subjects 
(blue points).   
Lines represent the least-squares linear regression best fit in each group; the shaded areas are the 95% 










5.3.4 Bronchodilator response 
 
The SCD children in the subgroup who had post-bronchodilator measurements of 
respiratory system resistance and pulmonary capillary blood volume, compared to 
the controls, before and after bronchodilator administration, had a higher median 
Rrs5 (p=0.0046, p=0.0419 respectively) and a higher median Vc/VA (p<0.0001, 
p<0.0001 respectively) (Table 5.5).  Both groups had a significant decrease in Rrs5 
post bronchodilator (p<0.0001 SCD children, p<0.0001 controls), but there was no 
significant difference in the magnitude of the reduction in Rrs5 post-bronchodilator 
between the SCD children and the controls (p=0.090) (Table 5.5).  There were no 
significant changes in Vc/VA post-bronchodilator in either group (p=0.484 SCD 
children; p=0.514 controls) and no significant difference in the magnitude of 
change between the two groups (p=0.090) (Table 5.5).  Four of the SCD children 
and two of the controls had a significant response to bronchodilator based on FEV1. 
In the SCD children, there were significant correlations between Rrs5 and Vc/VA 
both pre-bronchodilator (r=0.540, p=0.005) and post-bronchodilator (r=0.482, 
p=0.015).  In the controls, there were no significant correlations between Rrs5 and 













n 25 25  
 
Pre bronchodilator: 
     Rrs5  
 
132.7 (87.7 – 181.1) 
 
102.4 (83.3 – 184.2) 
 
0.0046 
     Vc/VA (ml/l) 25.7 (18.2 – 38.4) 18.4 (13.9 – 25.0) <0.0001 
    
Post bronchodilator: 
     Rrs5  
 
105.0 (78.7 –150.0) 
 
91.3 (64.3 – 147.4) 
 
0.049 
     Vc/VA (ml/l) 25.8 (18.5 – 41.9) 17.7 (13.1 – 27.0) <0.0001 
    
 
Change in Rrs5 post-
bronchodilator (%) 
 
-18.5 (-36.0 to -4.6) 
 
-12.5 (-28.9 – 5.6) 
 
0.090 
    
Change in Vc/VA post 
bronchodilator (%) 
-1.6 (-8.4 – 6.1) -2.4 (-6.3 – 2.0) 0.587 
 
Table 5-5 Peripheral airways resistance and pulmonary capillary blood volume pre- and post-bronchodilator 
according to SCD status.  





This study has demonstrated that SCD children compared to ethnic origin matched 
controls had higher respiratory system resistance and pulmonary capillary blood 
volume both before and after bronchodilator.  Respiratory system resistance and 
pulmonary capillary blood volume results were significantly correlated in the SCD 
children, but not in the controls, suggesting the raised respiratory system 
resistance in the SCD children was, at least partly, explained by their increased 
pulmonary capillary blood volume.  Furthermore, pulmonary capillary blood 
volume correlated with the other measures of airway obstruction.  In addition, a 
significant negative correlation was observed correlation between the pulmonary 
capillary blood volume and vital capacity.   The raised pulmonary capillary blood 
volume seen in the SCD children is a response to their chronic anemia resulting in a 
raised cardiac output and increased pulmonary blood volume and vascular 
recruitment [123, 198]. The increase in pulmonary blood volume resulting from the 
increase in cardiac output due to their chronic anemia may explain the relatively 
normal DLCO results we report despite lower lung volumes.  These results are 
consistent with raised pulmonary capillary blood volume reported in adults with 
SCD [130].   The significant correlation with between pulmonary capillary blood 
volume and the hemoglobin levels emphasizes the relationship between the levels 
of anaemia, pulmonary capillary blood volume and peripheral airway obstruction.   
The SCD children had a significantly higher mean Rrs5 than the controls indicating 
they had elevated peripheral airways resistance and a greater prevalence of 
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obstructive abnormalities, findings consistent with other studies showing 
obstructive abnormalities in SCD children [139, 140, 145, 204].  Spirometry and 
lung volume measurements demonstrated that the SCD children compared to the 
controls had significantly greater obstructive and restrictive abnormalities.   
In the bronchodilator subgroup, whilst we observed a statistically significant 
change in lung function following bronchodilator administration,   magnitude of 
change in respiratory system resistance in the SCD group was similar to that seen in 
the control children. Given that a degree of bronchial tone occurs even in healthy 
individuals, it is not surprising that a decrease in Rrs5 was seen in both SCD and 
controls after bronchodilator administration.  These data indicate that the 
obstructive abnormalities observed in children with SCD are associated with their 
increased pulmonary capillary blood volume, rather than solely due to reactive 
airways disease.   
 
Key strengths of this study are that comparison was made of SCD children to ethnic 
matched controls that were of similar age, and that an anticholinergic 
bronchodilator, ipratropium bromide, was used to assess bronchodilator response. 
Ipratropium bromide has small and clinically unimportant hemodynamic effects 
[199], and would, therefore, avoid the potential effects on cardiac output of β2-
agonists which might impact pulmonary capillary blood volume. Indeed, no change 
in pulmonary capillary blood volume was seen after bronchodilator administration.    
Impulse oscillometry was used to assess respiratory system resistance, as this 
technique has been found to be more sensitive in assessing peripheral airway 
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function than spirometry [200].   The respiratory system resistance results were 
related to reference ranges derived from Caucasian subjects with [201], but the 
two groups were matched for ethnic origin and the same reference ranges were 
used in both groups, thus comparisons between them were valid.  The correlations 
between impulse oscillometry results and pulmonary capillary blood volume were 
supported by spirometric  measures of airway obstruction also correlating with 
pulmonary capillary blood volume.  Blood samples were not taken to assess 
hemoglobin levels in the controls, but the levels determined using the Hb pulse 
oximetry were within the normal range, as would be expected in healthy controls. 
In addition, non-invasive measurement of hemoglobin concentration has been 
validated in healthy adult volunteers undergoing haemodilution [205] and in adult 




In conclusion, these results suggest that the raised pulmonary capillary blood 
volume seen in SCD children may, at least partially, explain their increased airways 
resistance.  Strategies to reduce anaemia and increased pulmonary capillary blood 
volume, such as hydroxyurea or blood transfusion, may be beneficial in those who 




6. THE ACUTE EFFECT OF BLOOD TRANSFUSION ON 
AIRWAYS OBSTRUCTION AND PULMONARY 
CAPILLARY BLOOD VOLUME IN CHILDREN WITH 
SICKLE CELL DISEASE 
 
Note: All lung function tests and statistical analyses were performed by the 




Children and adults with SCD have an increased pulmonary capillary blood volume 
which is a response to their chronic anemia resulting in a raised cardiac output and 
increased vascular recruitment and distension [123, 129, 130, 198, 208, 209].   
Experimental increases in thoracic blood volume have been shown to increase 
airways resistance. Rapid saline infusion has been shown to produce a significant 
decrease in FEV1 in healthy adults [126, 127] as well as in patients with left 
ventricular failure  [125].  Lorino et al found that the inflation of pneumatic trousers 
in healthy subjects caused an increase in oscillometric resistance  [124].   
Additionally, acute increases in thoracic blood volume have been shown to increase 
sensitivity to methacholine [210] in heathy adults suggesting a role for vascular 
expansion in reactive airways disease.    Such studies have not, however, been 
performed for obvious reasons in SCD children.  
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Some SCD children receive transfusion as part of routine care [211], ,hence this 
treatment would allow a natural experiment to investigate whether fluid loading 
with consequent transient increase in cardiac output [127] worsened airflow 
obstruction in SCD.  Demonstration of such an effect would support the hypothesis 
that anaemia and increased pulmonary capillary blood volume might be 
responsible for the increased airways obstruction and wheezing seen in SCD 
populations. The aim of this study therefore was to test the hypothesis that 
transfusion would result in an acute increase in pulmonary capillary blood volume 




Children with HbSS disease undergoing regular blood transfusion at King’s College 
Hospital, London were recruited.  Only children six years of age or greater were 
recruited as they were likely to be able to complete the lung function tests.  
Impulse oscillometry, spirometry, and pulmonary capillary blood volume were 
measured before and immediately after transfusion.  In order to further 
characterise the patients, static lung volumes were measured before transfusion.  
The volume of packed red cells (PRCV) administered to each patient was 
determined using the following formula: PRCV (mls/kg) = patient weight (kg) * 
change in haemoglobin to be achieved (g/dl) * transfusion factor (4), in order to 
achieve a target haemoglobin concentration of 13.5g/dl.  All transfusions were 
administered over an interval of approximately four hours. The study was approved 
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by the King's College Hospital Research Ethics Committee and parents gave 
informed written consent for their child to take part. 
 
 
6.2.1 Lung function assessments 
 
FEV1, VC, forced expiratory flow between 25 and 75% of VC, total lung capacity, 
residual volume and respiratory system resistance were measured as previously 
described (Section 3).  As before, Rrs was measured before any of the other lung 
function tests, and a resistance at 5 Hz was used (Rrs5) to capture changes in small 
airway function. The Rrs5 results were expressed as the percent predicted for 
height using the reference range of Nowoweijska et al [201]. The mean of two 
measurements within 5% of each other was reported. 
Patients were diagnosed with an obstructive abnormality if their FEV1:FVC was less 
than the lower limit of normal (LLN), based on the ethnic specific reference range 
of Quanjer et al [186]. A restrictive abnormality was diagnosed if the TLC was below 
the LLN based on the reference range of Rosenthal et al [202], with a −12% 
correction factor applied [136]. A mixed abnormality was diagnosed if the TLC and 





6.2.2 Pulmonary capillary blood volume 
 
Pulmonary capillary blood volume was measured using the single breath-hold 
method for gas transfer for carbon monoxide (DLCO) and nitric oxide (DLNO) as 
previously described.  Pulmonary capillary blood volume was expressed as Vc per 
unit alveolar volume (Vc/VA). The mean of two measurements within 5% was 
reported. Results were corrected for haemoglobin concentration [Hb] from a blood 
test taken immediately before transfusion.  
 
6.2.3 Sample size 
 
18 children studied pre- and post-transfusion allowed detection of a change in 
respiratory system resistance at 5Hz  of 0.31kPa/l/sec (one standard deviation of 
the normative data of Tomalak et al. [203] 
  before and after transfusion administration with 80% power at the 5% level. 
 
6.2.4 Statistical analysis 
 
Data were tested for normality using the D’Agostino and Pearson omnibus 
normality test. Since data were not normally-distributed, paired analyses were 
performed using paired-sample Wilcoxon matched-pairs signed rank tests for pre- 








Eighteen subjects with a median age of 14.2 (range 6.6-18.5) years were assessed, 
seven of whom (39%) were female.  Their median haemoglobin was 10.1 (range 8.2 
– 11.6) g/dl, and PRVC 10.8 (5.9 – 16.4) ml/kg.  Eight children (44%) had had at least 
one episode of ACS and four (22%) had a physician diagnosis of asthma. 
 
6.3.2 Lung function and pulmonary capillary blood volume 
 
Prior to transfusion, six children had an obstructive (33%) and two (11%) a 
restrictive abnormality.  Pulmonary capillary blood volume, Rrs(5), DLCOc and KCOc 
all increased significantly after transfusion (p <0.0001, p <0.0001, p =0.0001 
respectively), whereas FEV1, VC, and FEF25-75 all declined significantly (p = 0.0056, p 
= 0.0008, p = 0.0483).  No significant change was seen in FEV1:VC (p = 0.2462) 
(Table 6.1) (Figure 6.1 and 6.2). The percentage change from baseline in pulmonary 
capillary blood volume was significantly correlated with that in Rrs5 (r = 0.61, p = 
0.0129) (Figure 6.3), VC (r = -0.53, p = 0.0362) (Figure 6.3) and KCO (r = 0.59, p = 
0.0216) (Figure 6.3) but not with FEV1 (r = -0.14, p = 0.6174 ), FEF25-75 (r = -0.31, p 











     
   Vc/VA* (ml/L) 21.6 (13.6 – 47.3) 28.2 (14.9 – 57.1) 25.2 (5.4-106.6) <0.0001 
     
   Rrs5 127.4 (88.9-207.8) 141.3 (96.1-234.1) 10.7 (-3.6 - 22.0) <0.0001 
    FEV1  84.4 (66.2-139.6) 79.4 (63.5-132.9) -4.9 (-20.5 - 8.6) 0.0056 
    VC 94.2 (73.7-142.1) 90.72 (60.5-144.0) -5.5 (-9.8 - 6.1) 0.0008 
    FEV1:VC 91.2 (73.0-105.3) 92.7 (74.5-112.8) -2.6 (-12.0 –17.5) 0.2462 
   FEF25-75 59.9 (34.4-122.5) 62.5 (30.3-111.5) -8.9 (-55.8 - 45.6) 0.0483 
   DLCOc 88.3 (76.0-122.6) 108.9 (81.2-145.5) 10.7 (1.0 - 27.4) <0.0001 
   KCOc 86.8 (75.1-109.3) 105.9 (80.5-123.8) 17.0 (-3.8 -3 5.7) 0.0001 
    TLC  92.2 (71.6-135.1) -   
    RV  90.1 (61.7-104.3) -   
    RV:TLC 105.1 (87.4-134.8) -   
 
Table 6-1  Lung function and pulmonary capillary blood volume before and after transfusion.   
The results are expressed as median (range) and percent predicted for height except where indicated
*
.  












Figure 6-3  Change in VC/VA and lung function after transfusion.   
Lines represent the least-square linear regression best fit in each group, the shaded areas are the 95% 






This study has demonstrated significant changes in lung function immediately 
following blood transfusion in children with SCD. There was an increase in 
respiratory system resistance and gas transfer with corresponding decreases in 
FEV1 and VC.  Pulmonary capillary blood volume also increased significantly, and 
this change was correlated with the change in Rrs5, VC and KCO.  
The increase in Rrs5 and decrease in FEV1 are consistent with worsening airflow 
obstruction following fluid loading by transfusion.  The VC also decreased, resulting 
in no significant change in FEV1:VC.  Whilst this might suggest a role for increased 
pulmonary capillary blood volume in the aetiology of restrictive abnormalities in 
SCD, given that no significant correlation was found between pulmonary vascular 
volumes and TLC in both adults and children with SCD in previous studies (see 
Chapters 4 and 5 of this thesis) it seems more likely that this represents loss of VC 
due to hyperinflation as a consequence of increasing small airways obstruction 
[208, 209].  Those results reinforce the association between elevated pulmonary 
capillary blood volume and obstructive abnormalities in children with SCD.   
 
Compared to healthy controls, children with SCD have an elevated cardiac output 
and pulmonary blood flow at rest, as well as raised pulmonary capillary blood 
volume as a result of chronic anaemia [198, 212].  On exercise, both pulmonary 
blood flow and pulmonary capillary blood volume increase with workload in SCD 
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children and controls [212].  In children with SCD, however, the increase in 
pulmonary blood flow relative to pulmonary capillary blood volume is 
disproportionately high compared to control subjects, indicating a lack of 
pulmonary vascular reserve [212] due to the fact that the pulmonary capillary 
vessels are already over-distended at rest [198].  This baseline distension may make 
children with SCD particularly sensitive to any further volume load, resulting 
perhaps in mechanical compression of the peripheral airways.  This may explain 
that, although the rate of infusion in this study was much slower than that in the 
study of Puri et al in patients with left heart failure (four hours versus thirty 
minutes) for a similar total fluid volume in ml/kg, the change in FEV1 was 
comparable [125].  An increase in respiratory system resistance in healthy subjects 
in response to intravenous infusion of normal saline has also been demonstrated 
[126, 127]. These results suggest a causal link between increased pulmonary 
vascular volume and airflow obstruction in SCD, and that it is possible wheezing 
reported in some children with SCD may have been incorrectly attributed to 
asthma. 
 
This study has some strengths and some limitations.  The children who participated 
in the study all undergo regular transfusions as part of their clinical management, 
this means that they are, in general, likely to suffer from more severe disease  and  
may,  therefore, be at greater risk of SCD-related vasculopathy [48, 52, 53].   Such 
children may have early pulmonary vasculopathy and this may have modulated 
their response to fluid loading.  It would, however, be inappropriate to administer a 
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fluid load to an unselected cohort of SCD children.  Hence, investigating SCD 
children following a transfusion represents an appropriate methodology to study 
the effects of this potential disease mechanism. Haemoglobin levels take 
approximately 24 hours to stabilise after transfusion, hence the pre-transfusion Hb 
level was used to correct the DLCO measurement from which pulmonary capillary 
blood volume was derived, which may have resulted in an overestimation of the 
change in pulmonary capillary blood volume.  The median haemoglobin level in this 
cohort, however, was relatively high (10.1 g/dl) and therefore the error introduced 
by correcting for haemoglobin concentration was likely to have been small [131].  
Indeed the change in pulmonary capillary blood volume correlated with both the 
change in Rrs5 and VC neither of which are influenced by the haemoglobin 
correction.  A difficulty in the interpretation of these data is the lack of a control 
group. It would, however, not be ethically acceptable to administer blood 
transfusions or intravenous fluids to children in whom there was no medical 
requirement to do so.   The respiratory system resistance results were related to 
reference ranges derived from Caucasian subjects [201], but since the same 
reference range was used for both pre- and post-transfusion measurements, paired 
comparisons between them were valid.  Static lung volumes were not measured 
post-transfusion in order to minimize the time burden on the participants, and 
therefore, it is not possible to rule out an effect of blood transfusion on pulmonary 
restriction.  No association between TLC and measures of pulmonary vascular 






This study has demonstrated that significant increases in pulmonary capillary blood 
volume and airways resistance occur immediately following blood transfusion in 
children with SCD.  These changes are accompanied by significant reductions in 
FEV1 ,  VC and FEF25-75.  Furthermore, the change in lung function correlated with 














7. EXHALED NITRIC OXIDE AND PULMONARY BLOOD 
FLOW IN CHILDREN WITH SICKLE CELL DISEASE 
 
Note: All lung function tests and statistical analyses were performed by the 





Measurement of exhaled nitric oxide (feNO), which reflects airway NO production 
and is  a marker for eosinophilic airways inflammation, might help to further 
elucidate whether asthma is increased in SCD children as FeNO  is often elevated in 
patients with asthma [120]. Early studies suggested that feNO was reduced in SCD 
patients [121], which might reflect the reduced nitric oxide (NO) bioavailability due 
to scavenging by cell free haemoglobin resulting from chronic haemolysis [213]. A 
reduced FeNO, however, has not been found in other cohorts assessed more 
recently [204, 214]. FeNO has been previously measured at a single fixed exhalation 
flow of 50ml/s, but if feNO, is measured at multiple exhalation flows, it can be 
partitioned into flow-independent airway and alveolar components [171, 172].  
Using such a technique, children with SCD were found to have  an elevated airway 
nitric NO flux but the alveolar NO concentration did not differ significantly from 
that found in healthy controls [214]. The authors, therefore, suggested that 
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subclinical airway inflammation might occur in SCD patients [214].  A limitation of 
that study, however, was that the children in the control group were not matched 
for race and ethnic differences have been reported for feNO indices [215-217].  
Furthermore, as the transfer factor for NO (DLNO) was not measured [13], it was 
not possible from that study to determine the relative importance of NO 
production (as opposed to concentration, which may change as a results of changes 
in endogenous production or by accumulation due to impaired transfer of NO).  
Thus, it is important that flow independent FeNO in SCD patients is compared with 
appropriately matched controls to reliably determine whether or not FeNO is 
elevated in SCD children.  Exhaled NO has been shown to be elevated in patients 
with atrial septal defects or liver cirrhosis; both conditions are associated with a 
hyper-dynamic pulmonary circulation and feNO correlated with increased 
pulmonary blood flow [122, 218].   Children with SCD often have a hyper-dynamic 
circulation due to the raised cardiac output resulting from chronic anaemia [123, 
198], but whether that influences exhaled NO in SCD patients has not been 
investigated. The aim of this study, therefore, was to test the hypotheses that 
airway and alveolar nitric oxide production would differ between children with SCD 
and ethnic-matched controls and that alveolar NO production was related to a 
hyperdynamic pulmonary circulation and/or airways obstruction as assessed by 








Afro-Caribbean children with HbSS disease were recruited.  Age and ethnic 
matched children, who were siblings of the SCD children or from local schools, 
were recruited as controls. Controls were recruited such that overall group 
characteristics were matched (Table 7.1) all control subjects were of a similar 
ethnic background to the children in the SCD group. Only children over seven years 
of age were recruited as they were likely to be able to complete all the lung 
function tests. No child underwent testing within two weeks of an upper 
respiratory tract infection or an SCD child within a month of suffering a vaso-
occlusive crisis.  The study was approved by the King's College Hospital Research 
Ethics Committee and parents gave informed written consent for their child to take 
part. 
 
7.2.1 Lung function assessments 
 
FEV1, VC, FEF25-75, TLC, RV, DLCO and respiratory system resistance were measured 
as previously described (Section 3).  Rrs was measured before any of the other lung 
function tests and a resistance at 5 Hz was used (Rrs5) to capture changes in small 
airway function. The Rrs5 results were expressed as the percent predicted for 
height using the reference range of Nowoweijska et al [201]. Exhaled NO was 
measured before the remaining lung function tests were performed as recent 
forced expiration can influence FeNO.  Spirometry, static lung volumes and gas 
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transfer measurements were expressed as the percent predicted for height [186, 
202].  Ethnic-specific reference equations were not available for static lung volumes 
or gas transfer, therefore the predicted values were adjusted using appropriate 
correction factors [219]. The transfer factor for nitric oxide (DLNO) was obtained by 
the addition of 40ppm NO to the inspired gas mixture prior to commencing the 
single-breath DLCO measurement [167].  Patients were diagnosed with a restrictive 
abnormality if their TLC was less than the lower limit of normal (LLN) with a normal 
FEV1:VC, an obstructive abnormality if their FEV1:VC was less than LLN and a mixed 
pattern if both TLC and FEV1:VC were less than the LLN [136].  
 
7.2.2 Exhaled nitric oxide measurements 
 
Exhaled nitric oxide was measured at multiple flow rates to derive the total 
maximal airway NO flux (J’aw,NO) (nl/min) and the alveolar NO concentration (CA,NO) 
(ppb)  using the model of Condorelli et al [171] as described in chapter three.   The 
equation of Perillo et al [220] was used to derive the rate of alveolar NO production 
(V’A,NO) (nl/min) as follows:  
V’A,NO = DLNO. CA,NO.(Patm – PH2O).10
3 
Where PH2O is water vapour partial pressure (assumed to be 47mmHg) and Patm is 
the atmospheric pressure and DLNO is expressed in ml/min/mmHg.  Exhaled NO 
measurements were performed before the DLCO-DLNO manoeuvre to avoid 
contamination by inspired NO in the test gas mix.  
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7.2.3 Pulmonary blood flow measurements 
 
Effective pulmonary blood flow (Qpulm) was measured noninvasively by the inert-
gas rebreathing method as previously described.  The inspired gas mixture 
contained 0.5% nitrous oxide (N2O) and 0.1% sulphur hexafluoride (SF6) as the 
soluble and insoluble components respectively. To adjust for body size, the 
pulmonary blood flow index (QIpulm) was derived by dividing Qpulm by the 
predicted body surface area using the formula of Mosteller [175]. 
7.2.4 Statistical analysis 
 
Data were tested for normality using the D’Agostino and Pearson omnibus 
normality test. Since data were not normally-distributed, comparisons were made 
with Mann-Whitney U tests.  
 
7.2.5 Sample size 
 
Comparison of 18 children in each group allowed detection of a difference in the 
alveolar concentration of nitric oxide of one ppb (one standard deviation of the 










Eighteen children with SCD and eighteen healthy controls were assessed. The SCD 
children and the controls were of similar age and sex (Table 7.1). Two patients with 
SCD and one control had a physician diagnosis of asthma. One of the two children 
with SCD who had asthma had an elevated FeNO,50l/s (>35ppb) [221].  
 
 SCD children Controls p value 
n 18 n=18  
Sex (Female n (%)) 9(50%) 9(50%) 1.0000† 
Age (yrs) 16.0 (9 – 18) 17.0 (11 – 18) 0.2310‡ 
[Hb] (g/dl) 8.3 (6.0 – 10.3) -  
Hydroxyurea n (%) 5 (27%) -  
Transfusion n (%) 0 05%)   
 





7.3.2 Lung function, exhaled nitric oxide and pulmonary blood flow 
 
Compared to the controls, the SCD children had a significantly lower FEV1 
(p<0.0001), VC (p<0.0001), FEF25-75 (p=0.0071), FEV1:VC (p=0.0315), TLC (p=0.0024), 
and SpO2 (p=0.0023) and a significantly higher Rrs5 (p=0.0008) and KCO (p 
=0.0114) (Table 7.2). In the SCD group, three patients (17%) had restrictive, two 
obstructive (11%), and two mixed (11%) ventilatory defects. Three SCD patients 
(17%) had an isolated reduction in DLCO. None of the control subjects had a 
restrictive defect and one an obstructive pattern. One control subject had an 
isolated reduction in DLCO. 
There were no significant differences between the groups in FeNO, 50ml/s, or total 
maximal airway NO flux (J’aw,NO) (Table 7.3). Compared to the control group, the 
SCD patients had a significantly higher alveolar NO concentration (CA,NO) 
(p=0.0007), rate of alveolar NO production (V’A,NO) (p=0.0224), effective pulmonary 
blood flow (Qpulm) (p=0.0006), and pulmonary blood flow index (QIpulm) (p<0.0001). 
In the SCD group, there was no significant difference in FeNO,50ml/s, J’aw,NO, or CA,NO 
(p=0.5663, p=0.1433 and p=0.3877, respectively) in the patients on hydroxyurea 
treatment, although caution must be exercised when interpreting these results due 







 SCD children Controls p value† 
 n=18 n=18  
Rrs5 145.6(107.8-234.1) 111.7(67.2-168.6) 0.0008 
FEV1 79.1(47.5-105.8) 104.5(78.6-124.5) <0.0001 
VC 85.1(48.6-107.8) 107.5(80.2-125.6) <0.0001 
FEF25-75 58.5(29.2-138.2) 92.4(53.5-153.9) 0.0071 
FEV1:VC 91.0(75.2-104.5) 98.8(87.3-112.1) 0.0315 
TLC 83.1(73.8-106.5) 102.5(85.5-125.3) 0.0024 
RV 85.1(31.8-125.3) 93.0(58.11-155.3) 0.1461 
DLCO 88.5(65.0-122.0) 87.1(66.1-127.7) 0.5841 
KCO 97.4(70.0-132.0) 86.1(69.0-115.1) 0.0114 




62.7(37.9-83.8) 85.3(44.3-113.3) 0.0002 
 
Table 7-2  Lung function results by SCD status.   
Results are presented as median (range) and expressed as a percentage of the predicted value unless 
indicated
*.  





Figure 7-1 Impulse oscillometry and spirometry in SCD and control children. 
 Data are presented as  








Figure 7-2 Lung volumes and gas transfer in SCD and control children. Data are presented as  





 SCD children Controls p value† 
n 18 18  
FeNO,50ml/s 14.7 (1.6-92.3) 14.6 (1.2-56.1) 0.7569 
J’aw,NO 33.5 (6.1-403.6) 60.8 (1.4-319.1) 0.3038 
CA,NO 7.0 (1.3-7.3) 2.5 (0.6-5.9) 0.0007 
V’A,NO 319.0 (57.3-663.7) 151.0 (31.8-447.1) 0.0224 
Qpulm 7.80 (4.25-10.85) 5.50 (3.55-7.70) 0.0006 
QIpulm 4.97 (3.77-6.82) 3.29 (2.48-4.50) <0.0001 
 
Table 7-3 Exhaled NO and pulmonary haemodynamic measurements by SCD status.  






Figure 7-3  Exhaled nitric oxide measurements in SCD and control children. 






Figure 7-4  Pulmonary blood flow measurements in SCD children and controls.   







7.3.3 Relationships between lung function, exhaled nitric oxide and pulmonary 
haemodynamics 
 
In the SCD children and the control group, no significant correlations were 
observed between exhaled NO indices and Rrs5 or FEV1:VC (table 7.4). In the SCD 
group, Qpulm was positively correlated with FeNO,50ml/s (p = 0.036), CA,NO (p = 0.0343) 
and V’A,NO (p = 0.0002) (Table 7.5). QIpulm was positively correlated with FeNO (r = 
0.591, p = 0.0112), CA,NO (r = 0.742, p = 0.0006), and V’A,NO ( r = 0.806, p < 0.0001 
(Figure 1). No significant correlations were seen between exhaled NO indices and 














Correlated variables r† p† 
FeNO,50l/s FEV1:VC -0.340 0.1681 
FeNO,50l/s Rrs5 0.286 0.2493 
J’aw,NO FEV1:VC -0.161 0.5139 
J’aw,NO Rrs5 0.420 0.0840 
CA,NO FEV1:VC -0.179 0.4769 
CA,NO Rrs5 -0.214 0.3931 
 
Controls 
FeNO,50l/s FEV1:VC -0.311 0.2234 
FeNO,50l/s Rrs5 -0.245 0.3417 
J’aw,NO FEV1:VC -0.220 0.3805 
J’aw,NO Rrs5 -0.251 0.3153 
CA,NO FEV1:VC -0.094 0.7108 
CA,NO Rrs5 0.267 0.2834 
 
Table 7-4 Correlations between exhaled NO and markers of airflow obstruction.   




Correlated variables r† P† 
Qpulm FeNO,50l/s 0.496 0.036 
QIpulm FeNO,50l/s 0.591 0.0112 
Qpulm J’aw,NO 0.328 0.1834 
QIpulm J’aw,NO 0.290 0.2423 
Qpulm CA,NO 0.500 0.0343 
QIpulm CA,NO 0.742 0.0006 
Qpulm V’A,NO 0.761 0.0002 
QIpulm V’A,NO 0.806 <0.0001 
 
Controls 
Qpulm FeNO,50l/s -0.1030 0.7042 
QIpulm FeNO,50l/s -0.1235 0.6485 
Qpulm J’aw,NO -0.1511 0.5631 
QIpulm J’aw,NO -0.1680 0.5192 
Qpulm CA,NO 0.1804 0.4885 
QIpulm CA,NO 0.0233 0.9293 
Qpulm V’A,NO 0.4256 0.0886 
QIpulm  V’A,NO 0.1936 0.4550 
Table 7-5 Correlations between exhaled NO and pulmonary haemodynamic measurements. 






Figure 7-5  Alveolar nitric oxide production and pulmonary blood flow in SCD (blue points) and control 
subjects (red points).   
Lines represent the least-square linear regression best fit in each group, the shaded areas are the 95% 
















This study has demonstrated that children with SCD compared to controls had an 
elevated alveolar nitric oxide concentration and increased alveolar production, but 
their maximal airway nitric oxide flux did not differ from that of ethnic-matched 
controls. Alveolar production and NO concentration were strongly correlated with 
pulmonary blood flow in the SCD group but not in the controls, suggesting a link 
between pulmonary nitric oxide production and a hyper-dynamic circulation. These 
results differ from those of Radhakrishnan et al [214] who found that airway NO 
flux but not alveolar NO concentration nor exhaled NO at a flow of 50 ml/s was 
elevated in SCD. Those differences may be due to a number of factors. All the 
controls and SCD patients in this study were of African or Caribbean ethnic origin, 
whereas Radhakrishnan et al recruited controls of various ethnicities, the majority 
of whom were Caucasian.  Furthermore, that study [214] excluded all patients with 
evidence of airflow obstruction to ensure that patients with asthma and likely 
elevated feNO did not influence their results. The work presented earlier in this 
thesis has, however, suggested that airflow obstruction seen in SCD at least in 
certain patients may reflect increased pulmonary capillary blood volume rather 
than asthma [208], hence exclusion of such patients might bias the study 
population. In adults with SCD Girgis et al [121] reported a reduction in feNO 50ml/s 
but used a predominantly Caucasian control group. A larger, more recently 
reported study by Chaudry et al [204] reported, as in this study, no difference in 
feNO 50ml/s between children with SCD and ethnic matched controls.  Furthermore, 
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that study also reported that whilst airflow obstruction, as evidenced by a reduced 
FEV:VC, was present this was not associated with increased methacholine 
sensitivity or elevated fE,NO.   To the best of our knowledge, this study is the first to 
assess the relationship between pulmonary haemodynamics, exhaled nitric oxide, 
maximal airway NO flux and alveolar NO concentrations (to estimate alveolar NO 
production) in children with SCD. The findings that alveolar NO production and 
concentration were strongly correlated with pulmonary blood flow indices and 
alveolar NO production was elevated in the SCD group, despite a reduced DLNO, 
suggest that the altered pulmonary NO dynamics were associated with a 
hyperdynamic circulation in SCD patients. FeNO,50ml/s was also correlated with 
pulmonary blood flow, suggesting that the utility of the standard FeNO,50ml/s as a 
marker of airway inflammation may be limited in SCD due to potential 
contamination of NO from the alveolar region. 
In the study by Degano et al of patients with liver cirrhosis, including patients with 
hepatopulmonary syndrome, alveolar NO concentration and the rate of alveolar 
NO production were elevated compared to healthy controls [218] and positively 
correlated with cardiac index (cardiac output normalised for body surface area) 
measured during right-heart catheterisation. Exhaled NO is also elevated in 
patients with an ASD [122]. The elevated levels may be due to alveolar nitric oxide 
production, as the pulmonary haemodynamics were similar to those observed in 
the SCD patients in this study and the cardiac index was similar to the QIpulm. The 
authors of that study [122] report that the role of shear stress may be central as 
pulmonary blood flow, exhaled NO concentration and plasma NO levels dropped 
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significantly in children and adults after surgical repair of the ASD. Although a 
different method for NO measurement was used, the exhaled NO concentrations 
before ASD closure were similar to the alveolar NO production levels observed in 
this study. It is reasonable, therefore, to suggest that alveolar nitric oxide 
concentrations are elevated in children with SCD due to a shear stress and results 
from an increase in alveolar nitric oxide production. This increase, however, may 
also be due, at least in part to a greater perfused surface area rather than direct 
up-regulation of NO production in endothelial cells. The increased pulmonary 
production of NO occurs despite the functional deficiency of NO which is thought 
to be a feature of systemic vascular function in SCD disease [58]. 
This study has strengths and some limitations. A strength of this study was the use 
of multiple-flow exhaled NO measurements which enabled the maximal airway NO 
flux and alveolar NO concentration to be assessed. DLNO was also measured and it 
was therefore possible to demonstrate increased alveolar NO production. Ethnic-
specific reference values were used for spirometric results, but static lung volume 
and impulse oscillometry results were related to reference ranges derived from 
Caucasian subjects. The two groups, however, were matched for ethnic origin and 
the same reference ranges were used in both groups, thus the comparisons 
between them were valid. All of the study population were African or Caribbean, 
thereby avoiding confounding from ethnic differences in exhaled NO [215-217]. A 
non-invasive method was used to measure pulmonary blood flow rather than 
pulmonary artery catheterisation, but the method and device used has been 
previously validated in children [174]. Plasma NO products were not measured as 
197 
 
this would have required additional venipuncture, however this would potentially 





In conclusion, this study has demonstrated that pulmonary NO production in the 
alveolar compartment is elevated and correlated with pulmonary blood flow in 
children with SCD. This is likely to be the result of increased shear stress due to 
hyper-dynamic circulation. Airway NO flux did not differ from that in healthy 
ethnic-matched controls and was not related to the airflow obstruction 
demonstrated in the SCD children. Those results further suggest that airway 










8. LONGITUDINAL ASSESSMENT OF LUNG FUNCTION IN 
CHILDREN WITH SICKLE CELL DISEASE 
 
Note: Baseline lung function tests on Cohort Two were performed by Dr. Karl 
Sylvester.  All other lung function tests and statistical analyses were performed by 
the candidate.   
8.1 Introduction  
 
Lung function abnormalities have been reported even in young SCD children with 
SCD. One cross-sectional study suggested the occurrence of restrictive 
abnormalities may increase with increasing age in childhood [138].  More recently, 
longitudinal studies have been undertaken.  In a cohort of 45 children aged 
between 5 and 18 years measured at baseline and approximately four years later, a 
predominantly obstructive pattern was reported which increased in prevalence 
over time; the occurrence of restrictive abnormalities also increased, but to a lesser 
extent [145].  In contrast, retrospective analysis of a larger cohort of 413 SCD 
children aged between eight and eighteen years, who were measured on two 
separate occasions with a variable time to follow-up, demonstrated an increased 
prevalence of restrictive abnormalities with increasing age [148].  There was a 
decline in total lung capacity (TLC) of  2.3% per year [148] and a similar decline in 
forced expiratory volume in one second (FEV1), vital capacity (VC), and forced 
expiratory flow between 25% and 75% of VC (FEF25-75%).  Neither study [145, 148], 
however, included a control group and thus it is not possible to determine whether 
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the decline in lung function reported was only seen in SCD patients and hence the 
magnitude of the effect of SCD.   In addition, it is important to assess whether any 
difference increased with increasing age. 
 
In adults, acute chest syndrome (ACS) is the commonest cause of death [30, 78] 
and is associated with more severe restrictive disease [222].  In children, ACS 
episodes have been associated with reductions in lung function [88, 89].  The 
impact of ACS on longitudinal changes in lung function, however, has not been 
investigated [145, 148].  There is evidence that asthma may be a risk factor for ACS 
episodes [83, 86, 88-92].  Hence, in any subsequent longitudinal study the impact 
of asthma also needs to be considered.  
 
The aim of this prospective study was to examine the rate of decline in lung 
function in children with SCD in comparison to age and ethnic matched controls.  
Two cohorts were studied.  Cohort one were younger children who were followed 
for approximately two years, during an age when ACS episodes are more common 
[80].  Cohort two were older and followed for approximately ten years to allow the 
long-term changes in lung function during the transition to adulthood to be 
assessed.  Two cohorts were included as comparison of their results would allow 
the primary hypothesis that the rate of decline in lung function would be greater in 
the younger cohort as it would relate to their higher occurrence of ACS episodes to 
be tested.  Furthermore, in cohort two, the hypothesis that any obstructive 
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abnormalities demonstrated at the initial assessment would be replaced by 
restrictive abnormalities at the subsequent assessment was also tested.  As asthma 
may be a risk factor for ACS episodes [80, 83, 86, 88-92] the study also set out to 
determine whether asthma and hence baseline obstructive lung function 
abnormalities influenced any change in lung function and whether obstructive lung 
function abnormalities were associated with an increased risk of ACS episodes.  
Ethnic and age matched controls were recruited for both cohorts to determine 















8.2  Methods 
 
A prospective longitudinal study of children with SCD (homozygous for sickle cell 
haemoglobin (HbSS)) of African-Caribbean or West African descent was 
undertaken.  Age and ethnic matched children without HbSS were recruited as 
controls; they were siblings of the SCD children or recruited from local schools.  
Controls were recruited such that overall group characteristics were matched 
(Table 8.2); all control subjects were of a similar ethnic background to the children 
in the SCD group.  Two cohorts were tested, each on two occasions.  In cohort one 
changes in lung function over a median follow-up of approximately two years and 
in cohort two changes in lung function of children over a median follow up of ten 
years were determined.  Cohort two was recruited earlier during a previous period 
of research grant funding and both cohorts were followed up during a subsequent 
period of grant funding. Only patients who successfully performed both spirometry 
and body plethysmography were included in the analysis. The study was approved 
by the King's College Hospital Research Ethics Committee and parents gave 
informed written consent for their child to take part. 
 
8.2.1 Lung function assessments 
 
FEV1, vital capacity, total lung capacity and residual volume were measured as 
previously described (Section 3). Spirometry was repeated following administration 
of a bronchodilator (400μg salbutamol via a MDI and spacer: the MDI was 
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vigorously shaken between puffs and the delivery of each puff was followed by five 
normal breaths) and a positive response was defined as an increase in FEV1 of 
greater than or equal to 12% from baseline.  Results were expressed as percent 
predicted for height, age, and sex using the ethnic-specific reference equations for 
spirometry [186] and the European Community for Steel and Coal Statement of the 
European Respiratory Society reference equations for lung volumes and gas 
transfer [187] for patients over eighteen years of age and those of Rosenthal et al 
for children under eighteen [202]. The predicted values for total lung capacity were 
reduced by 12% and residual volume by 7% to correct for ethnicity [136]. Patients 
were diagnosed with a restrictive abnormality if their TLC was less than the lower 
limit of normal (LLN) with a normal FEV1:VC, an obstructive abnormality if their 
FEV1:VC was less than LLN and a mixed pattern if both TLC and FEV1:VC were less 
than the LLN [136].   
 
 
8.2.2 Clinical and haematological data 
 
The medical records for all SCD children were examined. ACS was documented by a 
review of all medical record entries during the follow-up period.  All SCD patients 
who completed two visits were managed clinically at King ’s College Hospital and 
complete records were available for the follow-up period. An ACS episode was 
diagnosed if the child had suffered chest pain, dyspnoea and pyrexia together with 
a new pulmonary infiltrate on chest radiograph [78]. SCD children and controls 
were diagnosed as having asthma if they were currently prescribed any anti-asthma 
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medications.  Prescriptions were issued based on diagnoses made by multiple 
clinicians.  Whether the child was on a chronic transfusion program or receiving 
hydroxyurea was also noted.  Haemoglobin concentrations for the SCD children 
were obtained from routine clinical blood samples taken within two months of lung 
function testing and when the patient was clinically stable. 
8.2.3 Statistical analysis 
 
Differences in lung function results at baseline and follow-up were assessed for 
statistical significance using the Wilcoxon signed-rank test, Fisher’s exact test or 
Chi-squared test as appropriate.   Individual lung function results were reported as 
the percentage predicted in order to normalise results for stature and where 
appropriate age. Linear mixed model (LMM) analysis was then used to analyse 
trajectories of decline in lung function in the SCD children relative to the control 
groups and to determine the influence of asthma, airways obstruction at baseline 
and the occurrence of ACS during the follow up period.  ACS, airways obstruction at 
baseline and diagnosis of asthma were coded as nominal variables (0 = absent; 1 = 
present).  Models were also fitted to compare the trajectories in the two cohorts.  
LMM analysis is an extension of multiple regression, which allows irregularly 
spaced serial data for individuals to be combined in a single linear regression 
model, providing estimates of both individual changes over time and group 
patterns.  SPPS version 21 (IBM Corp. Armonk, NY), was used to derive all LMMs. In 
the context of mixed-effect modelling, a fixed factor is defined as a categorical or 
classification variable, for which the investigator has included all levels (or 
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conditions) that are of interest in the study.  Levels of a fixed factor are chosen so 
that they represent specific conditions, and can therefore be used to define 
contrasts of interest in the research study.  Fixed effects, also referred to as 
regression coefficients or fixed-effect parameters, describe the relationship 
between the dependent variable and predictor variables (i.e., fixed factors or 
continuous covariates) for an entire population of units of analysis, or for a limited 
number of subpopulations defined by the levels of a fixed factor. Fixed effects may 
describe contrasts or differences between levels of a fixed factor (e.g. between 
patients with and without a history of ACS) in terms of mean responses for the 
continuous dependent variable, or they may describe the effect of a continuous 
covariate on the dependent variable.  Fixed effects are assumed to be unknown 
fixed quantities in an LMM (directly equivalent to the coefficients in a standard 
linear regression), and are estimated based on the analysis of the data collected in 
a given research study.   
Conversely, a ‘random factor’ is defined as a classification variable with levels that 
can be thought of as being randomly sampled from a population of levels being 
studied.  All possible levels of the random factor are not present in the data set, but 
it is the aim of the analysis to make inferences about the entire population of 
levels.  The term ‘random effects’, therefore, does not refer to the temporal or 
spatial distribution of the model variables, but to the fact that these values 
represent random deviations from the relationships described by the fixed effects.  
Specifically, random effects associated with the levels of a random factor can enter 
an LMM as random intercepts (representing random deviations for a given subject 
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from the overall fixed intercept), or as random coefficients (representing random 
deviations for a given subject from the overall fixed slope).  For a full technical 
discussion, see West [223] and West & Galecki [224].  Fixed effects in the models 
were: ACS during the study period, diagnosis of asthma, obstruction at baseline, 
age at measurement, and an intercept term.  In the models comparing SCD subjects 
with controls, and the two cohorts, SCD status or cohort membership, respectively, 
were entered as fixed effects. Random effect variables comprised age at 
measurement and an intercept term in addition to the subject study ID, to 
characterise the subject-level deviation from the estimated fixed effects. A first-
order autoregressive covariance structure was used for random effects.  Models 
were estimated using restricted maximum likelihood (REML), and separate models 
were fitted for each of the lung function results with all models grand-mean 
centred on age at baseline such that the intercept terms would be interpretable as 
the mean value of the result at baseline, and the slope would represent the annual 
rate of change. Interaction terms were introduced to test the equality of slopes 
between groups.  Initial models included all variables and interactions.  The validity 
of including the random effects, and the selection of an appropriate covariance 
structure for the residuals was assessed by likelihood ratio testing based on the -2 
REML log-likelihood difference between the original and modified models.  Models 
were then reduced by the sequential removal of non-significant terms.  Likelihood 
ratio tests based on the difference in -2 ML log-likelihood for initial and reduced 
models were used to determine whether a non-significant term should be removed 








Cohort 1: Forty-seven children with SCD and twenty-six controls were assessed; the 
two groups were of similar age and sex distribution (Table 8.1). Ten SCD children 
(21%) had had at least one ACS episode during the study.  Nine SCD children and 
two controls had a diagnosis of asthma (p = 0.308). Seven SCD children (14.9%) 
were prescribed hydroxyurea and one (2.1%) was on a chronic transfusion 
programme within the study period.  The majority of the SCD children patients (45) 
and controls (24) were aged five or above at baseline (96% and 92%, respectively). 
 
Cohort 2: Forty-five children with SCD and twenty-six controls were assessed; the 
two groups were of similar age and sex distribution (Table 8.1). Twelve SCD 
children (27%) had had at least one ACS episode during the study.  Three SCD 
children and four controls had a diagnosis of asthma (p = 0.227).  Eight SCD children 
(17.7%) were prescribed hydroxyurea and two (4.4%) was on a chronic transfusion 
programme within the study period. The majority of SCD children (43) and controls 
(24) were aged five or above  (96% and 96%, respectively). 
 
Cohort one was significantly younger at baseline compared to cohort two (p = 
0.007) (Table 8.1).  The only significant difference in lung function of the two SCD 
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cohorts at recruitment was that cohort one had a higher TLC (p=0.0247).  The 
children in Cohort One had a mean of 0.58 (range 0–8.7) ACS episodes/year and 
Cohort Two a mean of 0.09 (range 0–1.3) ACS episodes (p=0.0355). If only the 
children who had at least one ACS episode were considered, in Cohort One this was 
a median of 0.65 (range 0.38–8.7) episodes/year and in Cohort Two 0.11 (range 
0.08–1.26) episodes/year (p<0.0001).There were no significant differences in the 















  SCD Controls p 
Cohort 1    
n 47 26  
Males (%) 21 (45%) 7 (27%) 0.352‡ 
Age at baseline (years) 8.8 (3.0-13.1) 10.2 (4.0-14.6) 0.072† 
Time to follow-up (years) 2.0 (0.9-3.5) 1.7 (1.5-2.51) 0.518† 
Hb (g/dl) 8.2 (4.6-11.9) -  
Cohort 2    
n 45 24  
Males (%) 19 (42.2%) 8 (33.3%) 0.81‡ 
Age at baseline (years) 10.2 (4.3-16.0) 8.5 (4.0-17.8) 0.24† 
Time to follow-up (years) 9.9 (6.0-13.5) 11.4 (7.0-13.4) 0.063† 
Hb (g/dl) 8.2 (5.7-12.8) -  
 
Table 8-1 Demographics by SCD status.   









8.3.2 Lung function changes with increasing age 
 
In both cohorts, lung function declined significantly in the SCD children, but in 









FEV1 91.6 (70.5-117.5) 88.7 (55.5-122.6) 0.0297 
VC 97.2 (67.3-140.8) 91.8 (59.4-123.5) 0.0002 
FEF25-75 91.8 (40.4-189.6) 82.4 (29.7-146.7) 0.0001 
FEV1:VC 94.7 (71.8-109.8) 95 (72.2-111.8) 0.2318 
TLC 97.2 (72.1-127.1) 89.7 (68.5-121.4) <0.0001 
RV 107.4 (40.6-212.0) 95.5 (42.2-160.0) 0.0032 
RV/TLC 128.2 (68.2-218.5) 120.1 (52.5-182.8) 0.469 
Controls n=26 n=26  
FEV1 94.2 (73.4-129.3) 100.6 (76.7-131.0) 0.2427 
VC 98.9 (79.6 – 129.2) 99.2 (80.5 – 136.6) 0.0988 
FEF25-75 96.3 (37.5-160.1) 96.7 (45.5-158.6) 0.3219 
FEV1:VC 98.5 82.3-108.8) 97.3 (76.9-112.8) 0.5938 
TLC 94.8 (80.8-115.5) 98.2 (78.2-115.5) 0.8789 
RV 101.4 (66.6-172.2) 102.5 (57.2-161.6) 0.3539 
RV/TLC 104.7 (72.1-137.1) 100.2 (62.2-160.8) 0.4164 
 
Table 8-2 Lung function in cohort one by follow up status.   










FEV1 90.7 (64.0-117.2) 81.2 (66.4-106.7) 0.0002 
VC 97.6 (62.6-116.7) 85.4 (68.7-109.6) 0.0003 
FEF25-75 91.8 (45.9-144.9) 74.5 (28.9-122.7) <0.0001 
FEV1:VC 96.2 (69.7-109.4) 95.4 (64.4-108.1) 0.7648 
TLC 92.5 (67.6-127.1) 81.6 (61.0-108.3) <0.0001 
RV 101.2 (37.7-212.0) 88.9 (54.8-149.2) 0.0300 
RV/TLC 121.2 (73.4-194.3) 113.2 (67.5-221.5) 0.0692 
Controls n=24 n=24  
FEV1 99.8 (73.8-128.8) 100.3 (76.8-148.7) 0.0946 
VC 103.1 (71.3-131.2) 102.7 (86.2-124.6) 0.1747 
FEF25-75 92.7 (55.3-168.3) 102.3 (54.7-163.0) 0.0891 
FEV1:VC 98.8 (81.1-112.2) 96.3 (84.9-116.6) 0.7425 
TLC 98.3 (78.5-111.8) 94.0 (84.2-121.8) 0.9421 
RV 95.7 (50.5-165.1) 91.1 (33.0-154.3) 0.9431 
RV/TLC 110.2 (63.2-175.7) 94.6 (45.0-158.7) 0.0742 
 
Table 8-3 Lung function in cohort two by follow up status.   






Figure 8-1  Trajectories over time for FEV1 and FEF25/75 (shown as z-scores) in SCD and control groups.  








8.3.3 Lung function abnormalities 
 
 
At baseline, sixteen SCD children in cohort one (34%) had an obstructive pattern, 
and one (2%) a restrictive defect; no child had a mixed defect.  At follow-up, the 
number of subjects with an obstructive defect had declined to five (10.6%, p = 
0.021), the number with restrictive defects increased to eight (17%, p = 0.034) and 
two patients had a mixed pattern (4.3%, p = 0.495).  A positive bronchodilator was 
seen in four SCD children (16.7%) at baseline and three (12.5%) at follow-up (p= 
1.000).  In cohort two, at baseline, eleven SCD children (24%) had an obstructive 
pattern and five (11%) a restrictive defect; no child had a mixed defect. At follow-
up, five subjects had an obstructive defect (11.1%, p = 0.167), the number with 
restrictive defects had increased to twenty (44%, p = 0.0008) and three patients 
had a mixed pattern (6.7%, p = 0.242). A positive bronchodilator response was seen 
in seven subjects (15.6%) at baseline and one subject (2.2%) at follow-up (p=0.059).   
 
At baseline, the proportion of SCD children with obstructive and restrictive defects 
was similar in both cohorts (p = 0.364, p = 0.107 respectively). At follow-up, cohort 
two compared to cohort one had a greater proportion of SCD children with a 
restrictive defect (p = 0.006), but a similar number with an obstructive defect (p = 
0.792). In both cohorts, there were significant correlations in the SCD children 
between obstructive defects at baseline and ACS episodes (p=0.0003 for cohort 
one, p=0.028 for cohort two).  In cohorts one and two, in the SCD children the 
presence of obstructive defects at baseline was predictive of an ACS episode during 
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the study: odds ratio (OR) 13.9 (95%CI 2.5 – 77.0), p= 0.003 and 5.4 (95%CI 1.2 – 
23.7), p= 0.026 respectively.  In cohort one there was a trend in the SCD children 
for an independent association between asthma and a subsequent ACS episode: OR 
6.1 (95% CI -0.5 – 12.8, p = 0.070).  ACS episodes occurred more frequently in the 
SCD children in cohort one than cohort two (one episode per 1.93 patient/years 





Figure 8-2  Probability density plot indicating the occurrence of ACS as a function of age, for Cohort One (top 
panel), Cohort Two (middle panel) and Cohort One and Cohort Two combined (bottom panel). 
 
In neither control group was there a change in the patterns of lung function over 
the follow up period.  Amongst the controls in cohort one, three had an obstructive 
abnormality and none a restrictive abnormality at baseline and follow up.  Amongst 
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the controls in cohort two, two had an obstructive lung function abnormality and 
none a restrictive abnormality at baseline and follow up.   
 
In cohort 1, a significant decline was observed in the SCD children relative to the 
controls in FEV1 (p=0.027), VC (p<0.0001), FEF25-75 (p=0.042), TLC (p<0.0001) and RV 
(p=0.001) (Table 8.4).  In cohort 2, a significant decline was observed relative to the 
controls in FEV1 (p=0.001), VC (p=0.004), FEF25-75 (p=0.016) and TLC (p=0.002) (Table 
8.5).  The rate of decline was significantly greater in cohort one than cohort two for 
FEV1 (p = 0.008), VC (p = 0.001), FEF25-75 (p = 0.030), TLC (p = 0.004), and RV (p = 












 Difference from control 
group 
Test of difference from control group (p-
value) 
 Intercept Slope Intercept Slope 
FEV1 -7.64 -1.768 0.016 0.027 
VC -3.36 -4.062 0.320 <0.0001 
FEV1:VC -5.10 1.089 0.008 0.073 
FEF25-75 -14.7 -1.651 <0.0001 0.042 
TLC 0.77 -2.800 0.778 <0.0001 
RV 5.80 -3.316 0.342 0.001 
RV:TLC 5.16 -1.565 0.335 0.148 
 
Table 8-4 Linear mixed models for cohort one.   
















 Difference from control group Test of difference from control group 
 (p-value) 
 
 Intercept Slope Intercept Slope 
FEV1 -9.34 -0.908 0.003 0.001 
VC 2.15 -0.931 0.651 0.004 
FEV1:VC -3.65 0.166 0.011 0.200 
FEF25-75 -5.22 -1.803 0.330 0.016 
TLC -2.88 -0.985 0.242 0.002 
RV 6.19 -1.059 0.331 0.187 
RV:TLC 9.58 0.772 0.042 0.817 
 
Table 8-5 Linear mixed models for cohort two.   
















 Difference from cohort 1 Test of difference from cohort 1  
(p-value) 
 
 Intercept Slope Intercept Slope 
FEV1 -1.56 1.402 0.472 0.008 
VC -1.00 1.965 0.692 0.001 
FEV1:VC 0.16 0.014 0.919 0.971 
FEF25-75 5.48 2.253 0.310 0.030 
TLC -2.80 1.563 0.251 0.004 
RV -1.88 2.484 0.711 0.043 
RV:TLC 23.8 0.333 <0.0001 0.783 
 
Table 8-6 Linear mixed models for cohort two relative to cohort one.   
Intercepts are in percent predicted, slopes percent predicted per year 
 
In cohort two, SCD patients with an obstructive defect at baseline were more likely 
to have a restrictive abnormality at follow-up (univariate logistic regression, 
p=0.0289).  On LMM analysis on the SCD children in cohort one, obstructive defects 
at baseline were linked to a lower intercept for FEV1 (p = 0.027) and FEV1:VC (p < 
0.0001). The occurrence of ACS episodes were associated with a more rapid decline 
(indicated by a negative coefficient on ACS; table 8.7) greater negative slope in FEV1 
(p=0.005), VC (p=0.022), FEF25-75 (p=0.003) and TLC (p=0.004).  In cohort two, 
obstructive defects at baseline were linked to a lower intercept for FEV1 (p = 0.011), 
FEV1:VC (p < 0.0001), and FEF25-75 (p = 0.013), whilst ACS episodes were associated 
with a  more rapid decline in (indicated by a negative coefficient on ACS; table 8.8)  
VC (p = 0.031) and TLC (p = 0.026), and an increase in  for FEV1:VC over time (p = 
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0.049) (Tables 8.7 and 8.8). No significant effects of hydroxyurea use or chronic 
transfusion were seen during exploratory analysis when those factors were 
included as covariates in the models, nor did their inclusion as non-significant 


















 Covariate Coefficient (95%CI) † p 
FEV1 For Intercept   
 Obstructive -7.19 (-13.52 to -0.86) 0.027 
 For Slope   
 ACS -2.21 (-3.70 to -0.72) 0.005 
VC For Slope   
 ACS -3.04 (-5.61 to -0.46) 0.022 
FEV1:VC For Intercept   
 Obstructive -13.15 (-17.00 to -9.30) <0.0001 
FEF25-75 For Slope   
 ACS -3.75 (-6.18 to -1.33) 0.003 
TLC For Slope   
 ACS -3.11 (-5.21 to -1.00) 0.004 
RV For Slope   
 Obstructive 6.61 (4.10 to 9.11) 0.047 
RV:TLC For Slope   
 Obstructive 4.26 (0.06 to 8.460) 0.047 
 
Table 8-7 Final linear mixed models assessing the effect of covariates in cohort one.  
The coefficient on slope indicates the additional rate of decline with age when covariate is present; the 
coefficient on intercept represents the difference in baseline value when covariate is present.    
Intercepts are in percent predicted, slopes percent predicted per year.   









 Covariate Coefficient (95%CI)† p 
FEV1 For Intercept   
 Obstructive -8.78 (-15.45 to -2.11) 0.011 
VC For Slope   
 ACS -1.03 (-1.97 to -0.95) 0.031 
FEV1:VC For Intercept   
 Obstructive -16.65 (-21.46 to -11.83) <0.0001 
 For Slope   
 Obstructive 1.172 (0.68 to 1.66) <0.0001 
FEF25-75 For Intercept   
 Obstructive -13.29 0.013 
TLC For Intercept   
 ACS -1.08 (-2.04 to -0.13) 0.026 
 For Slope   
 ACS -1.068 0.030 
 
Table 8-8 Final linear mixed models assessing the effect of covariates in cohort two. 
 The coefficient on slope indicates the additional rate of decline with age when covariate is present; the 
coefficient on intercept represents the difference in baseline value when covariate is present. Interaction 
effects between predictors were not considered.   
Intercepts are in percent predicted, slopes percent predicted per year. 






8.3.4 Exploratory analysis of combined cohorts 
 
Noting the degree of overlap between Cohort One and Cohort Two, an exploratory 
analysis was performed to determine whether the two cohorts (including SCD and 
control subjects) could be merged.  This would increase statistical power and might 
demonstrate the age-dependency of the rate of decline of lung function more 
clearly.  Since this would be a departure from the prospective study design, 
preliminary statistical diagnostics were performed to determine whether it would 
be appropriate to fit mixed-effect models to the combined data-set.  A particular 
concern was the potential effect of the marked difference in time to follow-up 
between the two cohorts on the statistical properties of the combined data.  To 
examine this, a probability density plot was produced for the time to follow up 
using a Gaussian kernel density function [225]; an approximately normal (i.e., 
unimodal) distribution would suggest that model fitting as a single dataset would 
be valid.  Visual inspection of the plot suggested a strongly bimodal distribution 
(Figure 8.2).  Hartigan’s dip test was then used test the formal hypothesis that the 
distribution of time to follow-up did not differ significantly from the normal 
distribution [226]: this confirmed non-unimodality (p<0.0001).  To assess the 
impact on the validity of modelling the combined cohorts, LMMs were derived for 
FEV1, FEF25/75 and TLC. The model structure and covariates were the same 
described for the separate cohorts in section 8.3.2.  Quantile-quantile (Q-Q) plots 
were obtained to determine if the model residuals for each level of the random 
effects were normally distributed (Figures 8.3-8.6).  For each of the lung function 
indices, marked nonlinearities were observed on the Q-Q plot, indicating that the 
223 
 
residual distribution was strongly non-normal.  Regression model assumptions 
were, therefore not satisfied and any conclusions drawn from LMMs on the 
combined data would likely be invalid.  Based on the results of the exploratory 
analysis, it was decided to retain the original analysis scheme and not proceed 
further with analysis of the combined cohorts.  
 
 
Figure 8-2  Kernel density plot and histogram showing the probability density function for time to follow-up 






Figure 8-3  Quantile-quantile plot for the standardised residuals of a LMM for FEV1 in Cohort One and Cohort 
Two combined. 
  For a normal distribution, points should lie on a straight line y=αx.  Deviations from linearity indicate model 






Figure 8-4  Quantile-quantile plot for the standardised residuals of a LMM for FEF25/75 in Cohort One and 
Cohort Two combined.  
 For a normal distribution, points should lie on a straight line y=αx.  Deviations from linearity indicate model 





Figure 8-5  Quantile-quantile plot for the standardised residuals of a LMM for TLC in Cohort One and Cohort 
Two combined.  
 For a normal distribution, points should lie on a straight line y=αx.  Deviations from linearity indicate model 




This study has demonstrated that lung function declines in children with SCD 
compared to similar aged, ethnic matched controls.  The average annual rate of 
decline for all lung volumes was significantly greater in cohort one compared to 
cohort two, which suggests the most rapid period of deterioration takes place 
during early childhood. These data also demonstrated that ACS episodes were the 
only independent predictor of a greater decline in lung volumes. ACS episodes 
occurred more frequently per unit follow up period in cohort one who were 
followed up for two years compared to cohort two who were followed up for ten 
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years.  The impact of this finding on lung function decline is likely to reflect to the 
longer time to follow-up in Cohort One compared to Cohort Two. In both cohorts, 
the frequency of ACS was greatest when patients were younger.  In cohort two, 
therefore, ACS frequency would be dropping for much of the long follow-up period.  
Given that patients were measured at only two time points, this would tend to 
reduce the average rate of decline when compared with Cohort One, who were 
followed for a shorter time when younger.  The younger age of Cohort One at 
baseline is also likely to have boosted the ACS frequency in this group.  Probability 
density plots, indicating the frequency of ACS for the two Cohorts separately, and 
for Cohort One and Cohort Two combined are shown in Figure 8.x.  These findings 
suggest a nonlinear trajectory for lung function decline in children SCD: definitive 
confirmation of this hypothesis would, ideally, entail more frequent measurements 
over the entire course of childhood and adolescence with testing taking place 
between each successive episode of ACS.  Such a study would, however, be 
extremely challenging to implement and require substantial resources. with Thus 
ACS episodes might explain the greater rate of decline in lung function in cohort 
one and hence these results emphasize the need for more effective methods of 
preventing ACS episodes, such as an increased use of hydroxyurea.   
 
The rate of decline in lung volumes observed in the SCD children in cohort one, that 
is the younger children, was similar to that demonstrated by Maclean et al [148], 
who observed an annual reduction in TLC of around 2.3% per year, with 
proportionate reductions in FEV1, VC, and FEF25-75.  Unlike in the study of Maclean 
228 
 
et al, however, a decline in RV:TLC was not seen in the SCD children. This difference 
may be explained by Maclean not expressing RV:TLC as a percentage of the 
predicted value and therefore not accounting for age-related changes in RV:TLC 
[190].  
The prevalence of obstructive lung disease in the SCD children at baseline was 
similar in both cohorts (34 and 24% respectively) and to that observed by 
Koumbourlis et al (22%) [145], but higher than that reported by MacLean et al. The 
latter difference may be due to MacLean’s use of a fixed cutoff for FEV1:VC to 
define an obstructive defect, whereas this study used the lower limit of normal 
based on a reference range.   After criticism from Koumbourlis [227], Maclean and 
coworkers subsequently reanalyzed their data using the lower limit of normal to 
define abnormality and found that more patients  had a diagnosis of obstruction 
than reported in the original study [228].  The proportion of patients with 
restrictive disease at baseline was lower in the SCD children cohort one to that 
observed by Koumbourlis (22%), but similar in cohort two. Cohort one was, 
however, younger than the cohort of Koumbourlis (8.8 versus 10.6 years), whereas 
cohort two was of a similar age (10.2 years) [16]. The prevalence of restrictive 
defects at baseline was higher at follow-up in cohort two than in Maclean’s cohort 
when assessed at age seventeen (18.7%) [148]. That difference may be explained 
by Maclean using a fixed cutoff of <70% predicted for TLC to define restriction, 




Obstructive defects at baseline, but not asthma significantly increased the 
likelihood of the child suffering an ACS episode.  The incidence of obstructive 
defects at baseline was higher than that of a diagnosis of asthma, which suggests 
other mechanisms may be responsible for obstructive defects in SCD.  Indeed, in 
the studies described in chapters 4-6 of this thesis, an association between 
pulmonary vascular engorgement and obstructive lung function in both adults 
[208] and children with SCD [15] was demonstrated. Hence, any preventative 
strategy needs to consider this abnormality in SCD children. 
 
This study has strengths and some limitations.  A strength was the inclusion of two 
control groups of similar age, sex and race to the SCD children; to the best of the 
author’s knowledge, this is the first longitudinal study to include matched controls 
evaluated in parallel with SCD children. Patients were also monitored prospectively 
and a consistent definition used to document the occurrence of ACS episodes 
during the study period.  The inclusion of two SCD groups with two and ten-year 
follow-up periods respectively allowed both the short and long term changes in 
lung function in childhood to be evaluated.   Ethnic-specific reference equations 
were used for spirometric results, but the static lung volume results were related to 
two reference ranges derived from Caucasian children and adults with a fixed 
correction factor to account for ethnicity.  The change in lung function was, 
therefore, referenced to an ethnic-matched control group in each cohort so that 
interpretation of within-cohort changes in the SCD children was valid.  Indeed, the 
pattern of change in static lung volumes was similar to that in spirometric 
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measurements.  Patients who were treated with hydroxyurea or chronic 
transfusions were not excluded, as this would have biased the study population in 
favor of SCD children with less severe disease.  Inclusion of those treatments into 
the analysis did not result in any significant differences in the results, but the 
number of children receiving such treatments was small and hence it would be 
inappropriate to draw conclusions from those results.  SPSS version 21 was used for 
mixed-effect modelling:  SPSS uses the Satterthwaite approximation of Fai and 
Cornelius [229] to calculate degrees of freedom for testing fixed effects; this 
method can result in negatively biased model-based standard errors, particularly 
where sample-sizes are small, compared to the Kenward-Roger [230] method 
implemented by the SAS and R statistics packages, which may result in a greater 
degree of model uncertainty.  However, the internal consistency of the models 
across lung function indices suggests that this potential limitation did not 
substantially hamper interpretability.  Additionally, the final models for FEV1 and 
FEF25/75 given in Tables 8.4 and 8.5 were re-fitted using the ‘R’ statistical suite 
(package ‘lme4’), and the ‘lmerTest’ package was used to compare model F-
statistics generated by the  Satterthwaite and Kenward-Roger procedures [231].  
No substantial difference was noted, further suggesting that this limitation did not 








In conclusion, lung function in children with sickle cell disease declines and the rate 
of decline was greater in young children in whom ACS episodes were more 
common.  These results suggest treatment strategies to prevent ACS episodes need 
to be started in young SCD children if they are to be most effective in preventing 















9. GENERAL DISCUSSION AND CONCLUSIONS 
 
 
9.1  Lung function and pulmonary vascular abnormalities 
 
 
The data presented in chapter four and five of this thesis demonstrate an 
association between changes in pulmonary vascular morphology consistent with 
increased vascular volume and lung function abnormalities in adults and children 
with SCD.  In a cohort of adults with HbSS disease, two measures of small-vessel 
size were derived from CT scans.  The segmental A/B ratio and CSA<5 mm% (which 
provides a measure of the total cross-sectional area of pulmonary arteries and 
veins at the sub-subsegmental level) were both independently linked to reductions 
in FEV1, VC and FEF25/75 and to increased respiratory system resistance and RV:TLC. 
These results are consistent with those from the cohort of children assessed in 
chapter five, in whom pulmonary capillary blood volume was negatively correlated 
with FEV1, VC and FEF25-75 and positively correlated with respiratory system 
resistance.  The negative relationship between measures of pulmonary vascular 
volume and VC, FEV1 and FEF25/75 and a positive relationship with RV, RV:TLC and 
respiratory system resistance suggest that vascular dimensions are related to an 
obstructive defect. It should be noted, however, that VC, FEV and FEF25/75 can be 
reduced in both obstruction and restriction and thus the correlations with markers 
of vascular dilation and reductions in VC, FEV1 and FEF25-75 may also indicate a 
relationship between vascular dilation and the development of restrictive lung 
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function.  No relationships were observed, however, between vascular volume and 
TLC. Additionally, measures of pulmonary vascular volume correlated with reduced 
haemoglobin concentration in both studies, suggesting that haemolysis and chronic 
anaemia, rather than vaso occlusion, is the key process driving these pulmonary 
function abnormalities. 
In chapter six, evidence for a causal link between increased pulmonary capillary 
blood volume and airflow obstruction was acquired. Significant increases in 
pulmonary capillary blood volume and airways resistance were seen to occur 
immediately following blood transfusion in children with SCD.  Those changes were 
accompanied by significant reductions in FEV1, VC and FEF25-75 and the change in 
lung function correlated with the increase in pulmonary capillary blood volume.  
Chapter seven presented evidence that a hyper-dynamic pulmonary circulation also 
impacts on pulmonary nitric oxide dynamics. Elevated alveolar pulmonary NO 
production significantly correlated with pulmonary blood flow which may reflect 
the increased shear stress due to a hyper-dynamic circulation.  Airway NO flux was 
not elevated in the SCD children compared to the controls nor did it correlate with 
indices of airways obstruction.  The data from these four studies therefore suggest 







9.1.1 Interpretation of the results and speculation on possible mechanisms 
 
There are a number of pathways by means of which an engorged pulmonary 
circulation might impact on lung function. 
 
1. Compression via peribronchial sheaths  
 
The peripheral airways lie within bronchovascular sheaths which are embedded in 
the lung parenchyma.  These sheaths also enclose branches of the pulmonary 
vascular tree as well as lymphatic vessels, and the close anatomical proximity of the 
pulmonary vessels may allow engorged pulmonary vessels to directly compress the 
distal airways [232-234].   Studies in dogs with experimental pulmonary oedema 
have demonstrated an increase in peripheral airways resistance [233].  
Morphological analysis of these animals revealed that competition for space 
between pulmonary arteries/arterioles and small airways in the bronchovascular 
sheaths explained the increase in peripheral airways resistance observed when 
congestion was induced by elevating left atrial pressure.  Furthermore, the 
peripheral airflow obstruction was reversible when congestion was relieved [233], 
provided that left atrial pressure did not exceed approximately 15mmHg.  At higher 
pressures, the peripheral obstruction was irreversible, and was attributed to 
alveolar and interstitial oedema. It is also possible that engorged lymphatic vessels 
may impact on distal airways in a similar manner.  Interestingly, as described in 
chapter four, subpleural curvilinear bands were amongst the commonest 
parenchymal abnormalities observed in the cohort of adult SCD patients. This 
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unusual sign was noted on CT in 26% of SCD patients. Subpleural curvilinear bands 
have also been observed in subjects without lung disease undergoing 
lymphography and this has led to the suggestion that the sign may represent an 
engorged subpleural lymphatic network [195]. In patients with SCD this may occur 
as a result of interstitial oedema and increased lymphatic drainage. 
 
2. Bronchial vessel dilatation 
 
Interaction between with the pulmonary and bronchial circulation may also be 
involved in vascular-mediated airways disease.  The bronchial circulation serves 
primarily to supply nutrients to the bronchial and parenchymal structures of the 
lung [235, 236], including the tissues and bronchial mucosa of the large and small 
airways [237].  The bronchial mucosa is heavily vascularised with a dense network 
of interconnected vascular networks laid around and within each bronchiole.  
Importantly, the mucosal vascular plexus is situated close to the airway epithelial 
surface and it has been estimated that the majority of bronchial mucosal capillaries 
are located within 100 micrometres of the airway lumen; engorgement of these 
vessels may, therefore, result in airway oedema [238-240]. This may be relevant in 
situations where pulmonary vascular engorgement or vasculopathy are known to 
occur, since the bronchial vasculature has distinct flow characteristics which may 
enable interaction with the pulmonary venous circulation. In humans, the blood 
supply for the bronchial circulation originates in the systemic vascular system, 
primarily from branches of the descending aorta with successive divisions following 
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distally with increasing generations of the airway tree.  Crucially, a large fraction of 
the post-capillary bronchial vessels anastomose with the venous pulmonary 
circulation and approximately 65% or more of the total flow through the bronchial 
circulation returns to the left heart through these anastomoses [241-243].  This 
means that flow through the bronchial vasculature may be influenced by 
pulmonary vascular pressures, particularly pulmonary venous pressure. Indeed, as 
Lockhart et al have shown, any increase in the outflow pressure of the bronchial 
circulation, which is close to left atrial pressure, will facilitate microvascular leakage 
and hence airway oedema [244].  This is intriguing in light of one of the findings in 
adults with SCD presented in chapter four.  Here, a positive correlation was 
observed between CSA<5mm% (a CT measure of the aggregate cross-sectional area 
of the distal arteries and veins) and the echocardiographic E/e′ which is a marker of 
left atrial filling pressure. A higher E/e′ would result in some elevation of pulmonary 
venous pressure, and since the CSA<5mm% was the strongest predictor of impaired 
lung function, it is tempting to speculate that interaction between a hyperdynamic 
pulmonary circulation and the bronchial vasculature may have a role in the 
development of the obstructive lung function abnormalities observed.  
A further mechanism by which the bronchial circulation might become engorged 
and thereby impinge on the airways arises from its ability to undergo expansion in 
the event of a compromised pulmonary circulation [245].  This is thought to occur 
as a compensatory mechanism, as the engorged bronchial circulation is able to 
contribute substantially to gas exchange function [235]. In chronic lung disease 
where regional pulmonary perfusion is reduced the increase in bronchial blood 
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flow may be massive. For example, in patients with chronic thromboembolic 
pulmonary hypertension (CTPH), the bronchial circulation has been shown to 
expand to such a degree that it can constitute approximately 30% of total systemic 
circulation (compared to approximately 1% in healthy subjects) [246, 247].  Given 
that chronic microvascular occlusion is a feature of SCD, it is possible that the 
bronchial circulation undergoes expansion in response to loss of pulmonary 
vasculature.  Given that patients with SCD must accommodate an elevated cardiac 





Unmyelinated C-fibres are present throughout the lung parenchyma, bronchi and 
pulmonary vasculature.  These fibres have been proposed as stretch receptors 
which respond to increased fluid load in the interstitium or the 
pulmonary/bronchial circulation [248, 249].  In canine models, distension of the 
pulmonary vasculature and experimental interstitial oedema were independently 
shown to cause increased C-fibre activity resulting in vagally-mediated reflex 
bronchospasm [248-251].  It is possible that similar process is taking place as a 
consequence of pulmonary vascular distension in SCD.  In the children studied here, 
however, only a minority demonstrated bronchodilator responsiveness: of the 67 
children with SCD studied in chapter five only four (6%) had a significant 
improvement in FEV1 post bronchodilator. Furthermore, the magnitude of change 
in respiratory system resistance following bronchodilator did not differ between 
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SCD patients and controls. Of the children studied in chapter eight four SCD 
children (8.5%) in cohort one and seven (15.6%) in cohort two had a significant 
bronchodilator response at baseline.  In the adult patients with SCD studied in 
chapter four, six (17%) had a significant response to bronchodilator. It is possible 
that C-fibre mediated reflex bronchoconstriction arising from distention of the 
pulmonary vessels was a factor in causing bronchospasm in those with significant 
reversibility,   but the numbers of responders were too small to permit comparison 
of markers of pulmonary vascular volume between those patients who did and did 














9.2 Longitudinal changes in lung function 
 
Lung function declines in children with SCD compared to similar aged, ethnic-
matched controls.  The most rapid period of deterioration appears to take place 
during early childhood. In the children with SCD studied in chapter eight, the 
occurrence of ACS was the sole independent predictor of a more rapid progression 
of pulmonary restriction.  The key role of ACS is further supported by the fact that 
ACS episodes occurred more frequently per unit follow up period in the younger 
cohort one compared to cohort two; the annual rate of decline in lung volumes was 
also greater in cohort one. Airflow obstruction at baseline, but not asthma per se, 
was associated with a greater risk of developing ACS during the follow-up period.  
Obstructive abnormalities were much more common than restriction at baseline in 
both cohorts, but the prevalence of restrictive defects increased significantly over 
time.  In cohort two, who were assessed to determine the long term changes in 
lung function as children with SCD transition to adulthood, the number of patients 
with restrictive defects at follow-up compared to baseline increased by 33% whilst 
the number with evidence of airflow obstruction remained relatively stable, 
decreasing by 6.2%.  
In the subgroup of adults who were assessed longitudinally in chapter four, a 
different pattern of change was seen.  For the group as a whole, TLC did not decline 
significantly over the follow-up period whereas significant reductions in FEV1, VC, 
FEV1:VC and FEF25-75 were observed together with a significant increase in RV:TLC 
suggesting worsening airflow obstruction.  Furthermore, an increase in small-vessel 
pulmonary vascular distension (as evidenced by the CSA<5mm%) was associated 
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with a more rapid decline in lung function.  It should be noted, however, that the 
rate of decline in lung function in the adult cohort was considerably slower than 
that seen in the children.  Compared to the adult cohort, the rate of decline in VC 
for the children of cohort one (chapter eight) was on average 3.2%/year faster.  
These data suggest an initial, rapid decline in lung volume in childhood with the 
rate of decline slowing as children age and that during adult life pulmonary 
restriction is relatively stable, with further gradual deterioration in ventilatory 















9.3 Clinical implications 
  
The work presented in this thesis has implications for the clinical care of patients 
with SCD.  Patients with SCD with recurrent wheezing or asthma have increased 
morbidity and mortality and it is therefore important to understand the underlying 
cause of the airflow obstruction that this represents in order that the correct 
treatment is used.  Systemic and inhaled corticosteroids are an important part of 
the management of asthma, but are not likely to be efficacious in cases where 
airways disease is mediated by the pulmonary vasculature.  The data presented in 
chapters four, five, six and seven have demonstrated that the airflow obstruction 
seen in SCD is, at least in part, due to changes in pulmonary vascular volume 
resulting from chronic anaemia and a hyper-dynamic circulation.  In these 
circumstances, treatments directed at SCD itself such as hydroxyurea or 
transfusions are more likely to reduce respiratory morbidity.   Indeed, systemic 
corticosteroids have been linked to an increase in painful crises and 
cerebrovascular accidents in patients with SCD [252, 253].  The need for correct 
treatment of airflow obstruction is emphasised by the results of the study 
described in chapter eight.  Obstructive lung function abnormalities, regardless of a 
diagnosis of asthma, were predictive of subsequent ACS, and the occurrence of ACS 
was strongly associated with a more rapid decline in lung function and an increased 
likelihood of developing restrictive lung disease.  The more rapid decline observed 
in younger children highlights the importance of the timing of therapy in preventing 
chronic lung disease in patients with SCD. 
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9.4 Future work 
 
Further studies to determine the precise mechanisms underlying the link between 
vascular abnormalities and lung function would be beneficial to direct the 
development of possible future treatments.  In chapter four, echocardiographic 
evidence of elevated left atrial filling pressure was presented and a significant 
correlation was observed with engorgement of the small pulmonary vessels 
(including veins). Since this may result in bronchial microvascular leakage and 
airway oedema, exploring the relationship between the pulmonary and bronchial 
circulation might provide further insight into of the pathophysiology of lung 
function abnormalities in SCD (see section 9.1.1).  The recent development and 
validation by Wanner et al of a non-invasive technique based on uptake of the 
soluble gas dimethyl ether to measure total bronchial blood flow [254] might 
provide a means to do this, especially if combined with echocardiography and 
imaging studies.  Murine models expressing HbSS and employing micro-CT scanning 
might allow the impact of haemodynamic changes and fluid loading on the 
peripheral airways to be directly imaged, and since respiratory system resistance by 
forced oscillation can now be measured simply in mice the effect on lung function 
could also be explored.  Assessment of the peripheral vasculature might also be 
helpful to determine if the pulmonary vascular changes described in this thesis are 
part of a generalised vasculopathy. 
Large-scale longitudinal cohort studies would allow the results of physiological 
studies to be placed in a broader haematological context by assessing the 
relationships between lung disease and other complications such as renal and 
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hepatic dysfunction, and would allow the impact of lung function and pulmonary 
vascular abnormalities on important outcomes such as mortality, quality of life, and 
healthcare utilisation to be robustly assessed. 
Data on the effect of common treatments on lung function abnormalities in SCD 
are also lacking.  The data presented in this thesis suggest that treatments to 
reduce anaemia and increased pulmonary vascular volume or to prevent ACS, such 
as hydroxyurea or blood transfusion may be beneficial.  The efficacy of these 
treatments will need to be assessed in future clinical trials. 
 
9.5 Some general limitations regarding the presentation of lung 
function data 
 
The results of lung function tests presented in this thesis have been expressed as 
the percentage of the predicted value for age, sex and height (where appropriate).  
Whilst this was commonplace during the period when this programme of study was 
designed [136], more recently the use of z-scores has been increasingly favoured 
[255], particularly in studies of paediatric populations.  The presentation of z-scores 
carries some advantages over percentage predicted: chief amongst these is the fact 
that the z-score incorporates the effect of variation across age, sex and ethnicity 
[186, 190].  This facilitates the bias-free interpretation of within-individual serial 
measurements over the life-course and can be particularly helpful when examining 
graphical presentations of longitudinal lung function data.      When the results of 
Chapter Four were being prepared for publication, the use of z-scores was still very 
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uncommon in studies of adult subjects and to facilitate comparison with existing 
data, and on the advice of Prof Athol Wells (Royal Brompton and Harefield NHS 
Foundation Trust) who has extensive experience reporting studies of pulmonary 
structure-function relationships, we elected to present the lung function data as 
percentage predicted.  Subsequently, it was felt that it would aid clarity to maintain 
a consistent presentation scheme across the thesis.  Additionally, the studies 
described in Chapters Five to Seven were also published using percentage 
predicted data [208, 256-259], so it was decided to maintain consistency so far as 
possible between thesis and published manuscripts.  If the studies comprising this 
thesis were to be conducted now, however, the wider cultural acceptance of the z-
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10.4. Longitudinal Assessment of Lung Function in Children 
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